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ABSTRACT 
Ischaemic heart disease (IHD) is the most prevalent of the cardiovascular diseases and the 
largest single leading cause of death in Australia and other Western nations. Currently, there 
are no effective treatments that salvage the ischaemic myocardium as well as limiting the 
deleterious effects of reperfusion. Cardioprotection is a promising novel therapeutic for the 
treatment of IHD as cardioprotective interventions have been shown to limit both ischaemic 
and reperfusion (I-R) injury. However, its clinical translation has been limited due to its poor 
efficacy in the aged heart. Cardioprotective interventions such as ischaemic preconditioning 
as well as numerous pharmacological approaches are reliant on the presence of caveolae and 
present a novel therapeutic target as enhanced expression of caveolae has been shown to be 
protective against variety of stressors such as I-R injury in the aged heart. The unique 
morphology of caveolae arise from the expression of its coat proteins belonging to those of 
caveolin, cavin and Popdc family of proteins with differential expression of these protein 
shown to result in tissue-specific formation of caveolae.   
Whilst the age-related expression of Caveolin-3 (Cav3) has been investigated in the hearts, 
the expression of other caveolae-related transcripts is largely uncharactiersed. Their 
involvement may help partially explain age-related changes in cardioprotection. To show this, 
we sought to characterise age-dependant expression of caveolins, cavins and Popdcs in the 
ageing normoxic and post-ischaemic Langendorff model using transcriptional and 
immunoblotting analysis. Most murine ageing studies have focused on the aged/senescent 
phenotype (>74-week old), which show the efficacy of cardioprotective interventions as well 
as I-R tolerance is lost when compared to young (8-16 week old) counterparts.  
Here we show that the loss of ischaemic tolerance is evident in male middle-aged mouse 
hearts (48-week old) as shown by enhanced LDH release and post-ischaemic contractile 
dysfunction. Aged-related down-regulation of crucial caveolae transcripts Cav3, Cavin1 and 
Popdc1 was observed in middle-aged male hearts, which may partially explain the loss of 
protection in these hearts. We also characterised caveolar gene expression in the ageing 
female myocardium. As previous experimental and epidemiological studies in the ageing 
female hearts suggests they are more ischaemic tolerant. However, we did not observe this 
cardioprotective phenotype in ageing female hearts when compared to male counterparts. 
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Coincident with the loss of cardioprotection in female hearts, the expression of Cav3 and 
Cavin1 showed similar patterns to male counterparts, although the relation between mRNA 
and protein was less consistent in females. 
We sought to further investigate the involvement of caveolae (specifically Cav3) in ischaemic 
tolerance by employing an RNAi cell culture model. Whilst this transfection rate was 
comparable to that of literature using chemical transfection methods, the degree of 
knockdown obtained with such rates is not associated with reliable repression of Cav3 mRNA. 
Thus, pharmacological disruption (MβCD) of caveolae was employed to show caveolae 
involvement in modifying ischaemic tolerance. MβCD-treatment following simulated 
ischaemia-reperfusion resulted in increased cell death when compared to non-treated 
simulated ischaemia-reperfused HL-1 cardiac cells. 
Recently, a novel type of small RNA molecules termed microRNAs (miRNAs) have emerged as 
important regulators of ageing, ischaemia-reperfusion injury and ischaemic conditioning. We 
sought to investigate the expression of several key miRNAs in the ageing male hearts, namely 
those implicated to have a role in ageing and ischaemia-reperfusion. Of the miRNAs 
associated with ageing, only miR-378 was differentially expressed in both the normoxic and 
post-ischaemic ageing hearts. Bioinformatic prediction was used to identify miRNA 
candidates targeting Cav3 and Cavin1 transcripts. No inverse-relationship was observed for 
miRNAs predicted to target Cav3 and Cavin1 in the ageing heart. 
Increasing evidence suggests that caveolae and their coat proteins are crucial contributors to 
the plasma membrane response. This is shown by the accumulation of caveolae-like vesicles 
near the sites of injury. Of the plasma membrane repair transcripts, only Anxa5 showed 
significant down-regulation with ageing in the normoxic hearts.  There was also marked 
induction of proteases Trim54 and Calpain3, these may be responsible for the reduction of 
recovery observed in the young-adult and middle-aged hearts although this remains to be 
shown at the protein level.  
In conclusion, here we show significant age-related reductions in I-R tolerance in both male 
and female hearts, evident by 32-weeks of age (prior to ‘middle-age’), with middle aged 
hearts exhibiting marked exaggeration of oncosis and contractile dysfunction. Age-dependent 
impairment of stress-tolerance was associated with significant baseline reductions in cardiac 
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transcript for all three caveolins in male but not female tissue, which was conserved for Cav3 
in post-ischaemic tissue. These data reveal age-dependent repression of transcript and 
protein for critical caveolar proteins (Cav3, Cavin1 and Popdc1) that are more pronounced in 
male hearts compared to female counterparts. Through mechanisms yet identified, age 
appears to suppress transcription and expression of multiple caveolar proteins relevant to 
cardiac stress responses, although female hearts exhibit lesser changes than males. Taken 
together, age-related down-regulation of caveolae which co-localise several crucial 
cardioprotective receptors and caveolar coat proteins which help target plasma membrane 
repair proteins to sites of injury may help partially explain reduced ischaemic tolerance in 
these hearts as well as reduced responsiveness to therapeutic intervention. Indeed, 
restoration of caveolae in the aged heart is associated with increased recovery and 
mechanisms leading to restoration of caveolae in the aged hearts have been suggested to be 
therapeutic for IHD. 
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1. Chapter One 
General Introduction 
  
 
 
2 
 
1.1 Cardiovascular Disease 
Cardiovascular disease (CVD) is the leading cause of death and was responsible for over 17 
million (or 30%) of non-communicable worldwide deaths in 2008 (WHO 2011). In 2013, CVD 
in Australia was responsible for claiming the lives of approximately 43,950 Australians, or 30% 
of all annual deaths (Heart Foundation 2012). CVD is a broad category of diseases including 
ischaemic heart disease (IHD), cerebrovascular disease (including stroke), congestive heart 
failure, rheumatic heart disease and hypertension. IHD (a.k.a. coronary heart disease) is the 
most prevalent CVD contributing to 44% of CVD cases. As shown in Figure 1.1B, IHD is the 
largest single leading cause of death in Australia with over 19,000 reported deaths (or 15%) 
in 2011 (ABS 2011; Heart Foundation 2012). The incidence of IHD increases with age, affecting 
29% of those aged 75 years and over and 47% of those aged 85 years and over. In addition, 
men more likely to have a heart attack and die as a result of IHD when compared to females 
(ABS 2014; AIHW 2015). As shown in Figure 1.1A, IHD was the leading cause of death for males 
and females in Australia in 2013. Several risk factors contribute to development of IHD 
including smoking, diabetes, high cholesterol and triglycerides, unhealthy diets and sedentary 
life styles (Anderson et al. 1991).  
IHD occurs when the heart is deprived of oxygen and nutrients received from the coronary 
arteries. These arteries can be blocked through gradual plaque formation often due to 
atherosclerosis. The formation of this plaque involves a complex interaction of immune cells, 
changes in the extracellular matrix around the intima, and deposition of cholesterol particles 
which enlarge over time and can be accelerated by several risk factors of IHD (see review 
Libby, Ridker & Hannson 2011). The occlusion can rupture causing a complete clot and 
blockage of the artery resulting in acute myocardial infarction (AMI) of the downstream tissue 
(Figure 1.2). Without immediate intervention, development of myocardial necrosis develops 
due to inadequate perfusion of the distal tissue which can be observed as the “wavefront 
necrosis” phenomenon. Current AMI treatment guidelines emphasise percutaneous coronary 
intervention to re-establish reperfusion to myocardium with fibrinolytic and other 
anticoagulant therapies used at pre-hospital scenarios (O’Gara et al. 2013). Although 
reperfusion has been shown to be beneficial in salvaging myocardium, reperfusion has been 
widely recognised as to contribute as much as 50% to the final infarct size (Braunwald & 
Kloner 1985). 
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Figure 1.1 A) In Australia 2012 & 2013, IHD was the leading cause of death (≈19,000) in both 
the male and female population. B) IHD outranks cerebrovascular, mental illnesses, lung 
cancer, chronic obstructive pulmonary diseases and diabetes (Compiled from ABS 2012; AIHW 
2013).  
 
 
 
 
4 
 
 
 
Figure 1.2 Occlusion of a major coronary artery results in ischaemia and progressive necrotic cell 
death of distal myocardial tissue. (Taken from Kumar et al. 2007). 
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1.2 Ischaemia-Reperfusion 
Ischaemia results from insufficient blood flow providing inadequate oxygenation and 
nutrients to a tissue (Klabunde 2010). The most common cause of ischaemia in the heart is 
the narrowing or blockage of a major coronary vessel (i.e. clotting, atherosclerosis) which 
results in substrate deprivation of the downstream tissue. As shown in Figure 1.2, coronary 
occlusion induces ischaemia at the distal perfused tissue with wavefront of necrosis extending 
from the endocardium to the epicardium which can be observed within a 3-4 hour period. 
The final infarct size is dependent on the duration and severity of the ischaemic period and 
availability of arterial collateral supply with irreversible cell injury beginning around 30-60 
minutes in the endocardium (Buja 2005; Reimer & Jennings 1979). Necrosis, apoptosis and 
oncosis have all been shown to contribute to cell death in the ischaemic zones. However, 
there has been some debate about the extent of apoptosis occurring in the ischaemic 
myocardium and whether oncosis or apoptosis is the major mechanism of cell death. These 
differences can be mainly attributed to variations observed in human versus animal human 
studies (Elsässer et al. 2000). 
Ischaemia leads to a dramatic reduction in mitochondrial ATP production which has several 
consequences on the cell. Oxygen deprivation results in a metabolic switch from oxidative 
phosphorylation to anaerobic glycolysis, which cumulates in intracellular acidosis (Williamson 
et al. 1976). Intracellular accumulation of protons activates the Na+/H+ ion exchanger with 
concomitant loss of 3Na+/2K+ ATPase resulting in intracellular Na+ overload (Karmazyn et al. 
1996). Persistent ischaemia leads to swelling of the lysosomes, mitochondria and the cell due 
to a loss of Na+ pumps; these are typical indicators of irreversible cell injury.  Build-up of Na+ 
ions in turn causes reverse-activation of the 2Na+/Ca2+ ion exchanger which results in Ca2+ 
overload as shown in Figure 1.3 (Kristian et al. 1998). Increased cytoplasmic Ca2+ leads to 
mitochondrial dysfunction with leakage of pro-apoptotic proteins such as cytochrome C 
through the opening of mitochondrial permeability transition pores (mPTP) resulting in 
apoptotic cell death (Kumar et al. 2007). Furthermore, ischaemia causes damage to the 
electron transport chain (complex I and III) resulting in increased ROS, which also further 
contributes to mitochondrial injury (Chen et al. 2008; Chen, Hoppel & Lesnefsky 2006). 
Ischaemia has been shown to suppress transcription and translation, affecting the 
sarcolemmal dystrophin complex implicated in plasma membrane repair and contraction 
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apparatus, which further contribute to pathogenesis of ischaemic insult (Rodriguez et al. 
2005; Gumerson & Michele 2011).  
The restoration of blood flow (known as reperfusion) can mitigate the effects of ischaemia 
and preserve tissue if performed quickly. Reperfusion therapy was first introduced by Chazov 
and colleagues in 1975 by the use of streptokinase infusion as a thrombolytic into the 
coronary arteries of AMI patients. Since then, more potent fibrinolytic and antiplatelet 
reagents have been developed which reduce MI-related mortalities compared to older 
generation fibronolytics (Wong & White 2011). These methods have further evolved into 
more refined approaches, including drug-eluting stents and aspiration thrombectomy with 
primary percutaneous intervention (Braunwold 2012). Early reperfusion of the ischaemic 
myocardium results in greater myocardial salvage leading to greater functional recovery and 
improved prognosis (Ortiz-Pérez et al. 2010).  
Reperfusion, although necessary to salvage the ischaemic myocardium from reversible injury, 
has been recognised to contribute to final infarct size. Jennings and colleagues (1960) 
observed that 30-60 minutes of ischaemia-reperfusion (I-R) is histologically comparable to 
that of 24-hour coronary artery occlusion in canine hearts and concluded that reperfusion 
accelerates development of necrosis (Jennings et al. 1960). Indeed, similar observations have 
been made in intestinal mucosal lesion formations with 3-hour ischaemia and 1-hour 
reperfusion resulting in significantly higher injury than 4-hour ischaemia alone (Parks & 
Granger 1986). For some time, reperfusion injury had been deemed as a laboratory artefact 
due to accumulation of negative findings in infarct size reduction and in discrepancies in 
animal models (Kloner 1993; Zahger et al. 1995; see review Ibáñez et al. 2015). However, with 
the discovery of ischaemic post-conditioning and emergence of pathways that are activated 
during reperfusion, reperfusion injury is nowadays a widely accepted concept (Zhao et al. 
2003; Hausenloy & Yellon 2007).  
Similar to ischaemic injury, reperfusion also results in reversible and irreversible injury. 
Reperfusion can induce ventricular arrhythmia in patients which correlates with significantly 
lower left ventricular ejection fraction and increased final infarct size when compared to 
controls (Majidi et al. 2009). Reoxygenation and energization of the ischaemic tissue by 
reperfusion, compounded by calcium overload from the ischaemic phase, can result in the 
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development of hypercontracture phenomena, which further exacerbates cellular injury by 
rupturing adjacent cells (Piper, Garcia-Dorado & Ovize 1998; Ruiz Meana et al. 1999). 
Similarly, myocardial stunning may also occur as a result of reperfusion, developing due to 
transient calcium overload. Calcium-dependent proteases may also be activated resulting in 
degradation of myofibrils leading to contractile depression, although this type of injury is 
reversible (Bolli & Marban 1999). Cardiomyocyte death is further complicated with the 
emergence of microvascular dysfunction. Areas of no-reflow prevent arterial blood and 
pharmacological agents from entering the ischaemic region and the no-reflow phenomena 
has been estimated to account for approximately 40% of the anterior AMI patients (Ito et al. 
1996). Microvascular dysfunction has been shown to correlate with reduced myocardial 
salvage, increased infarct size, adverse ventricular remodelling and adverse clinical outcomes 
(Ortiz-Pérez  et al. 2010; Ito et al. 1996; Lund et al. 2007). The aetiology of no-reflow involves 
neutrophil plugs, formation of emboli at capillaries, severe alterations in endothelial cell 
morphology, oedema and extravasation of blood (Niccolo et al. 2009; Kloner 2011). 
 
Figure 1.3 Ischaemia induces anaerobic glycolysis resulting in pH decrease and intracellular 
accumulation of calcium, which results in closure of the mPTP and myofibril contraction 
inhibition. Upon reperfusion, restoration of pH results in the re-energised mitochondria which 
resulting in opening of the mPTP. Opening of the mPTP in turn results in production of ROS 
which damage mitochondrial electron transport chain proteins and serve to attract 
neutrophils contributing to reperfusion injury (Taken from Hausenloy & Yellon 2013). 
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1.3 Ischaemia-Reperfusion Models 
Three general approaches are available to study I-R injury in animals: 1) in vivo, 2) ex vivo and 
3) in vitro. The in vivo “open chest” approach first described in 1995 involves tracheotomy 
incision to establish stable ventilation followed by chest incision to reach the heart and 
expose the lower anterior descending artery (LAD) (Michael et al. 1995). Prior to chest 
incision, blood vessels are coagulated using available means followed by series of incisions to 
expose the pericardium as described in Conci and Metzler (2006). Once the LAD is visualised, 
a ligature (i.e. PE-10 tubing for I-R) is carefully tied underneath and over the artery with 
positive occlusion indicated by anterior wall of the left ventricle becoming pale (Tarnavaski et 
al. 2004). This open chest model permits the study of inflammatory responses as a result of I-
R which are lacking in ex vivo and in vitro methods (Nossulli et al. 2000). Additionally, the 
chest may be resealed with the heart in place which allows follow-up studies (1-2 week) 
investigating remodelling of the heart in response to I-R injury (Perez et al. 2009). 
The ex vivo approach, also known as Langendorff perfusion was popularised by the German 
physiologist Oscar Langendorff in 1897 for its relative simplicity and the broad spectrum of 
measurements which can be obtained using this method. This method relies on the 
cannulation of the aorta for perfusion into the heart with Krebs and Henseleit solution 
typically used for perfusion (Skrzypiec-Spring et al. 2007). Though seemingly simple, care and 
a degree of dexterity must be introduced between heart isolation and instrumentation as the 
heart my inadvertently undergo ischaemic preconditioning or even contusion injuries 
(Skrzypiec-Spring et al. 2007). A typical Langendorff perfusion follows stabilisation (15-30 
min), induction of ischaemia (≈30 min), followed by end of reperfusion (≈45 min) and final 
infarct measurement by transverse slicing of the heart to expose the left ventricle (Bell, 
Mocanu & Yellon 2011). The Langendorff method allows the use of many physiological 
parameters as indicators of recovery, including left ventricular developed and end-diastolic 
pressure, and measurements of cell death can also be obtained using LDH efflux or 
triphenyltetrazolium chloride staining (Headrick et al. 2001).  
In vitro approaches involve the use primary cardiomyocytes (typically from neonatal or adult 
hearts) or immortalised cardiac cells in culture. Isolated neonatal cardiomyocytes are easier 
to isolate and culture compared to adult counterparts, however they are more resistant to 
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hypoxia/ischaemia and do not express some of the sarcomeric proteins (e.g. α-MHC) typically 
associated with the adult phenotype (Claycomb et al. 1998). Isolated adult cardiomyocytes 
strive to resemble closest approach to in vivo studies and can be maintained up to two weeks 
under proper culture conditions. However, these cell cultures need to be continually 
monitored for signs of deterioration, as in vitro adult cardiomyocytes suffer from attrition, 
lose morphology, reduced t-tubule density and other challenging issues associated with this 
approach (Louch, Sheehan & Wolska 2011). As an alternative, immortalised cell culture 
models consisting of H9C2 myoblast cells and HL-1 cardiomyocytes can be employed.  
H9C2 cells are neonatal myoblast originally isolated from rat ventricular tissue; they have 
been shown to resemble similar cardiac hypertrophy response when compared to their 
primary neonatal counterparts (Watkins, Borthwick & Arthur 2011). H9C2 cells have been 
suggested as a viable model to study metabolic capacity of the heart as H9C2 cells expressed 
similar level of cytochrome P450 genes when compared to the rat heart (Zordoky & El-Kadi 
2007). However, H9C2 cells do not express gap junctions, caveolae, T tubules or myofibrils 
with organised sarcomeres, which are associated with adult counterparts. Although they 
were found to preserve electrical and hormonal signalling pathway found in adult cardiac cells 
(Hescheler et al. 1991). Alternatively, the HL-1 atrial cardiomyocyte cell line has been 
suggested to resemble adult primary cardiomyocytes as it expresses many sarcomeric 
associated proteins (e.g. α-MHC, α-cardiac actin) and lack of expression of any foetal-
associated transcripts (Claycomb et al. 1998). Electron micrographic and 
immunofluorescence studies of high-passage HL-1 cells show these cells remain 
differentiated after high passages unlike their embryonic counterparts (Claycomb et al. 1998). 
HL-1 cardiomyocytes have also been used pharmacologically to study ion channels, as they 
display action potentials and currents similar to that of primary adult cardiomyocytes 
(Claycomb et al. 1998). In addition, unlike their neonatal counterparts, HL-1 cells are not 
resistant to I-R injury. HL-1 cells and its parent AT-1 cells have been shown to display 
ultrastructural characteristics typical of in vivo atrial cardiac muscle cells, including well-
organized myofibrils, gap junctions, and atrial-specific cytoplasmic granules (Claycomb et al. 
1998; del Carpio et al. 1991). However, there are some divergent instances where HL-1 
cardiomyocytes do not resemble adult cardiomyocyte phenotype such as in energy 
metabolism in HL-1 cardiac cell which show a distinct glycolytic phenotype and possess 
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mitochondria with deficient respiratory chain complex I (Eimre et al. 2008). Although 
cardiomyocyte cultures have been shown to be a good model for studying cardioprotective 
responses, some crucial physiological phenomenon such as hypercontracture and the ensuing 
inflammation cannot be replicated in vitro (Diaz & Wilson 2006). Therefore, their use should 
be carefully considered and may best serve as a supplementary approach. 
 
1.4 Cardioprotection 
 
As previously discussed, following AMI, timely reperfusion of the ischaemic myocardium can 
result in preservation of over 50% of the myocardial tissue (Schömig, Ndrepepa & Kastrati 
2006). However, reperfusion is a ‘double-edged sword’ as restoration of blood flow may 
contribute to as much as 50% of the final infarct size (Jennings et al. 1960). Decades of 
research have shown that the heart possesses many intrinsic defence mechanisms. These 
mechanisms can be activated endogenously or exogenously and are capable of reducing or 
preventing myocardial damage.  Cardioprotection can be defined as prevention or reduction 
of injuries (oncosis, arrhythmias, contractile dysfunction) from myocardial infarction and I-R 
(Heusch 2013). This phenomenon was first recognised by the use of ‘ischaemic-
preconditioning’ (IPC) technique in canine hearts by Murry and colleagues in 1986. IPC results 
from the application of brief sub-lethal episodes of I-R before the main lethal ischaemic phase. 
Following IPC, infarct size was reduced by as much as 75%; the accompanying reperfusion 
injury was also significantly reduced (Murry et al. 1986). Similarly, several types of 
‘conditioning’ methods have been developed including post-conditioning (IPOST), remote IPC 
and remote IPOST (Bousselmi, Lebbi & Ferjani 2013). The increased tolerance to I-R injury 
afforded by these methods is determined in part by the activation of endogenous signalling 
pathways within the cardiac cells.  
Since then, numerous pharmacological manipulations of these same endogenous pathways 
have also clearly demonstrated to elicit similar cardioprotective responses in both humans 
and animal models (Hausenloy & Yellon 2009; Sanada, Komuro & Kitakaze 2011). However, 
in the majority of the cases, this response is triggered by receptor activation at the cell surface 
which transduce their signals resulting in activation of multiple survival kinases, alterations in 
gene transcription and changing status of the mitochondrial channels/pores (Vinten-
Johansen & Shi 2011).  Thus, the current signalling paradigm can be summarised as 1) trigger 
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phase (e.g. cell surface receptors), 2) mediators (e.g. survival kinases) and 3) end-effectors 
(e.g. gene expression and mitochondria) as collectively summarised in figure 1.4 (Vinten-
Johansen & Shi 2011).  It is noteworthy that cardioprotective stimuli can produce two 
windows of protection, termed first window of protection and second window of protection. 
The first window of protection relies on immediate changes in proteins, i.e. by 
phosphorylation, has a greater reduction in infarct size and lasts approximately 2 hours 
following the application of the IPC. The second window of protection relies on increased 
transcriptional activity and de novo protein synthesis which begins approximately 24 hours 
and lasts up to 72 hours with a smaller degree of reduction of infarct size (see review Yellon 
& Downey 2003; Hausenloy & Yellon 2010). Following is a brief summary of cardioprotective 
signalling, for more details on historical perspective, clinical trials, effects of comorbidities on 
cardioprotection and pharmacological agents used to induce cardioprotection see Hausenloy 
& Yellon (2016) and Ferdinandy et al. (2014). 
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Figure 1.4 Current paradigm of myocardial protective signalling whereby signal transduction 
from the plasma membrane leads to activation of cystolic kinases (i.e. Akt) affecting 
mitochondrial targets (mPTP, mKATP). (Taken from Peart et al. 2014).  
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1.4.1 The Trigger Phase 
The first insight of mimicking IPC pharmacologically was shown by Liu and colleagues in 1991, 
where they showed that selective A1 adenosine receptor (A1AR) agonism reduces infarct size 
whilst A1AR antagonism resulted in loss of IPC and A1AR agonism. Experimentally, several G-
protein coupled receptors (GPCRs) such as the adenosine (A1, A2A, A2B, A3), opioid (κ and δ 
subtypes), β-adrenergic (β1 and β2 subtypes) and B2 bradykinin receptors are widely used to 
promote ischaemic tolerance comparable to that of IPC (Zhan, McIntosh & Lasley 2011; 
Tanaka, Kersten & Riess 2014; Salie, Moolman & Lochner 2011; Manolis et al. 2010).   The 
GPCR gene family consists of over 1,000 unique members and accounts for approximately 4% 
of all genes (Insel et al. 2005). The heart expresses approximately 200 different GPCRs and 
this family represents the largest gene products targeted by therapeutics in clinical use (Devi 
2001). In the cardiovascular system, GPCRs control heart rate, vascular tone, contractility, and 
blood volume. Changes in GPCR expression and signalling feature prominently in many 
cardiovascular pathologies including AMI, heart failure, hypertension, and cardiomyopathy, 
thus making them key pharmacological targets (Belmonte & Blaxall 2012). For example, 
clinically antagonism of β-receptor receptors has been used to treat heart failure since 1975 
(Gheorghiade, Colucci & Swedberg 2003).  GPCR signalling is complex and involves many 
proteins. GPCRs are labelled as seven transmembrane receptors that interact with 
heterotrimeric G-proteins composed of α-, β- and γ-subunits that are GDP bound in the 
resting state. A brief discussion of GPCR signal transduction will entail as the formation of the 
second messenger system following receptor activation is crucial for activation of 
cardioprotective kinases  
Agonist binding triggers a conformational change in the receptor, which catalyses the 
dissociation of GDP from the α-subunit followed by GTP-binding to Gα and the dissociation of 
Gα from Gβγ subunits. There are several types of Gα subunits these are classified into positive 
regulators of cAMP (Gαs and Gαi subunits), negative regulators of cAMP (Gαq subunit) and 
positive regulator of phospholipases C (Gq) (Sanada, Komuro & Kitakaze 2011).  A single GPCR 
can couple to one or more families of Gα proteins such as in the case of A1AR and the δ-opioid 
receptor. The importance of the G-protein subunits in relaying cardioprotective signalling is 
demonstrated by the antagonism of the Gi protein which results in increased susceptibility to 
I-R injury and become unresponsive to A1AR agonism (De George et al. 2008; Germack, Griffin 
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& Dickenson 2004).  The formation of the second messengers PIP3, cAMP and DAG is 
necessary for activation of the protein kinase family of proteins (PKB/Akt) involved in relaying 
cardioprotective signalling to mitochondria and the nucleus (Hausenloy & Yellon 2006; 
Salazar, Chen & Rockman 2007). The DAG and PIP3 messengers also affect heart rate, 
contractility and energy metabolism (Xiao et al. 2006). IPC has been shown to enhance DAG 
expression which is thought to result in activation of PKC, an important mediator of 
cardioprotection (Cohen et al. 1996).  Similarly, PIP3 generated by PI3K has been shown bring 
Akt to the membrane and alter Akt its conformation as well as activating PDK which in turn 
activates variety of effectors such as PKC and p70S6K involved in cardioprotection (Figure 1.4) 
(see review Murphy & Steenbergen, 2008).  It is noteworthy that the specialised microdomain 
termed caveolae are particularly enriched in PIP2 and its activator PLC which forms PIP3 
(Lanzafame et al. 2006).  
It is now widely believed that the protection afforded by IPC is from autocrine/paracrine 
release of endogenous ligands for GPCRs such as catecholamine and adenosine released from 
the ischaemic heart, which becomes focally accumulated upon reperfusion (Liu et al. 1991; 
Kitakaze & Hori 1998). Indeed, post-conditioning results in reduced endogenous adenosine 
washout which is attributed to activation of adenosine receptor resulting in reduced infarct 
sizes compared to controls (Kin et al. 2005). In the clinical setting, pharmacological 
manipulation of these receptors presents an attractive opportunity in lieu of applying IPC as 
they can be administered during the infarction and/or reperfusion phase and does not require 
an invasive procedure (Gross & Gross 2006). Besides reducing infarct size, pharmacological 
agonism of κ-opioid or the A1AR also have notable anti-arrhythmic affect, as well as enhancing 
contractile recovery (Wang et al. 2001; Ashton et al. 2003; Peart & Gross 2004). Stimulation 
of these receptors results in activation of kinases involved in Reperfusion Injury Salvage 
Kinase pathway (RISK). To further support this, non-selective adenosine receptor blockers 
have been shown to reduce IPC and A1AR agonist mediated phosphorylation of survival 
kinases including Akt/Protein kinase B and extracellular receptor kinase 1/2 (Erk1/2), linked 
to increased infarct sizes in these hearts (Solenkova et al. 2006; Germack & Dickenson 2005).  
In summary, phosphorylation of these kinases are associated with reduced infarct sizes and 
improved cardiac function whilst antagonism of their upstream components reverses this 
(Porter et al. 2012).  
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The importance of receptor activation can be seen with antagonism of these cardioprotective 
receptors. For example, antagonism of δ1 opioid receptor results in an infarct size comparable 
to that of controls (Schultz et al. 1998). It is interesting to note that receptor antagonism 
within a receptor family, e.g. κ-opioid-receptor antagonism can result in ablation of δ1 opioid 
receptor-induced cardioprotection (Peart & Gross 2004). Furthermore, there is evidence of 
cross-talk between receptors, including the A1AR and δ-opioid receptor. For example, A1AR 
antagonism results in the loss of protection afforded by δ-opioid-receptor agonism and vice 
versa (Peart & Gross 2003). At the transcriptional level, cross-regulation of receptor mRNA 
expression can also be seen with A1AR agonism repressing δ-opioid-receptor transcription 
and vice versa (Pritchard, Peart & Headrick 2008). It has been hypothesised that these 
receptors dimerise together and is supported by immunoprecipitation studies (Surendra et 
al. 2013). Similarly, δ-opioid receptor mediated infarct reduction has been shown to be 
negated by β2-adrenoceptor antagonism, with co-localisation of these receptors also shown 
by co-immunoprecipitation (Huang et al. 2007; Jordan et al. 2001).  
Besides GPCR to GPCR crosstalk, there is also cross-talk between GPCRs and receptor tyrosine 
kinases (RTK). RTKs are key regulators of critical cellular processes such as cell proliferation 
and differentiation, survival and metabolism, migration and cell cycle control (Lemmon & 
Schlessinger 2010). RTKs have been characterised with 58 known RTKs identified in humans 
to date (Lemmon & Schlessinger 2010). Similar to GPCRs, RTKs are also present in the plasma 
membrane and numerous endogenous ligands for RTKs have been implicated in 
cardioprotective signalling. Namely, these include fibroblast growth factors, vascular 
endothelial growth factors and extracellular growth factors (Hausenloy & Yellon 2009; Roth 
& Patel 2011). RTKs are generally activated by ligand-induced dimerization, which brings its 
two subunits in close proximity to each other. The activated RTKs subsequently recruit second 
messenger systems through Grb2 and Shp2, which activate RAS and Erk1/2 or DAG and IP3 in 
a similar manner to GPCR activation (Lemmon & Schlessinger 2011). Consequently, depending 
on the second messenger system, activation of RTKs results in broad category of responses 
including apoptosis, inflammation, hypertrophic response and fibrosis (Detillieux et al. 2003). 
Activation of epidermal growth factor receptor (EGFR) has recently been shown to be 
involved in cardioprotection, with evidence that EGFR transactivation triggers β1-adrenergic, 
A1AR, δ-opioid-receptor and acetylcholine mediated cardioprotection (Noma et al. 2007; 
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Pritchard et al. 2011; Fryer et al. 2001; Krieg et al. 2002). A1AR agonism via CCPA has been 
shown to increase phosphorylation of EGFR, Erk1/2 and Akt, which are blocked by EGFR 
antagonism (Pritchard et al. 2011). GPCR-EGFR transactivation is mediated by at least two 
mechanisms, either through matrix metalloproteinases (MMPs) or the β-arrestin family of 
proteins (Pritchard et al. 2011; Noma et al. 2007). 
MMPs are large family of proteins that are able to digest extracellular matrix proteins such as 
collagen and fibronectin (Visse & Nagase 2003). MMPs have been shown to cleave the EGFR 
ligand Hb-EGF, which in turn has been shown to activate EGFR and induce cardioprotection 
(Cheng, Xie & Raufman 2007). Pharmacological inhibition of MMP results in the loss of 
adenosine-mediated cardioprotection and an associated decrease in Ek1/2 and Akt 
phosphorylation (Pritchard et al. 2011). Another important regulator of GPCR and EGFR 
transactivation has been shown to involve β-arrestins of which there are two known subtypes, 
β-arrestin 1 and β-arrestin 2. The β-arrestin family of proteins has been implicated in the 
uncoupling G-proteins from their receptors, function as scaffold proteins that interact with 
several cytoplasmic proteins, and link GPCRs to intracellular signalling pathways including 
MAPK cascades (Ma & Pei 2007). β-arrestin 1/2 co-precipitate with over 300 distinct proteins, 
implicating that β-arrestins might link GPCRs to a wide range of signalling pathways (Xiao et 
al. 2007). β-arrestins have also been implicated in desensitisation, sequestration, intracellular 
trafficking of GPCRs and interacts with transcription factor such as NF-κB (Luttrell & Lefkowitz 
2002; Ma & Pei 2007). Desensitisation of GPCR is initiated by the phosphorylation of the 
receptor through GRKs and is dependent on the presence of β-arrestins. In the case of the β2 
adrenergic receptor, β-arrestins have been shown to enhance the binding affinity GRK to 
GPCRs (Lohse et al. 1993). Intracellular trafficking of GPCRs through endocytosis has also been 
shown to involve the recruitment of β-arrestins (Reiter & Lefkowitz 2006).  
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1.4.2 The Mediator Phase 
Activation of cardioprotective GPCRs results in changes in phosphorylation status of 
downstream signalling kinases including the members of MAPKs, Erk1/2 and p38 MAPK, 
serine/threonine kinases such as various isoforms of PKC, Akt and JAK/STAT which have pro-
survival effects on the cell. Expression and phosphorylation status of MAPKs, Erk1/2, p38 
MAPK and the Akt serine/threonine kinase are typically used as indicators of cardioprotection 
(via immunoblotting) as well. A1AR, δ-opioid-receptor and bradykinin B2 activation have all 
been shown to elicit cardioprotection through phosphorylation of Erk1/2, Akt and p38 MAPK 
(Peart & Gross 2005; Pritchard et al. 2011; Dana et al. 2000; Peart et al. 2007). Conversely, 
pharmacological antagonism of these receptors results in reduced phosphorylation of these 
kinases and their distal targets. Generally, the phosphorylation status of these kinases does 
not change significantly during ischaemia, however significant activation is observed within 5 
minutes of reperfusion (Fryer et al. 2001a; Fryer et al. 2001b). Hence, the classification 
convention for these kinases has been suggested to be Reperfusion Injury Kinase Pathway or 
RISK (Hausenloy, Tsang & Yellon DM 2005). Pharmacological antagonism of these kinases (p38 
and Erk1/2) ablates IPC, GPCR and RTK mediated phosphorylation of these prosurvival kinases 
resulting in increased infarct sizes (Hausenloy et al. 2005; Fryer, Hsu & Gross 2001; Chai et al. 
2008). Phosphorylation of Erk1/2 results in the translocation of Erk1/2 to the nucleus where 
it activates many stress-responsive transcription factors including c-Fos and c-Myc (Plotnikov 
et al. 2011). Activation of Akt leads to inactivation of the pro-apoptotic proteins (e.g. GSK3β 
and BAD) and influences transcription of several translation factors and ribosomal proteins 
(Fang et al. 2000; Sussman et al. 2011; Luna-Ortiz et al. 2011). PKC with its various isoforms is 
involved in various modes of cardioprotection including IPC, pharmacological and other forms 
of conditioning (Simkhovich, Przyklenk & Kloner 2013). Depending on the isoforms, PKCs can 
be cardioprotective or cardiodetrimental, as observed with PKCε and PKCδ (Sivaraman et al. 
2009). PKC isoforms targets within the cell include eNOS, the mitochondrial KATP channels and 
permeability transition pores and L-type Ca2+ channels (Ohnuma et al. 2002; McHugh et al. 
2000 Budas; see review Churchill & Mochly-Rosen 2007).  
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1.4.3 The Effector Phase 
Regardless of the original stimulus, all cardioprotective signalling converge on the 
mitochondria and the nucleus leading to reduction in cell death. The heart is a high-energy 
organ due to its reliance on aerobic mitochondrial metabolism; it is also consequently 
vulnerable to a decrease in oxygen supply as encountered during ischaemia. Besides being 
the energy powerhouses in the heart, mitochondria are also pivotal decision-makers 
regarding cell survival. More specifically, mitochondria are capable of release of pro-apoptotic 
factors such as cytochrome C following I-R injury (Borutaite et al. 2003). Both ischaemic stress 
and ROS results in damage and inhibition of mitochondrial proteins such as ATPase, as well as 
resulting in increased entry of Ca2+ into the mitochondria which causes mitochondrial swelling 
(Chen et al. 2008; Lee et al. 2012). Preservation of mitochondria following I-R is a key feature 
of several cardioprotective methods and is associated with enhanced recovery (Sun et al. 
2015; Chen et al. 2007). Pharmacological manipulations have shown notable cardioprotective 
targets in the mitochondria including the mitoKATP channel, voltage-dependent anion 
channels (VDAC), mitochondrial permeability transition pore (mPTP) and glycogen synthase 
kinase-3β (GSK3β).  
Cardioprotective stimuli such as IPC have been shown to open the mitoKATP channel which is 
thought to have several consequences including membrane depolarisation, matrix swelling, 
enhanced respiration and reduced Ca2+ overload (Gross & Fryer 1999). Whereas, agonism of 
the mitoKATP channel have been shown to reduce infarct size (Pain et al. 2000). Recent 
evidence suggests that the mitoKATP channel is not an end-effector, with the channel playing 
a more upstream role. Opening of the mitoKATP channel has been suggested to orchestrate a 
series of events including ROS formation in the matrix, eventually leading to the closure of 
the mPTP (Cohen & Downey 2008; Garlid et al. 2009). PKCε appears to be the only isoforms 
that opens the mitoKATP as pharmacological antagonism of it does not block PKCε-dependent 
mitoKATP opening (Costa et al. 2005). 
The mPTP is a non-specific channel thought to span both mitochondrial membranes and is 
responsible for maintaining the H+ gradient for ATP synthesis. The mPTP remains closed 
during ischaemia, however the accumulation of Ca2+, ROS and inorganic phosphate during 
reperfusion results in the activation of the mPTP (Baines 2009). Inhibition of the opening of 
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this pore by administration of cyclosporin A and IPC in I-R hearts results in mPTP closure, 
leading a reduction in mitochondrial Ca2+ loading, stunning and necrotic injury (Griffiths & 
Halestrap 1993; Javadov et al. 2003). Both Akt and Erk1/2 can also inhibit the opening of the 
mPTP following I-R by activation of downstream mediators such as ornithine 
decarboxylase/polyamine system following I-R (Zhang et al. 2014). GSK-3β has been 
implicated as an important mediator of mPTP-mediated cardioprotection as phosphorylation 
of GSK3β prevents mPTP opening (Juhaszova et al. 2004). The exact mechanism of GSK3β-
mediated prevention of mPTP opening is still unknown, although several possibilities have 
been suggested (see review Miura & Tanno 2010). The impact of VDAC in I-R resistance is also 
currently unknown, as its closure on apoptosis status has been met with contrasting results 
(see review Das & Steenbergen 2012). Studying VDAC has been made difficult due to lack of 
specific pharmacological tools and embryonic lethality observed with VDAC2-deficient mice 
(Cheng et al. 2003). However, knockdown of Vdac2 using RNA interference in mouse 
embryonic fibroblasts resulted in increased cell death following oxidative stress, whilst Vdac1- 
and Vdac3-knockdown showed no change in susceptibility (Baines et al. 2007). Similarly, 
Vdac2 is necessary for mitochondrial translocation of GSK3β as knockdown of Vdac2 (but not 
Vdac1 and Vdac3) results in mPTP opening under oxidative stress (Tanno et al. 2014). 
Besides affecting mitochondria, alterations in nuclear signalling is pivotal for cardioprotection 
as studies have shown that Erk1/2, Akt, MAPK isoforms and even G-protein subunits (e.g. Gα) 
interact with transcription factors and chromatin regulatory molecules such as histone 
deacetylases (Vaniotis, Allen & Hebert 2011). Nuclear signalling is of particular importance for 
late preconditioning (the second window of protection) which alters the expression of 
transcripts encoding for cardioprotective proteins, including iNOS and COX-2 (Hausenloy & 
Yellon 2010). Activation of p38 MAPK has been shown to result in increased NFκB 
translocation to the nucleus and is an important mediator of A3AR agonism and IPC (Das et al. 
1999; Zhao & Kukreja 2002; Xuan et al. 1999). NFκB has been shown to impact the 
transcription of diverse groups of genes involved in apoptosis, cell development and 
angiogenesis (Tranter et al. 2010). The activation of Janus kinase (JAK) and signal transducer 
and activator of transcription 3 (STAT-3) from the Survivor Activating Factor Enhancement 
(SAFE) pathway have also been implicated in nuclear signalling following pharmacological 
preconditioning (Lecour et al. 2005). Activation of the SAFE pathway also leads to JAK-STAT-
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mediated transcription of genes encoding Bcl-2, Bcl-xL, Mcl-1, Fas, cyclin D1, cyclin E1 and 
p21, which are involved in cell survival and proliferation (Lecour & James 2011). More 
recently, a sub-population of phospho-Erk1/2 has been shown to be directed to the 
mitochondrial membrane, leading to increased phosphorylation levels of mitochondrial 
proteins and inhibition of mPTP opening (Hernández-Reséndiz & Zazueta 2014). In summary, 
cardioprotective signalling converges on the mitochondria targets such as the mitochondrial 
KATP channels, and mPTP leading to preservation of mitochondria which is associated with 
improved recovery (Fridolfsson et al. 2012). Nuclear expression profile is also affected which 
causes increased de novo synthesis of cardioprotective antioxidant enzymes, COX2 and heat 
shock proteins (Yellon & Downey 2003).  
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1.5 Loss of Cardioprotection in the Aged Heart 
 
The general process of ageing is associated with cardiac susceptibility to disease and 
responsiveness to therapy. The aged heart is most likely to suffer I-R insult, with 
approximately 75% of infarcts occurring in those 65 years of age or older (Mariani et al. 2000). 
In the ageing mouse heart, 75% of ischaemic intolerance develops before 12-months 
(‘middle-aged’) and precedes morphological changes (Willems et al. 2005). This reduction in 
ischaemic tolerance has been shown to be independent of ischaemic duration, and collateral 
flow, further indicating an ageing-related decline of intrinsic myocardial resistance to 
ischaemic injury (Willems et al. 2005; Fenton et al. 2000). Furthermore, both ischaemic and 
pharmacological preconditioning of animal and human hearts have yielded mostly negative 
results, which fail in the aged hearts unlike in the young counterparts (Boengler, Schulz & 
Heusch 2009; Sivaraman & Yellon 2014). Similarly, protection due to preinfarction angina, 
thought to mimic IPC resulting in a lower incidence of in-hospital mortality, heart failure, 
cardiogenic shock, and myocardial necrosis observed in younger patients, has been reported 
to be both retained and lost in the elderly (Ishihara et al. 2000; Loubani, Ghosh & Galiñanes 
2003). As the therapeutic promise of cardioprotective methods has not been realised due to 
poor clinical translation, it has been suggested that there is a bias to publication of positive 
rather than negative findings in the scientific literature, which in turn may inadvertently bias 
views on the efficacy of a particular response (Peart & Headrick 2009). For example, the 
AMIDSTAD II trial showed that adenosine treated group anterior MI group resulted in 67% 
reduction (vs. placebo) in infarct size although it did not reduce the primary end point of 
survival (Ross et al. 2005). The cellular mechanisms and molecular basis of these altered 
responses in the aged hearts are only just beginning to be understood.  Furthermore, 
confounding effects of age, sex and comorbidities are also beginning to be understood, 
further unravelling the stress-intolerant aged phenotype and will be briefly discussed in the 
following sections.  
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1.6 Ageing in the Heart 
 
1.6.1 General Characteristics  
Ageing affects cardiomyocytes at several subcellular and molecular levels including telomere 
shortening, mitochondrial dysfunction, changes in transcription and translation (Kovacic et al. 
2011; Ashton et al. 2006). There are also notable physiological changes, linked to molecular 
changes including cardiac hypertrophy and left ventricular fibrosis (Sangaralingham et al. 
2011). For example, aged-related loss of ventricular mass is compensated by cardiomyocyte 
hyperplasia and fibrosis due to continual loss of cardiomyocytes (Anversa et al. 1990). It is 
noteworthy that these histological evident changes occur with cellular senescence (>19-21 
months old) but not in the middle-aged (10-12 months old) hearts (Anversa et al. 1986). 
Ageing is also accompanied by notable vascular changes such as arterial wall thickening, 
endothelial dysfunction, and increased systolic blood pressure accompanied by decreased 
diastolic blood pressure which increases the workload of the heart (See review; Kovavic et al. 
2011b). Cardiomyocyte ageing has been shown to lead to alterations in telomeres, 
telomerase activity, oxidative stress response, and expression of p16INK4a and p53 which are 
determinants of cellular senescence, impairing cell growth and promoting cell death (Torella 
et al. 2004). Replicative senescence of the cardiomyocyte is paralleled in the cardiac stem cell 
population, which also becomes mostly senescent (c-kitPOS) although some telomerase-
competent cardiac stem cells are still able to differentiate into cardiomyocytes (Chimenti et 
al. 2003; Gonzalaz et al. 2008). However, continual replacement of the dying cardiomyocyte 
population with a declining pool of available cardiac stem cells leads to a progressive 
depletion of the growth reserve of the heart (Chimenti et al. 2003). There are notable sex-
related differences in the accumulation of senescent cardiomyocytes, 0.68% per year in 
women and 0.89% per year in men (Kajstura et al. 2010). Furthermore, the female heart has 
been shown to possess a larger pool of functionally competent cardiac stem cells and younger 
myocytes than the male myocardium (Kajstura et al. 2010). 
The heart is enriched with mitochondria, which provide 70% of the ATP through oxidative 
phosphorylation (Saraste 1999). Mitochondrial dysfunction is central to the theory of ageing 
and was noted for its role in ROS generation linked to the main cause for age-related damage 
in the early 1970s (Harman 1972). Indeed, the decline of cardiac performance correlates well 
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with decline of cardiac mitochondria as shown in Table 1 of Dai, Rabinovitch & Ungvari (2012). 
Age-related mitochondrial changes have been shown to include increased ROS, impaired 
oxidative phosphorylation, reduced ATP generation, and impaired fatty acid oxidation. These 
dysfunctions are thought to arise from increased instability of the mitochondria by increased 
mitochondrial DNA mutations and reduced autophagy (Brink et al. 2009; Marín-García, Pi & 
Goldenthal 2006).  The effects of increased mitochondrial DNA mutations can be mimicked 
by mice models employing homozygous mutation of mitochondrial polymerase gamma (DNA 
proofreading enzyme) with these mice showing several age-related diseases such as greying 
and loss of hair, osteoporosis, sarcopenia and shortened life span of approximately 15 months 
(Trifunovic et al. 2004). Another prominent change that has been shown to contribute to 
ageing is the reduced efficacy of mitochondrial autophagy, a self-recycling process where 
faulty mitochondria are removed. To highlight the role of autophagy in maintenance of 
cardiac structure and aging, cardiac-specific Atg5 (autophagy-related gene 5)-deficient mice 
show disorganised sarcomere structure and begin to die after the age of 6 months (Taneike 
et al. 2010).  
Ageing has been shown to result in significant alterations in transcriptional response in both 
normoxic and post-ischaemic hearts which impact crucial cardioprotective signalling 
networks including GPCR, WNT, JAK-STAT, and MAPK (Ashton et al. 2006). Although 
cardiomyocytes occupy 75% of the ventricular tissue volume, they have been shown to 
account for only 30–40% of the total number of cells in the adult heart with fibroblast 
population being second highest non-muscle type cell (Nag 1980). The ageing heart displays 
dysfunctional mesenchymal fibroblasts, which result in upregulated collagen deposition from 
7% in the young heart (4-week old) to 20% in the senescent heart (88-week old) (Cieslik et al. 
2013; Eghbali et al. 1989; see review Biernacka & Frangogiannis, 2011). All of these have been 
estimated to result in loss of 35% of cardiomyocytes and a 20% decrease of sinoatrial nodal 
pacemaker cells due to apoptosis, necrosis and potentially autophagy (Olivetti et al. 1991; 
Chien & Karsenty 2005). It is noteworthy to mention that cardiac ageing in the murine models 
mentioned previously resembles the age-related cardiac changes in healthy human 
population (Dai & Rabinovitch 2009). For a summary of cardiovascular ageing see Lakatta et 
al. (2015).  
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1.6.2 Clinical Trials  
Since the discovery of IPC, more than 3,000 cardiovascular investigations have been published 
to understand the underlying mechanisms of IPC and clinical translation of IPC (Peart & 
Headrick 2009). Furthermore, the discovery of post-conditioning revitalised the pursuit of 
cardioprotective methods in the clinical setting as it can be applied during reperfusion (Zhao 
et al. 2003). As mentioned previously, pharmacological recruitment of cardioprotective 
receptors can also yield in reduction in I-R injury as shown by various animal models and 
pharmacological agonists (Hausenloy & Yellon 2009; Sanada, Komuro & Kitakaze 2011). In 
concordance with the ageing animal models, the results with pharmacological activation of 
cardioprotection signalling are mostly disappointing as reduced infarct size was seen in some 
clinical studies provided no prognostic benefits (Boengler, Schulz & Heusch 2009; Heusch 
2013). For example, A1AR agonism in 2 clinical trials, Acute Myocardial Infarction Study of 
Adenosine (AMISTAD-I and AMISTAD-II), consistently showed reduced infarct size (33% and 
67%, respectively) without improved survival (Mahaffey et al. 1999; Ross et al. 2005). 
However, issues have been raised including whether the bolus was sufficient enough to elicit 
a response during the reperfusion phase, which was also limited by the hypotensive side 
effect of adenosine, and its half-life (Kloner et al. 2013). It was later found in a post-hoc 
analysis that 3 hours of adenosine administration as an adjunct to reperfusion therapy within 
the first 3.17 h onset of AMI (anterior ST-segment elevation) enhances early and late survival, 
as well as reducing the clinical endpoint of death or congestive heart failure at 6 months 
(Kloner et al. 2006).  This is in agreement with animal experiments that even preconditioning 
methods cannot elicit a cardioprotective response after 3 hours of ischaemia (Murry et al. 
1991).  
Similar to pharmacological trials, post-conditioning trials have also produced mostly negative 
results, although a single trial has shown a reduction in infarct size or a trend toward a 
reduction (see review Kloner 2013). Phase III clinical trials (CIRCUS) inhibiting opening of 
mitochondrial permeability transition pore with Cyclosporin-A is also underway with small 
pilot studies in the context of AMI and CABG showing promising results (Hausenloy et al. 2014; 
Piot et al. 2008). Despite these failures, there is still optimism of cardioprotective methods as 
an adjunctive therapy for reducing reperfusion injury although the great promise of 
cardioprotection lies in salvaging the ischaemic myocardium during the infarction process 
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when the availability of salvageable tissue is large (Heide & Steenbergen 2013). Indeed, the 
translation of experimental and pre-clinical data into clinical data to this data has not been 
fully realised despite the large body of work. More recently, a multicentre randomized 
controlled trial called CAESAR has been developed to evaluate potentially cardioprotective 
therapies thereby sparing millions of dollars and years of work involved in performing clinical 
trials of agents (Jones et al. 2015). More specifically, the use of CAESAR protocols has been 
shown to produce reproducible results in mice, rabbit and pig models in assessment of 
potential infarct-sparing therapies (Jones et al. 2015). However, as mentioned by the its 
authors, another complication encountered with clinical trials is the existence of multiple 
comorbidities and the lack of aged models which have both been shown to affect 
cardioprotective signalling and are not replicated in animal models. For a summary of the 
clinical trials of cardioprotection see Heusch (2013).  
 
1.6.3 Effect of Comorbidities and Medications 
Ageing hearts with IHD are also associated with multiple underlying diseases, thus 
necessitating efficacy of preconditioning stimulus or other protective modalities be effective 
across age group sand disease. Unfortunately, in animal models multiple comorbidities and 
current drug use does not accurately reflect the clinical scenario of AMI which may help 
partially explain the lack of clinical progress. Indeed, increasing number of comorbidities has 
been associated with higher 30-day and 1-year post admission death rates in patients 
hospitalized with AMI (McManus et al. 2013). Thus, another possible underlying condition 
limiting the efficacy of cardioprotection in the aged hearts is the existence of multiple 
comorbidities. These comorbidities have been shown to include atrial fibrillation, heart 
failure, prior MI, diabetes mellitus, hypertension and stroke (McManus et al. 2013).  
Due to its growing near epidemic prevalence in Australia and the rest of the world, Diabetes 
mellitus will be discussed briefly here as an example (for further details see review McCafferty 
et al. 2014). In 2013 in Australia, there were approximately 50% of deaths due to Type 2 
Diabetes with IHD as an associated cause of death (ABS 2013). Despite its growing prevalence, 
there is still paucity of data investigating both myocardial conditioning in ageing and diabetic 
cohorts (Przyklenk et al. 2011). Diabetes is associated with larger infarct sizes and poor 
 
 
26 
 
outcomes when compared with non-diabetic patients (Haffner et al. 1998; Stevens et al. 
2004). Consistent with experimental findings, Diabetes mellitus has been shown to block the 
protective effects of IPC, angina, anaesthetic and other forms of pharmacological conditioning 
(Ishihara et al. 2001; Tai et al. 2012; see review Peart & Headrick 2009). Mechanisms of this 
reduced protection in diabetic hearts have shown to involve reduced phosphorylation of 
survival kinases such as JAK/STAT, PI3k, MAPK and GSK3β by various forms on conditioning 
methods (Gross, Hsu, & Gross 2007; Tai et al. 2012; Whittington et al. 2013). Therefore, the 
imposition of the diabetic heart on top of the already failing ageing heart may further 
exacerbate age-related dysfunctional signalling in the heart. Diabetic animal models are also 
a major hurdle as it has been suggested that none of the models accurately reflect the human 
pathology of diabetes and have yielded conflicting results (see review Whittington et al. 
2012).  Use of medications such as β-blockers, statins, nitrates, and antidiabetic drugs for the 
comorbidities have also have been shown to impact cardioprotective signalling in certain 
cases (Ferdinandy et al. 2014). Sulfonylurea, an antidiabetic drug, has been associated with 
an increased risk of in-hospital mortality among diabetic patients undergoing coronary 
angioplasty for acute myocardial infarction whilst it has no negative effects on the long-term 
survival (Garratt et al. 1999; Meier et al. 2003).   
 
1.6.4 Sex-Related Differences 
As previously mentioned, males are twice as likely to have a heart attack when compared to 
females (AIHW 2015). Historically, upon the clinical presentation of IHD, women have been 
treated less aggressively than men, as woman were often misdiagnosed or significantly less 
likely to report chest pain or discomfort compared with men (Tobin et al. 1987; Canto et al. 
2007). Nowadays, although women are less likely to be admitted to coronary care units, the 
overall treatment is as intensive for women as it is for men (Alfredsson et al. 2009). In certain 
instances, there are notable differences in pharmacotherapy for woman with IHD. For 
example, women are less likely to receive aspirin or glycoprotein IIb/IIIa inhibitors and are 
less often discharged on aspirin or statin (Akhter et al. 2009; see review Ostadal & Ostadal 
2012). Due to their older age at clinical presentation of IHD, women are more likely to have a 
history of hypertension and diabetes, which as previously discussed worsens the outcomes of 
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IHD (Alfredsson et al. 2007). Although it was generally believed that males displayed greater 
IHD-related mortality, multivariate analysis correcting for age and co-morbidities show these 
apparent sex-related mortalities to disappear (Dey et al. 2009). However, there are notable 
sex-related responses to AMI/I-R both clinically and experimentally. Compared to males, the 
female myocardium appears resistant to variety of stressors such as ischaemic damage and 
associated arrhythmias, stress-induced hypertrophy and heart failure (Bell et al. 2013). 
Consistent with experimental findings, females display reduced prevalence of CVD/IHD, 
developing IHD on average 10 years later than males, with myocardial infarction occurring 20 
years later (Willems et al. 2005; Duvall 2003; Bassuk & Manson 2010). There are also notable 
differences in myocardial salvage using PCI following AMI between males and females. More 
specifically, being female has been shown to be an independent predictor of greater 
myocardial salvage (0.64 vs. 0.50) after PCI (Mehilli et al. 2005). Despite greater myocardial 
salvage, four-year mortality studies suggest that following multivariate analysis, there are no 
sex-related differences in mortality and cardiac morbidity after PCI (Tillmanns et al. 2005; see 
review Bucholz et al. 2014). As discussed later in Chapter 4, the mechanism of this protection 
in the female heart is thought to include a dependence on estrogen receptor signalling.  
 
1.6.5 Molecular Dysfunction in the Aged Heart 
As previously discussed, the ageing heart is more susceptible to damage from I-R relative to 
the younger heart. The aged heart displays diminished functional capacity due to fibrosis, 
abnormal calcium handling as well an increased susceptibility to damage (Biernacka & 
Frangogiannis 2011; Zhou, Lakatta & Xiao 1998). In mice, aged hearts also demonstrate 
impaired tolerance to I-R as early as 8 months (mature) without any morphological changes 
(Willems et al. 2005). In addition, aged hearts also do not respond to pharmacological and 
ischaemic preconditioning (Headrick et al. 2003). The exact mechanism of attenuated 
cardioprotection in the aged heart is currently unknown. It has been hypothesised that the 
GPCR system is only partially inactivated by ageing whilst the RTK-mediated system is severely 
impaired (Yeo & Park 2002). This lack of protection in the aged heart is not likely due to sole 
receptor dysfunction; for example, A1AR expression has been shown to be similar in young 
and aged hearts (Headrick et al. 2003). However, β1-adrenergic receptors have been shown 
to be decreased in aged hearts (Cerbai et al. 1995). G-protein coupling mechanisms are also 
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affected with ageing as shown for the A1AR and β1-adrenergic receptor. The basal coupling of 
Gα with A1AR has been shown to decrease by approximately 20% (Cai et al. 1997). Whilst 
A1AR agonism in the aged hearts resulted in 50% less coupling when compared to young 
counterparts (Cai et al. 1997). A similar decrease in β-adrenergic responsiveness with ageing 
involving decreased agonist binding of β1-receptors, uncoupling of β2-receptors, and altered 
G protein-mediated signal transduction is observed in human hearts (White et al. 1994; see 
review Ferrara et al. 2014). RTKs also show aged-related impairment, as EGFR receptor 
expression as well as its autophosphorylation is significantly reduced (80%) in senescent 
fibroblasts, although the status of RTK signalling is unknown in the heart (Tran et al. 2003).  
At the mediator level, crucial proteins and kinases that trigger cardioprotection such as Akt 
Erk1/2 and p70S6k are present and functional in the aged heart, similar to levels seen in the 
young counterparts. Rather, there is an age-related loss of activation of p38 MAPK (Peart et 
al. 2007). When p38 MAPK is directly activated (anisomycin), phosphorylation of p38 as well 
as its downstream target HSP27 is restored accompanied by enhanced recovery in these 
hearts (Peart et al. 2007). Age-associated impairment of p38 MAPK signalling has been 
observed in the aged rat brain as well as in aged hypertensive rats and human end stage heart 
failure (Lemke et al. 2001; Aoyagi & Izumo 2001; Zhen et al. 1999). Pharmacological PKC (α, δ 
and ε) activation is impaired as PKC agonism, reduces infarct size in young but not aged hearts 
(Schulman, Latchman & Yellon 2001). This may be due to impaired translocation of PKC 
isoforms, which display differential expression and localisation with ageing (Tani et al. 2001; 
Hunter & Korzick 2005). The failure of translocation of the PKC isoforms may be due to age-
related decrease in their scaffolding protein, receptors for activated C-kinase (RACKs), which 
are also decreased in the aged brain leading to impaired translocation of PKC isoforms 
(Korzich et al. 2001; Pascale et al. 1996). The failed activation of these kinases (Erk1/2, PKC, 
etc.) in the aged heart may result in impaired phosphorylation of GSK3β, which may affect 
the distal targets of GSK3β including the mPTP. 
Similar to GPCR and PKC insensitivity, pharmacological preconditioning targeting mPTP and 
mitoKATP channel also fail in the aged hearts. More specifically, aged hearts display 
insensitivity to cyclosporine A, which inhibits opening of mPTP in the young heart but not in 
the aged heart, leading to a significant increase in infarct size (Liu et al. 2011). Similarly, aged 
hearts are also insensitive to pharmacological activation (via diazoxide) of mitochondrial KATP 
and display reduced recovery and enhanced oncosis compared to young counterparts (Peart 
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et al. 2014). Similar to unperturbed levels of survival kinases, the expression of GSK-3β is 
similar between the young and aged hearts, however aged hearts display >2-fold increase in 
phospho-GSK-3β (Kinnard et al. 2005). Aged hearts are also insensitive to direct GSK-3β 
inhibition (SB-216763), which reduces I-R injury in the young but not aged hearts (Zhu et al. 
2011). The mechanism behind the aged-related insensitivity to GSK-3β pharmacological 
inhibition is unknown, although several hypotheses have been suggested (See Zhu et al. 
2011). Regarding the enhanced phosphorylation status of GSK-3β in the aged heart, as 
phospho-p70s6K inhibits GSK3β, it is conceivable that declining expression of phospho-
p70s6K may be responsible for elevated phospho-GSK3β in aged tissue (Sutherland, Leighton 
& Cohen 1993; Peart et al. 2014). 
As a proof of concept, cardioprotection in the aged heart can be restored as shown with 
transgenic approaches such as A1AR overexpression, pharmacological approaches such as 
sustained ligand preconditioning (SLP) and caloric restriction (Headrick et al. 2003; Kidd et al. 
2010; Peart & Gross 2004; Shinmura, Tamaki & Bolli 2008). These methods have been shown 
to display a cardioprotective phenotype as indicated by reduced oncosis and improve post-
ischaemic recovery, the ideal outcomes of cardioprotective interventions. A1AR 
overexpression reduces necrosis, contractile dysfunction and the incidence of 
tachyarrhythmia with and without the addition of adenosine in aged hearts (Headrick et al. 
2003). It is noteworthy that A1AR overexpression produces a more cardioprotective 
phenotype in the young heart whilst aged hearts display enhanced cardioprotection 
compared to their wild-type aged counterparts (Headrick et al. 2003).  Thus far, the most 
characterised mechanism of the aforementioned interventions is SLP.  Interestingly, SLP does 
not involve canonical protective RISK signalling elements, but induces non-canonical 
transcriptional changes involved in mediators of inflammation/immunity, sarcomere 
function, and cardiovascular growth and development (Ashton et al. 2013). The mechanisms 
of SLP protection appear different to conventional δ-opioid receptor agonism, as depletion of 
specialised microdomains in the plasma membrane does not affect the efficacy of SLP (See 
Hoe et al. 2014). Although caloric restriction does not improve ischaemic tolerance in the 
senescent hearts, it does attenuate the age-associated changes in the heart and major vessels 
such as collagen deposition in the heart and aorta (Ahmet et al. 2011). Microarray analysis of 
caloric restricted hearts show gene expression changes related to preserved fatty acid 
metabolism, reduced endogenous DNA damage, decreased innate immune activity, apoptosis 
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modulation, and a marked cytoskeletal reorganization (Lee et al. 2002). Taken together, these 
studies suggest that while the machinery to affect cardioprotection is present, there is an age-
related impairment in the organisation and regulation of the stress activated signalling 
cascade. Recent evidence involving the organisation and sequestering of signalling molecules 
in specialised microdomains termed caveolae have shown additional evidence of this (Kidd et 
al. 2010; Peart et al. 2014). 
 
1.7 Lipid Rafts and Caveolae 
The plasma membrane of a cell is not a homogenous sea of phospholipids, but consists of 
highly organised microdomains known as lipid rafts. Lipid rafts display a unique biochemistry 
compared to the rest of the plasma membrane as they are particularly enriched in 
gangliosides, sphingomyelin and cholesterol rendering them detergent-resistant. Due to 
enrichment of cholesterol, lipid rafts exhibit less fluidity compared to the surrounding plasma 
membrane (Pike 2003). The sizes of lipid rafts can vary, but are generally considered to be 
50nm in diameter, of which there can be 106 rafts in a plasma membrane with each raft 
carrying about 20 protein molecules (Simons & Ehehalt 2003). Lipid rafts can also be enriched 
in particular group of proteins such as flotillin, which have variety of roles depending on the 
cell type (Figure 1.5) (Otto & Nichols 2013). Currently there is no universal consensus on how 
many types of lipid rafts there are, although a model consisting of: 1) rafts, 2) clustered rafts, 
3) detergent resistant membranes and 4) caveolae has been proposed (Simons & Toomre 
2000). Caveolae were initially identified by Palade and colleagues in the early 1950s, although 
this was not published until much later when caveolae were described as 50-100 nm “flask 
shape and elongated neck-like invaginations” in blood capillary of rat tongue (Palade & Bruns 
1968). Caveolae can occupy as much as 50% of the plasma membrane in some cell types, with 
adipocytes estimated to have as many as a million caveolae per single cell (Thorn et al. 2003). 
Unlike lipid rafts, which are continuous and morphologically indistinguishable from each 
other, caveolae are invaginations within the membrane and are therefore distinguishable 
morphologically to the other three types of lipid rafts described above (see Figure 1.5).  
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Caveolae have been shown to participate in a variety of cellular processes including vesicle 
trafficking, cholesterol homeostasis, tumour suppression and signal transduction. The 
selective entry of some bacterial toxins and viruses including SV40 into cells has shown to 
involve caveolae instead of clathrin (Norkin 2001; Pelkmans, Puntener & Helenius 2002). 
Similarly, some proteins have been shown to endocytose through caveolae (Razani et al. 
2001). Clathrin-mediated endocytosis and caveolae-mediated endocytosis appear to be 
independent events and do not associate together (Oh, McIntosh, & Schnitzer 1998). Newly 
synthesised cholesterol from the endoplasmic reticulum first appears at the caveolae before 
moving to the surrounding plasma membrane through currently unidentified mechanisms 
(Monier et al. 1996). The sequence responsible for cholesterol interaction has been mapped 
to tyrosine 14 and serine 80 although it should be noted that these two sequences differ in 
the mechanism of interaction with cholesterol (Fielding et al. 2004). Caveolae internalisation 
relies on cholesterol, as antagonism of cholesterol with progesterone reduces the 
internalisation of caveolae membranes (Smart et al. 1996). Caveolae have been implicated in 
oncogenic cell transformation, tumourigenesis and metastasis. This is based on evidence from 
cultured cells, animal models and human tumour tissue (Scherer et al. 1997; Bonuccelli et al. 
2009).  
 
The role of caveolae in signal transduction can be noted by caveolae orchestration and the 
co-localisations of several receptors as well as their subunits as shown in Table 1.1.  Notably, 
caveolae house a plethora of canonical cardioprotective receptors, including the A1AR and 
the δ-opioid GPCRs, as well as their G-protein subunits. The relationship between receptors 
and caveolae is dynamic, with receptors either moving in or out of caveolae upon activation. 
For example, under basal conditions, A1AR is present in caveolae membranes but following 
A1AR agonism using CCPA treatment, A1AR relocates to the plasma membrane fractions as 
shown by co-immunoprecipitation and immunoelectron microscopy (Lasley et al. 2000). 
Activation of A1AR is required for its translocation as A1AR antagonism with DPCPX followed 
by agonism prevents the redistribution of A1AR to plasma membrane fractions from caveolae 
(Lasley et al. 2000).  
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Figure 1.5 Caveolae are distinguished from the rest of the plasma membrane and lipid rafts 
by the presence of caveolin, cavin and Popeye-domain containing proteins which give it the 
unique flask-shaped morphology. It should be noted that caveolae may display varying 
morphology depending on the cell type when viewed under the electron microscope, with 
structures resembling grape-like clusters, rosette and tubular forms (above) as demonstrated 
in Figure 1 of Razani, Woodman & Lisanti (2002). In addition, caveolae compartmentalise 
GPCRs, their subunits and other type of receptors (non-GPCR) which has led to the formation 
of the caveolae signalling hypothesis. (Modified from Rothberg KG et al. 1992; Allen, 
Halverson-Tamboli & Rasenick 2007). 
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Table 1.1 Caveolae proteins localise and interact with many GPCRs, their subunits and 
receptor kinases. Modified from Razani, Woodman & Lisanti (2002a).  
 
Caveolae Localisation Morphological 
Evidence 
Biochemical 
Evidence 
Interact with 
Caveolae 
proteins 
G-protein coupled receptors: 
    A1 adenosine receptor  + + 
    Delta opioid receptor + +  
    Bradykinin B2 receptor + +  
    β1 and β2 adrenergic receptor + + + 
G-proteins: 
    Gαs + + + 
    Gα11  + + 
    Gα12  + + 
    Gα0   + 
    Gβγ  +  
    Gαq  +  
Receptor tyrosine kinases: 
    Epidermal growth factor receptor   + 
Non-receptor tyrosine kinases: 
    Src  + + 
    JAK2  +  
    STAT3  +  
Non-receptor Ser/Thr kinases: 
   Protein kinase A + + + 
   Protein kinase C   +  
   ERK +  + 
   MEK   + 
   PI3-kinase  + + 
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1.7.1 Caveolins 
Caveolae can be distinguished from other members of the lipid raft family due to the 
expression of the caveolin family of scaffolding proteins. It has been estimated that each 
caveolae coat may have as much as 140-160 caveolin protein molecules (Pelkmans & Zerial 
2005). The caveolin protein family consists of three members (Caveolin-1, -2 and -3), each 
encoded by a distinct gene (CAV1, CAV2 and CAV3). The resulting proteins are structurally 
related, with all three containing an identical stretch of eight amino acids (FEDVIAEP) within 
their N-terminus end. The significance of this structural/functional motif is unknown, 
although it is highly conserved across species (Razani, Woodman & Lisanti 2002). CAV1 and 
CAV2 have been found to map to the 7q31 region of human chromosome 7 while CAV3 maps 
to 3p25 (Engelman et al. 1998). Although CAV1 and CAV2 map upstream to tumour 
suppressor gene on human chromosome 7q31.1, the role of CAV1 as a breast tumour 
suppressor gene has been refuted (Hurlstone et al. 1999). All three caveolin proteins display 
several isoforms and are similar in size (22-24 kD) and structure (Williams & Lisanti 2004). All 
caveolin proteins possess a scaffolding domain, oligomerisation domain, transmembrane 
domain and palmitoylation sites (Schegel, Pestell & Lisanti 2000).   
 
The scaffolding domain is a negative regulator of variety of proteins involved in signalling such 
as G-protein subunits (Gi2a), eNOS, PKC isoforms and receptors such as EGFR (Razani, 
Woodman & Lisanti 2002). Compilation of proteins which interact with Cav1 and Cav3 
scaffolding domain shows the interacting ligands almost invariably have the motifs ΦXΦΦ, 
ΦΦΦ, ΦXΦΦΦ, where Φ is an aromatic residue (Phe, Tyr, or Trp) and X is any amino acid 
(Couet et al. 1997). This ligand interaction does not occur with Cav2 scaffolding domain under 
the same conditions for Cav1 and Cav3 (Couet et al. 1997). Cav1 and Cav3 also possess the 
ability to form high molecular weight oligomers together ranging 200-400 kDs in size (Volonte 
et al. 2008). As shown by sucrose density gradients and confocal microscopy, caveolae have 
been shown to compartmentalise GPCRs and their subunits (Table 1.1) (Head et al. 2005). 
Confocal and electron microscopy demonstrates co-localisation of Cav3 and Gαs within the 
intercalated disks of cardiomyocytes and in the sarcolemma (Head et al. 2005). It has been 
suggested that G-protein subunits tether their receptors to caveolae. To support this, 
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decreased bradykinin2 receptors and caveolae FRET measurements were observed when Gαq-
Caveolin-1 association was reduced by peptide inhibition (Calizo & Scarlata 2012).  
 
It should be noted that caveolae, in addition to enhancing signalling, are also capable of 
inhibiting signalling. Disruption of caveolae via caveolin knockdown and cholesterol depletion 
has been shown to alter Gαs trafficking in caveolae, prevent Gαs internalization, and elevate 
Gαs/AC activity in the mouse brain (Allen et al. 2009). The putative caveolin scaffolding 
domain (82-101) has been shown to inhibit many ligands including eNOS (García-Cardeña et 
al. 1997). All of these findings suggest that caveolae in conjunction with caveolins concentrate 
GPCR and their subunits to allow efficient signal transduction (Insel et al. 2005).  
 
 
 
Figure 1.6 A) Caveolins are found in regions of the membrane that are particularly enriched 
in cholesterol and spingolipids. B) A single caveolin protein has many domains such as the 
oligomerisation and transmembrane domains that give caveolins proteins the ability to 
dimerise together and attach to the plasma membrane. For simplicity the caveolin oligomer 
is depicted as a dimer. Taken from Williams & Lisanti (2004). 
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1.7.1.1 Caveolin-1 
Caveolin-1 was the first caveolae marker protein to be discovered (Rothberg et al. 1992). Cav1 
displays 58% homology to Cav2 and 85% to Cav3 (Schlegel, Pestell  & Lisanti 2000). On the 
human chromosome (7q31.1), CAV1 and CAV2 are in very close proximity to each other (≈19 
kilobases apart) while CAV3 is located on a different chromosome (3p25) (Williams & Lisanti 
2004). Cav1 protein is ubiquitously expressed and is responsible for caveolae formation in 
non-muscle type cells such as endothelial, adipose and epithelial type tissue (Hansen et al. 
2013; Drab et al. 2001). Two isoforms of Cav1 exist, the longer 178 amino acids long Cav1α 
and Cav1β which is truncated by 31 residues (Kogo & Fujimoto, 2000). There appears to be 
differences in forming caveolae efficacy between the Cav1 isoforms as differential 
introduction of Cav1 isoforms in HepG2 cells, which lack caveolae, show Cav1α is more 
efficient than the Cav1β isoform in forming caveolae (Fujimoto et al. 2000). Cav1 is believed 
to act as a tumour suppressor and a negative regulator of the EGFR-MAPK signalling cascade. 
In fact, Cav1 was first described as a protein that became tyrosine-phosphorylated (Tyr14) in 
Rous sarcoma virus transformed chick fibroblasts. The Tyr14 phosphorylation is believed to 
override the growth inhibitory activity of Cav1 (Li, Seitz & Lisanti 1996). Similarly, a CAV1 
mutation (P132L) observed in approximately 16% of human breast cancers is also believed to 
inactivate the same growth suppression, contributing to mammary cell invasiveness 
(Bonuccelli et al. 2009). Other notable CAV1 mutations observed clinically was a single case 
of Berardinelli-Seip congenital lipodystrophy (BSCL), a rare recessive disease characterised by 
near absence of adipose tissue, and for a case of hypertriglyceridemia (Kim et al. 2008; Cao 
et al. 2008). 
 
The absence of detectable Cav1 protein expression in common cancer cell lines including 
HeLa, Jurkat and 3T3 L1 cells further supports its role as a tumour suppressor (Scherer et al. 
1997). Consistent with these findings, the reintroduction of the Cav1 gene into Cav1 deficient 
NIH 3T3 cells abrogates abnormal cell growth and even causes apoptotic cell death (Engelman 
et al. 1997). For further summary please refer to Williams & Lisanti (2004). Cav1-deficient 
mice show dramatic reduction (≈50%) in life span when compared to wild-type mice (Park et 
al. 2003). Phenotypically, Cav1-deficient mice show a combination of pulmonary fibrosis, 
pulmonary hypertension, and cardiac hypertrophy (Park et al. 2003). Cardiac hypertrophy 
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observed in Cav1-deficient mice is thought to arise from the loss of Cav1 inhibiting Erk1/2 
kinase pathways in cardiac fibroblasts and myocytes (Galbiati et al. 1998; Page & Doubell 
1996). As shown by electron micrography, double Cav1/Cav3-deficient mice show caveolae 
disappear in cardiomyocytes and in the adjacent endothelial cells while Cav3-deficient mice 
show loss of caveolae in the cardiomyocyte but not in the adjacent endothelial cell (Park et 
al. 2002). Whilst Cav1-deficient animals show disappearance of caveolae in the endothelial 
cells but not in cardiomyocytes (Park et al. 2002). Although not widely associated with 
cardioprotection, Cav1 has been shown to be required for cardioprotective effects of 
methods such as IPC and anaesthetics preconditioning with infusion of Cav1 peptide shown 
to be cardioprotection as well (Das et al. 2012; Patel et al. 2007; Tsutsumi et al. 2010; Young, 
Ikeda & Lefer 2001; Shen et al. 2011). The mechanisms of this protection has been shown to 
involve Src-mediated phosphorylation of Cav1 and eNOS release as antagonism of Src and 
eNOS shown to reverse the cardioprotective effects of Cav1 peptide infusion (Patel et al. 
2007; Young, Ikeda & Allan 2001). Similarly, in MDCK cells phospho-Cav1 has been shown to 
promote cell survival following oxidative stress although its molecular mechanisms remain 
uncharacterized (Percy et al. 2008). Growth factors such EGF and insulin which activate the 
cardioprotective receptors EGFR and IGFR (respectively) have been shown to result in 
significant increase of Cav1 phosphorylation (Kim et al. 2000; Kimura et al. 2002). The 
internalization of the cardioprotective tyrosine kinase receptor such as insulin-like growth 
Factor-I receptor (IGF-IR) and EGFR also requires phospho-Cav1 although this has yet to be 
shown in cardiomyocytes (Salani et al. 2010; Monaghan-Benson, Mastick & McKeown 2008). 
 
Although it has yet to be shown in cardiomyocytes, Cav1 is crucial for mechanoprotection and 
stress resistance in several types of cells.  In 3T3 fibroblasts phosphorylation of Cav1 has been 
shown to be required for Dynamin1-mediated internalization of caveolae, with internalization 
of caveolae thought to be a crucial step in membrane repair (del Pozo et al. 2005; Corrette et 
al. 2013). Dynamin-dependent endocytosis has been shown to be crucial component of 
plasma membrane repair following membrane injury in T lymphocytes and in endothelial cells 
(Kang-Decker et al., 2007; Bernatchez et al. 2009). Similarly, endothelial caveolae have been 
shown to protect cells from membrane damage during increases in cardiac output and 
hypoxia in vivo as Cav1-deficiency shown to result in decreased membrane integrity following 
increased cardiac output and hypoxia (Cheng et al. 2015). Cav1 is also implicated in autophagy 
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in endothelial cells as Cav1 knockdown (siRNA) has been shown to result in increased 
autophagy and oxidative stress (Shiroto et al. 2014). Despite the growing evidence that Cav1 
is a prerequisite to variety of cellular functions (i.e. autophagy, membrane repair) as 
mentioned previously, the exact mechanisms of Cav1-mediated cardioprotection remain 
largely uncharacterised, perhaps owing to the popularity of Cav3.  
 
1.7.1.2 Caveolin-2 
The discovery of Caveolin-2 led to the formation of caveolin family of genes (Scherer et al. 
1996). Cav2 has 59% homology to Cav1 and 60% homology to Cav3 (Schlegel, Pestell  & Lisanti 
2000). It is hypothesised that Cav2 is the genomic precursor of Cav1 and Cav3, which are 
thought to be products of the fusion of the exon 2 in Cav2 (Williams & Lisanti 2004). Cav2 
expression parallels that of Cav1. Three isoforms of Cav2 have been identified to date, Cav2α, 
Cav2β and Cav2γ (Razani et al. 2002a). Their roles in the cell and in forming caveolae are 
unknown. However, they are differentially expressed in lung, adipose and heart tissue with 
the heart expressing Cav2γ (Razani et al. 2002b). Cav2-deficient animals do not show 
perturbations of Cav1 levels in the fat and lung issue whilst heart tissue show reduced Cav1 
(Razani et al. 2002b). This decrease in Cav1 expression may be due to decreased Cav2 
targeting of Cav1 to membrane, which forms heterooligomers together targeting to the 
plasma membrane and caveolae (Lahtinen et al. 2003). Skeletal muscles of Cav2-deficient 
mice show tubular aggregate formation, and display delayed skeletal muscle regeneration 
following injury (Schubert et al. 2007). Although not essential for the formation of caveolae, 
phosphorylation of Cav2 appears vital for attachment of Cav1-dependant caveolae as 
mutations of a single Cav2 phosphorylation residue greatly reduces attachment of caveolae 
to the plasma membrane, whilst mutations in two residues results in ablation of caveolae 
(Sowa et al. 2003).  Cav3 levels are not perturbed in Cav2-deficient mice, which retain 
caveolae in muscle type cells (Razani et al. 2002b; Schubert et al. 2007). Cav2-deficient 
animals show significantly reduced tolerance to exercise which may be attributed to lung 
abnormalities observed in Cav2-deficient phenotype (Razani et al. 2002b).  
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1.7.1.3 Caveolin-3 
Unlike Cav1 and Cav2, Cav3 has not been shown to produce multiple isotypes. Cav3 displays 
85% similarity to Cav1 whilst this is 60% to Cav2 (Schlegel, Pestell  & Lisanti 2000). Cav3 
expression is limited to muscle-type tissue with skeletal muscle and cardiomyocytes shown 
to have high expression of Cav3 (Liu et al. 2008). The importance of Cav3 in these tissues can 
be highlighted by existence of “caveolinopathies” with to date 30 known mutations in CAV3 
gene, which result in variety of clinical phenotypes (Gazzerro et al. 2010). Briefly, mutations 
in the CAV3 gene results in a variety of muscle and cardiac disorders including Limb Girdle 
Muscular Dystrophy 1-C, idiopathic persistent elevation of serum creatine kinase, inherited 
rippling muscle disease, distal myopathy and familial hypertrophic cardiomyopathy and some 
cases of sudden infant death syndrome (Gazzerro et al. 2010; Cronk et al. 2007).  
Although the Cav3 protein is a relatively small peptide composed of 151 amino acids, it 
displays several domains which assist Cav3 in membrane attachment, oligmerasation and 
protein interactions. Most notably the caveolin scaffolding domain which is conserved in both 
Cav1 and Cav3 (residues 82-101) contains the signature motif which typically bind to other 
motifs containing фXфф, ффф or фXффф, where ф is an aromatic and X an unspecified amino 
acid (Byrne, Dart & Rigden 2012).  The caveolin scaffolding domain has been shown to interact 
with GPCRs such as A1AR, RTKs such as EGFR and other cardioprotective proteins including 
eNOS (Roth & Patel 2011). The delivery of a modified Cav3 peptide composing of only the 
scaffolding domain (82-101) is cardioprotective (Young et al. 2001).  
Cardioprotective stimulus such as IPC is known to increase caveolae formation. IPC-mediated 
protection can be abolished by disruption of caveolae through cholesterol depletion via 
methly-β-cyclodextrin treatment (Horikawa et al. 2008). Cholesterol depletion has been 
shown to abrogate the cardioprotective benefits of IPC, non-GPCR and GPCR induced 
preconditioning thus highlighting caveolae as important signalling centres (Horikawa et al. 
2008; Tsutsumi et al. 2010). As previously discussed, Cav3 is expressed in cardiomyocytes and 
is responsible for caveolae formation in cardiomyocytes (Park et al. 2002). Caveolae in 
cardiomyocytes has been shown to host numerous GPCRs as well as their subunits (Head et 
al. 2005). Under basal conditions, Cav3 is particularly enriched in fractions 4-5 and to a lesser 
degree in 6-12 (Head et al. 2005). Ischaemia causes re-localisation of Cav3; 90% of Cav3 
immunoreactivity was found in fractions 4–7 in normal non-ischaemic cells while it was found 
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to be 70% of fractions 4-7 in ischaemic and non-ischaemic zones (Ballard-Croft et al. 2006). 
As caveolae membranes are primarily enriched in fractions 4-7, no change in total protein 
expression accompanied by a shift in fraction migration may represent a different localisation 
within the plasma membrane.  
Caveolae have been shown to localise GPCR such as A1AR and the δ-opioid receptor which 
are key cardioprotective receptors (see Table 1.1) (Patel et al. 2006; Lasley & Smart 2001). 
Under basal conditions, A1AR is present in Cav3 caveolae membranes, following A1AR agonism 
using CCPA treatment A1AR relocates to other plasma membrane fractions as shown by co-
immunoprecipitation and immunoelectron microscopy (Lasley et al. 2000). A1AR antagonism 
with DPCPX followed by agonism prevents the redistribution of A1AR, suggesting activation 
may be necessary to redistribute A1AR to plasma membrane fractions from caveolae (Lasley 
et al. 2000). CCPA agonism results in increased translocation of PKCδ and PKCε into Cav3 
caveolae as evidenced by immunoprecipitation and confocal microscopy (Yang, Sung & Hu 
2009). CCPA treatment co-immunoprecipitates eNOS with Cav3, which suggests eNOS may 
be a target of A1AR activation (Lasley et al. 2000). The presence of A1AR and adenosine 
deaminase within internalising vesicles “caveosomes” has been shown at certain occasions 
although their return back to cell membrane differed as adenosine deaminase recycles 
toward caveolae-like structures, whereas A1AR recycles to non-caveolae membrane regions 
(Eschriche et al. 2003). It is currently unclear whether A2AAR, A2BAR and A3AR play a role in 
caveolae-mediated signalling although they do express caveolin-binding motifs and therefore 
may potentially localise or interact with residents of caveolae and the caveolin proteins. The 
C-terminus of A1AR has been shown to interact with Cav1 via the caveolin binding motifs 
(Eschriche et al. 2003). 
Immunohistochemistry staining and co-immunoprecipitation demonstrates co-localisation of 
δ-opioid receptor and Cav3 at the plasma membrane and in a transverse pattern along the 
length of the cardiomyocyte (Patel et al. 2006). The extent of this co-localisation has been 
estimated to be approximately 78% (Patel et al. 2006). δ-opioid receptor agonism (by SNC-
121) results in a reduction in cell death but when combined with cholesterol depletion (by 
MβCD) this reduction in cell death is abrogated (Patel et al. 2006). This implicates that δ-
opioid receptor-mediated cardioprotection is reliant on caveolae. The B2 bradykinin receptor 
is another cardioprotective receptor found in caveolae. Prior to stimulation, B2 bradykinin 
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receptors display a random distribution within the plasma membrane (Haasemann et al. 
1998). Beyond the fact that Cav3 and B2 bradykinin receptors co-localise with eNOS little is 
currently known regarding the relationship of Cav3 and this receptor in cardiomyocytes 
(Quinlan et al. 2008). However, in A431 epidermoid carcinoma cells, B2 receptor agonism 
results in co-localisation with Cav1, in contrast to A1AR agonism, which causes A1AR to 
relocate to other plasma membrane fractions from the caveolae membrane (Haasemann et 
al. 1998).  
Cav3 co-localises with eNOS in the heart although it must be noted that this localisation of 
eNOS is not exclusive to caveolae as eNOS is also present in non-caveolae fractions (Massion 
et al. 2004). In addition, Cav3 does not positively regulate activity of eNOS as well as other 
NOS isoform in the heart as Cav3-overexpression does not result in increased NOS activity in 
the heart (Tsutsumi et al. 2008). Electron microscopy has identified caveolae adjacent to 
mitochondria in subsarcolemmal and interfibrillary mitochondria, which express Cav3 mostly 
in the inner mitochondrial matrix (Fridolfsson et al. 2012). IPC and sub lethal ischaemia results 
in movement of sarcolemmal caveolae into the mitochondria with this trafficking shown to 
be dependent on Gi protein (Wang et al. 2014). Cav3 overexpression results in enhanced 
resistance to calcium tolerance, greater respiratory rate during I-R and reduced ROS 
production following hypoxia-reoxygenation when compared to wild-types (Fridolfsson et al. 
2012). As a result, marked preservation of the mitochondria in the Cav3 overexpressing hearts 
may contribute to enhanced recovery of these hearts (Fridolfsson et al. 2012). The molecular 
effectors of this interaction are beginning to be unravelled. Mitochondrial proteins have been 
shown to be targets of caveolae-derived eNOS S-nitroyslation as Cav3-deficiency and MβCD 
treatment results in loss of IPC-mediated S-nitroyslation of mitochondrial preparations (Sun 
et al. 2012; Sun et al. 2015). Surprisingly, Cav3-overexpression does not increase the 
expression of the NOS isoforms, which localise in caveolae fractions, with NOS activity and 
translocation in the membrane was also unaltered (Tsutsumi et al. 2008).    
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1.7.2 Cavin Proteins 
Recently, a new family of caveolae proteins termed cavins (Cavin1, 2, 3 and 4) have been re-
classified for their roles in caveolae biogenesis and localisation. These four cavin proteins 
share varying degrees of homology relative to each other with all cavin proteins displaying 
two PEST (proline, glutamic acid, serine and threonine-rich domains) as a signature motif 
(Briand, Dugail & Le Lay 2011). It is not known what function PEST domains have in the cavin 
proteins, it is known that PEST domains can promote protein degradation through µ-calpain 
and 26S proteasome system (Shumway, Maki & Miyamoto 1999; Revert et al. 2001). All cavin 
proteins also share a conserved coiled-coil domain and a membrane association domain 
(Parton & del Pazo 2013). Unlike CAV1 and CAV2 which map on the same chromosome, all 
cavins map to distinct regions in the human chromosome, CAVİN1 maps to 17q21.2, CAVİN2 
to 2q32.3, CAVİN3 to 11p15.4 and CAVİN4 to 9q31.1. Using sequence homology search, the 
human and mouse Cavin1 protein shares strong homology (93% identical) as do the human 
and mouse Cavin2 (83%), Cavin3 (78%) and Cavin4 (89%) homologs. All cavin proteins are 
larger in size when compared to the caveolins; Cavin1 is 390 amino acids long, Cavin2 425 
amino acids, Cavin3 261 amino acids and Cavin4 364 amino acids in size (Parton & del Pozo 
2013). Whilst the caveolin proteins function as coat proteins within the caveolae, the cavins 
are thought to function as support or accessory proteins and in some cell types crucial for 
caveolae formation as discussed in their respective sections. Similar to caveolins, all members 
of the cavin family possess one or more phosphorylation sites, although it is unknown what 
impact this has on their functions (Hansen & Nichols 2010). The expression of cavin proteins 
has been shown to be uniform around the caveolae bulb as shown by immunogold labelling 
(Ludwig et al. 2013). Single-molecule fluorescence measurements suggest that cavin 
monomers consist of 50 molecules and have a limit of formation perhaps imposed by the size 
of the caveolae curvature (Gambin et al. 2014). Interestingly, caveolae regions with cavin 
proteins do not assemble under the same complexes, with Cavin1 subcomplexes not having 
Cavin2 and Cavin3 at the same time but rather containing distinct Cavin1-Cavin2 and Cavin1-
Cavin3 complexes (Gambin et al. 2014). 
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Table 1.2 Revised nomenclature for the cavin family of proteins. (Modified from Bastiani et 
al. 2009).  
Old Nomenclature New Proposed Nomenclature 
Polymerase I and transcript factor (PTRF) 
Cav-p60 
Cavin 
Cavin1 
Serum deprivation response protein (SDPR) 
Phosphatidylserine-binding protein 
Cavin2 
Protein kinase C delta binding protein (PKRCBP) 
Serum deprivation response factor-related gene 
product that binds to C-kinase (SRBC) 
Cavin3 
Muscle-restricted coiled-coil protein (MURC) Cavin4 
 
 
1.7.2.1 Cavin1 
Cavin1 was initially described as a Polymerase I and transcript release factor (PTRF) as the 
dissociation of transcripts from Polymerase I and its tertiary structure required the presence 
of this protein (Jansa et al. 1998). It was later reclassified as it was particularly enriched 
caveolae fractions and immunogold labelling showed distinct caveolae localisation (Vinten et 
al. 2005). In terms of homology, Cavin1 is 66% to Cavin2, 59% to Cavin3 and Cavin4 (Bastiani 
et al. 2009).  Cavin1 is moderately expressed in the heart with adipose and lung tissue also 
showing notable expression of Cavin1 (Liu et al. 2008). In the heart, Cavin1 is enriched in 
sucrose density fractions 4-12 whilst Cav3 is enriched in fractions 11-12 suggesting there may 
be distinct subcomplexes (See Table 1.3) (Hansen et al. 2013; Tsutsumi et al. 2008). However, 
IPC causes increased translocation of Cav3 to fractions 4-5 which are particularly enriched in 
Cavin1 protein (Hansen et al. 20130; Tsutsumi et al. 2008). Cavin1 localises with Cav3 and is 
essential for caveolae formation in some cell types while also simultaneously acting as an 
accessory protein (Liu et al. 2008; Hansen et al. 2013). Cavin1-deficiency results in loss of 
caveolae in lung epithelium, intestinal smooth muscle, endothelial cells, skeletal muscle and 
cardiomyocytes (Liu et al. 2008; Kasahara et al. 2014). Interestingly, caveolin mRNA is up-
regulated in Cavin1-deficient tissue although at the proteomic level there is a reduction in 
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expression compared to their wild-type counterparts (Liu et al. 2088). Cavin1 has been shown 
to be involved in stability of Cav1 and Cav3 as knockdown of Cavin1 results in caveolins to 
diffuse freely in the plasma membrane which eventually becomes internalized into the 
endolysosomal system for degradation (Hill et al. 2008). Similarly, rats with heart failure show 
significant Cavin1 down-regulation accompanied by Cav1 and Cav3 down-regulation, 
suggesting Cavin1 may stabilise caveolins (Norman et al. 2014). The exact role of Cavin1 in 
cardioprotection is unknown, however Cavin1 has been shown to interact with the plasma 
membrane repair proteins such as Mg53 and Smpd1 (Zhu et al. 2011; Corrette et al. 2013). 
Loss of Cavin1 via mutations or knockout approaches show a phenotype of generalised 
lipodystrophy, glucose intolerance, cardiodystrophy and muscular dystrophy (Hayashi et al. 
2009; Liu et al. 2008; Kasahara et al. 2014).  
 
1.7.2.2 Cavin2 
Cavin2 is also known as serum deprivation response protein (Sdpr) was discovered in the early 
1990s as an mRNA that was highly induced in serum starved 3T3 fibroblasts (Gustincich & 
Schneider 1993). Its relation to caveolae was discovered in the late 1990s as a protein that 
binds PKCα to caveolae (Mineo et al. 1998). Cavin2 is expressed abundantly in the heart with 
lung and fat tissue also showing notable Cavin2 expression (Hansen et al. 2013). It is currently 
unknown whether Cavin2 has isoforms. Cavin2 protein is 66% identical to Cavin1, 68% to 
Cavin3 and 57% to Cavin4 (Bastiani et al. 2009). In the heart, Cavin2 mainly fractionates in 5-
9, whilst Cav1 and Cav3 mainly in 11 and 12 (Hansen et al. 20130; Tsutsumi et al. 2008).  Unlike 
Cavin1, Cavin2-deficient animals do not show any perturbations in caveolin and cavin 
expression in the heart. Although not essential for caveolae formation in some cells, Cavin2 
is required for caveolae formation in lung endothelium but not in heart endothelium (Hansen 
et al. 2013). Similar to Cav2, Cavin2 may act as an accessory protein by controlling caveolae 
depth and targeting Cavin1 to caveolae as Cavin2 knockdown has been shown to lead to 
retention of Cavin1 in the cytoplasm and decrease in the membrane fraction in 3T3 
adipocytes (Breen et al. 2012). To support its role as an accessory protein, unlike 
overexpression of Cavin1, Cavin2 overexpression results in deformation of caveolae and 
extensive tubulation of the plasma membrane (Hansen et al. 2009). In terms of 
cardioprotection Cavin2 remains largely uncharacterised. However, it is possible that Cavin2 
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is a negative regulator of Akt and Erk1/2 signalling as Cavin2-deficient hearts display 
hypertrophy and are resistant to apoptosis induced by hypoxia and H2O2 stimulation 
(Maruyama et al. 2014).  
 
1.7.2.3 Cavin3 
Similar to Cavin2, Cavin3 was initially identified as a PKC binding protein although it was later 
associated with caveolins and caveolae (McMahon et al. 2009). Cavin3 protein is moderately 
similar to Cavin1 (59%), Cavin2 (68%) and Cavin4 (51%) (Bastiani et al. 2009). Cavin3 is 
expressed at comparable levels to the caveolins in the heart (Hansen et al. 2013). Alternative 
splicing of Cavin3 mRNA can yield up to five isoforms with sizes ranging from 14 to 31-kDa 
(McHahon et al. 2009). Cavin3 is expressed in variety of cell types such as adipocytes, brain 
and is interestingly expressed highest in the heart according to proteomic studies by others 
(Bastiani et al. 2009). In the heart, Cavin3 mainly co-fractionates in fractions 3-10 with small 
fractionation in 11-12, whilst Cav1 and Cav3 are observed mostly in 11 and 12 (Hansen et al. 
20130; Tsutsumi et al. 2008). Cavin3 appears important in cell signalling as Cavin3 can 
regulate Erk, Akt and EGFR signalling and is thought to couple these signalling components to 
intracellular transport machinery (Hernandez et al. 2013; McMahon et al. 2009). Cavin3 may 
couple caveolae signalling through budding of vesicles from caveolae termed “cavicles” using 
microtubules as absence of Cavin3 reduces cavicle trafficking (McMahon et al. 2009). 
Furthermore, recent studies suggest the existence of two caveolae types, caveolae that are 
stably associated with the cell surface and “kiss-and-run” type of caveolae which undergo 
rounds of fission and fusion (Mohan et al. 2015). The contents of these cavicles are unknown 
and should be investigated. Lung tissue deficient of Cavin3 show reduced phospho-Erk levels 
and increased phospho-Akt levels when compared to wild-type (Hernandez et al. 2013). 
Cavin3-deficieny in the heart does not alter caveolin and cavin expression (Hansen et al. 
2013). Pleiotropic phenotype is seen in Cavin3-deficient animals, most notably shortened life 
span and late onset cachexia (Hernandez et al. 2013). Cavin3-deficient hearts show 
differential expression in a variety of genes notably caveolae transcripts such as ≈1-fold 
increase in Cav1-2 and Cavin1-2 (Liu et al. 2014). The role of Cavin3 remains uncharacterised 
in cardioprotection. 
  
 
 
46 
 
1.7.2.4 Cavin4 
Cavin4 is the most recent addition to the cavin family. In both humans and mouse, Cavin4 is 
encoded by two exons that are conserved in both species yielding a Cavin4 protein that is 362 
amino acids long (Bastiani et al. 2009). Currently there is no sucrose density fractionation data 
available for Cavin4, although it is unknown Cav3 and Cavin4 co-localise together in the 
sarcolemma of myoblasts (Bastiani et al. 2009).  Cavin4 has no known splice variants. Unlike 
the other cavins, Cavin4 is a muscle specific protein expressed only in heart and muscle tissue 
(Bastiani et al. 2009). Cavin4 is thought to not be essential for caveolae formation although it 
can influence caveolae morphology as Cavin4-overexpression results in increased size of 
caveolae compared mock-treated cells (Ogata et al. 2014). Maturation of cardiomyocytes and 
cultured myocytes involves up-regulation of Cavin4 with expression of Cavin4 being shown to 
be perturbed in myopathies along with Cav3 (Ogata et al. 2008; Bastiani et al. 2009). Cavin4 
localises in caveolae and T-tubules of cardiomyocytes and also localises phospho-Erk 1/2 to 
caveolae as shown by immunoelectron labelling (Ogata et al. 2012). Cavin4 together with 
Cav3 co-localises with α1-adrenoceptor which is dependent on Cav3 as knockdown of Cav3 
does not affect the trafficking and localisation of α1-adrenoceptor, whilst Cavin4 accumulates 
in the cytosol (Ogata et al. 2014). Cavin4 overexpression in mice hearts has been shown to 
induce fibrosis, ventricular hypertrophy, atrial arrhythmias, and changes in gene expression 
including contractile-related transcripts such as Mhy7 and Serca (Ogata et al. 2008). 
Conversely, Cavin4-deficient hearts show reduced PE-induced hypertrophy when compared 
to wild-types (Ogata et al. 2012). Similar phenotypic correlations were made in a large human 
study, which identified six mutations in the human CAVİN4 gene which resulted in 
hypertrophic cardiomyopathy (Rodriguez et al. 2011). Hypoxia has been shown to increase 
Cavin4 expression in rat cardiomyocytes, which has been attributed to increased hypoxia-
induced Cavin4 promoter activity mediated by the DNA binding protein Serum Response 
Factor (Shyu et al. 2014).  
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1.7.3  Popdc Proteins 
Although not widely associated with caveolae, members of the Popeye domain-containing 
(POPDC) gene family have also shown to be crucial for caveolae formation and caveolae-
related functions (Alcalay et al. 2013). The POPDC family consists of three members: POPDC1, 
POPDC2 and POPDC3. In humans POPDC1 and POPDC3 genes are organized in tandem on 
chromosome 6q21 while POPDC2 is located on chromosome 3q13.33 (Shindler et al. 2012). 
As POPDC2 is uniquely present in vertebrates, it is hypothesised that POPDC2 appeared by 
gene duplication from POPDC3 (Shindler et al. 2012). Popdc2 and Popdc3 display 50% 
sequence identity on the protein level, while Popdc1 is only 25% similar to Popdc2 and Popdc3 
(Andree et al. 2002).  Popdc expression is restricted to muscle-type cells although some 
epithelial cells also express Popdcs such as those found central and autonomic nervous 
system and in epithelial cells of the epidermis, gastrointestinal tract, retina, lens, and cornea 
(Schindler et al. 2012). Popdcs are ≈43-kDa transmembrane proteins that contain the two 
highly conserved sequence motifs (FL/IDSPEW/F and FQVT/SL/I) crucial for cAMP binding 
(Brand et al. 2014). The amino terminus of Popdc can be N-glycosylated, which is responsible 
for the apparent molecular mass of 58-kDa of Popdc1 on PAGE gels although it has a predicted 
mass of 43-kDa (Andree et al. 2000).  
 
Figure 1.7 Proposed model for Popdc proteins which contain a transmembrane domain that 
spans the plasma membrane three times, cytoplasmic domain which contains the Popeye 
domain and dimerization domain. (Taken from Brand 2005). 
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Popdc1 (a.k.a. Blood vessel/epicardial substance) is predicted to have two isoforms, Popdc2 
with five, whilst the existence of Popdc3 isoforms are uncharacterised (Breher et al. 2004). 
Popdc1 is 359 amino acids long, Popdc2 is 367 amino acids and Popdc3 is 292 amino acids 
(Andree et al. 2000). Similar to caveolins, Popdcs can homodimerise together in complexes 
97-212 kDa in size (Knight, Bader & Backstrom 2003). Dimerisation of Popdc1 involves lysines 
272 and 273 at the carboxylic terminal (Kawaguchi et al. 2008). Currently, very little is known 
about the exact physiological function of Popdcs. They have been implicated in variety of 
processes such as chronotropic response, cell regeneration and regulation of membrane 
processes (Froese et al. 2012; Hager et al. 2010; Alcalay et al. 2013). In the heart Popdcs are 
thought to maintain cardiac pace making as Popdc1 and Popdc2 disruption results in stress-
induced sinus node dysfunction, resulting in chronotropic incompetence and long sinus 
pauses (Froese et al. 2012). It is thought that the arrhythmias associated with Popdc 
disruption is due to loss of TREK-1 potassium channel activity, which co-localises with Popdc1 
and Popdc2 (Froese et al. 2012). Popdcs are also involved in membrane processes such as 
membrane trafficking and caveolae formation. Popdc1 co-immunoprecipitates with VAMP3, 
which is a component VAMP-SNARE complex involved in the docking and/or fusion of 
caveolae with the target membrane (Hager et al. 2010; Mehta & Malik 2006). VAMPs are 
required for caveolae-mediated trafficking as VAMP inhibition results in accumulation of 
caveolae ligands as well as reduced export of natriuretic peptide (McIntosh & Schnitzer 1999; 
Ferlito et al. 2010). Popdc1 has been shown to influence caveolae formation as Popdc1-
deficient cardiomyocytes display reduced size and number of caveolae (Alcalay et al. 2013). 
To date, whether there is any role of Popdc2 and Podpc3 in caveolae biogenesis remain 
uncharacterised. 
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         BF           non-BF   
Fraction # 1 2 3 4 5 6 7 8 9 10 11 12 
Cav1     + + + + + + + + 
Cav2 nd nd nd nd nd nd nd nd nd nd nd nd 
Cav3          + + + 
Cavin1   + + + + + + + + + + 
Cavin2     + + + + +    
Cavin3   + + + + + + + + +  
Cavin4 nd nd nd nd nd nd nd nd nd nd nd nd 
Popdc1     + + + + + + + + 
Popdc2 nd nd nd nd nd nd nd nd nd nd nd nd 
Popdc3 nd nd nd nd nd nd nd nd nd nd nd nd 
Table 1.3 Sucrose density sedimentation of caveolins, cavins and Popdcs. Compiled from Tsutsumi et al. (2008); Hansen et al. (2013); Alcalay et 
al. (2013). BF= Buoyant Fraction, non-BF= Non-Buoyant Fraction, nd = not determined.
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1.8 Hypothesis & Aims 
As previously discussed, caveolae and its coat proteins have been shown to be required for 
cardioprotective effects of ischaemic and pharmacological preconditioning. However, the 
aged heart displays refractoriness to these protective stimuli with the expression of caveolar 
coat proteins being poorly characterised in the aged hearts, which may partially be 
responsible for the loss of the efficacy of these stimuli in these hearts. Furthermore, there are 
sex-related differences in cardioprotection as shown by epidemiological and experimental 
studies, which implicates sex-related differences in Cav3. The age and sex-dependant 
expression of caveolins, cavins and Popdcs remain largely uncharacterised which as discussed 
previously contribute to caveolar biogenesis and signalling. For the ageing model, we 
employed a time-course analysis of 8-, 16-, 32- and 48-week old normoxic and post-ischaemic 
hearts which have previously been shown to display age-related loss of cardioprotection at 
48-weeks whilst most studies have shown this for >74-week old hearts (Willems et al. 2006). 
The objectives of this dissertation were to elucidate the expression of caveolae structural 
protein caveolins, cavins and Popdcs in cardiac ageing. Thus the expressions of caveolins, 
cavins and Popdc transcripts in the ageing male and female hearts was analysed in Chapters 
3 and 4, respectively.  
The objective of Chapter 5 was to further investigate the involvement of Cav3, major 
structural protein of caveolae, in the involvement of I-R tolerance using in vitro methods. The 
objective of Chapter 6 was to elucidate the expression of several candidate miRNAs involved 
in ageing/senescence and I-R as miRNA have been shown to display differential expression 
with ageing and I-R. Furthermore, using bioinformatics prediction, miRNA that were predicted 
to target the crucial caveolae forming transcripts Cav3 and Cavin1 were analysed in the ageing 
male normoxic and post-ischaemic hearts. The objectives of Chapter 7 were to investigate the 
expression of several plasma membrane repair proteins and proteases which remain largely 
uncharacterised in the ageing male heart. Plasma membrane-repair mechanisms have been 
shown to be reliant on caveolae and their coat proteins for normal trafficking and targeting 
to sites of injury. Chapter 8 presents an overall summary of the key findings within the 
dissertations, including the implication of the results and future directions to better 
understand the role of caveolae coat proteins. 
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2. Chapter Two 
Materials and Methods 
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2.1 Samples 
2.1.1 Perfused mouse heart model 
All hearts used in this study were obtained from a cardiac biobank established from male and 
female wild-type C57BL/6 mice. The collection of these hearts were previously approved by 
and performed in accordance with the guidelines of the Animal Ethics Committee of Griffith 
University, which is accredited by the Queensland Government, Department of Primary 
Industries and Fisheries under the guidelines of “The Animal Care and Protection Act 2001, 
Section 757”. Hearts were acquired from male and female C57BL/6 mice aged 8 (young), 16 
(young-mature), 32 (adult) and 48-week old (middle-aged) (n=8-12/group). We chose these 
timepoints as Willems et al. (2005) has shown significant sex and age-dependant changes in 
oncosis and contractile dysfunction are present in these time points well before the aged (74-
week old) phenotype.  This type of ageing model has been adopted by other investigators to 
understand pathophysiology of variety of diseases including I-R  and have a high degree of 
relevance to humans (Vanhooren et al. Libert 2013; Willems et al. 2005). Despite these 
significant changes, the molecular basis of I-R injury remains largely uncharacterised for both 
males and females. 
Mice were anesthetized with 60 mg/kg sodium pentobarbital and hearts excised. The details 
of the isolated heart perfusion model and the I-R protocols employed are outlined in detail in 
prior works (Headrick et al. 2003; Peart et al. 2007; Willems et al. 2006).  Briefly, hearts were 
subjected to normoxic perfusion or 20 minutes of global normothermic ischaemia and 60 
minutes of reperfusion. All hearts were immediately stored in RNAlater® solution (Life 
Technologies, Carlsbad, CA, USA) and stored at 4°C overnight. For long-term biobanking, 
hearts were transferred to -80°C storage to protect RNA integrity and expression levels prior 
to ventricular dissection and RNA and protein extraction. Coronary venous effluent was 
sampled during the 60-minute post-ischaemic period. Effluent was stored at 4°C and assayed 
the following day for lactate dehydrogenase (LDH) activity using the Cytotox 96® Non-
radioactive Cytotoxicity Assay (Promega, Madison, WI, USA).  
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2.1.2 HL-1 cardiomyocyte cell culture 
Cells of the murine atrial-derived cardiac cell line HL-1 were a kind gift from Professor William 
C. Claycomb (Louisiana State University, Baton Rouge, LA). Cells were grown in culture vessels 
pre-coated with 0.00125% fibronectin in 0.02% gelatin and maintained in Claycomb medium 
(Sigma Aldrich, St. Louise, MO, USA) supplemented with 10% foetal bovine serum (Life 
Technologies, Carlsbad, CA, USA), 0.1 mM norepinephrine, 2 mM L-glutamine, 100 U/mL 
penicillin/streptomycin, and 0.25 µg/mL amphotericin B. Cells were cultured at 37°C in a 
humidified atmosphere of 5% CO2 and 95% air. Media was replaced every second day and 
cells passaged at >80% confluency when required using 0.25% Trypsin-EDTA (Life 
Technologies). For transfection experiments, cells were passaged during logarithmic growth 
(~50%). Cells were screened every two months for mycoplasma contamination using the 
MycoAlert™ Mycoplasma Detection Kit (Lonza, Basel, Switzerland). Passaged cells were 
continually monitored for viability using Countess cell counting slides (Thermo-Fisher, 
Waltham, MA, USA)).  
 
2.1.3 3T3 fibroblast cell culture 
3T3 mouse embryo fibroblasts (CRL-1658) were obtained from the ATCC (Manassas, VA, USA) 
and were grown in fully supplemented DMEM with 10% foetal bovine serum, 2 mM L-
glutamine, 100 U/mL penicillin/streptomycin, and 0.25 µg/ amphotericin B (Life 
Technologies). Cells were cultured at 37°C in a humidified atmosphere of 5% CO2 and 95% air. 
Media was replaced every second day and cells passaged when required using 0.25% Trypsin-
EDTA (Life Technologies). Cells were screened every two months for mycoplasma 
contamination using the MycoAlert™ Mycoplasma Detection Kit (Lonza, Basel, Switzerland). 
Passaged cells were continually monitored for viability using Countess cell counting slides 
(Thermo-Fisher).  
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2.2 RNA isolation and cDNA synthesis 
 
2.2.1 RNA isolation from left ventricular tissue 
RNAlater® stabilised whole hearts were removed from -80°C storage and allowed to thaw on 
ice. Atrial and vascular tissue was removed with a scalpel and left ventricular myocardium 
dissected from each heart. Each left ventricle was dissected into 12-16 pieces, of which 3-4 
pieces were used for RNA isolation. The remaining left ventricular pieces were returned to 
RNAlater® solution and stored at -80°C. The pieces of left ventricular tissue were syringe 
homogenised in 1 mL TRIzol© reagent (Life Technologies, Carlsbad, CA, USA) until it passed 
through an 18- then 21-gauge needle, total RNA was then isolated according to 
manufacturer’s guidelines. Total RNA was further purified using RNeasy spin columns 
(Qiagen, Limburg, Netherlands). The RNA yield and purity were determined using a NanoDrop 
ND-1000 (Thermo Fisher Scientific) and diluted to a final concentration of 50 ng/µL. RNA 
integrity was assessed using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), 
with RNA integrity (RIN) scores ≥8.0 for each sample (Figure 2.1). Total RNA was stored at -
80°C prior to cDNA synthesis. Total RNA was isolated from HL-1 and 3T3 cells in a similar 
manner using 1 X 106 cells per isolation. For cDNA synthesis 500 ng of total RNA was reverse 
transcribed using the Superscript III First Strand cDNA Synthesis System (Life Technologies) 
according to manufacturer’s protocols. Synthesised cDNA was diluted with nuclease free 
water 1:20 and stored at -20°C before use. 
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Figure 2.1 RNA integrity of total RNA isolated from murine ventricular tissue A) 
Representative digital gel image demonstrating 28S and 18S rRNA bands from total RNA 
isolated from 12 different hearts (Lanes 1-12); RNA size ladder (L). B) Representative 
electropherogram demonstrating good quality RNA showing distinct 28S and 18S rRNA peaks 
(RIN=8.7). 
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2.3 Reverse Transcription-quantitative PCR 
 
2.3.1 RT-qPCR 
All RT-qPCR studies were conducted using “The Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments (MIQE)” guidelines as outlined by Bustin and 
colleges (2009). By following MIQE guidelines more reliable and reproducible qPCR results are 
obtained. Two-step RT-qPCR was performed on a CFX96 Real-Time PCR Detection System 
(Bio-Rad, Hercules, CA, USA) utilising SYBR Green I chemistry. PCR primers (Table 2.1) were 
designed with PerlPrimer software (Marshall 2004) according to standard guidelines (Ashton 
& Headrick 2007). Briefly, primer pairs for each transcript were designed to have a target 
annealing temperature of 61°C, span an intron/exon boundary and generate an amplicon 
between 75-150bp in size. The final reaction volume (10 µL) included 1X iQ SYBR Green 
Supermix (Bio-Rad), 100nM of each primer and 5 µL of diluted (1:20) cDNA. Optimal qPCR 
cycling conditions consisted of an initial denaturation at 95°C for 3 minutes followed by 40 
cycles of 95°C for 15 seconds and 61°C for 60 seconds. After the final PCR cycle, reactions 
underwent melt curve analysis to detect non-specific amplicons. All reactions were 
performed in triplicate with each plate containing an equal number of samples from each 
group, a calibrator control derived from a pool of all cDNA samples, and a no template control 
(NTC). PCR amplification efficiencies (90-110%) for each primer pair were calculated using a 
4-log serial dilution of the calibrator sample. PCR data were analysed using CFX Manager v2.0 
(Bio-Rad, Hercules, CA). Following automatic baseline correction, the threshold level was set 
during the geometric phase of PCR amplification for quantitative measurement (Figure 2.2). 
The calibrator sample was used to normalise inter-assay variations, with the threshold 
coefficient of variance for intra- and inter-assay replicates <1% and <5%, respectively. 
Normalised expression (Cq) was calculated, with expression normalised to reference gene 
levels (as determined in Section 2.3.2) and the calibrator control then log2 transformed. 
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Table 2.1 RT-qPCR primer sequences. 
Gene name 
Gene 
symbol 
NCBI 
GeneID 
Forward primer (5'-3') Reverse primer (5'-3') 
Reference Genes 
Actin, beta Actb 11461 ATGAGCTGCCTGACGGCCAGGTCATC TGGTACCACCAGACAGCACTGTGTTG 
Glyceraldehyde-3-phosphate 
dehydrogenase 
Gapdh 14433 TGACGTGCCGCCTGGAGAAA AGTGTAGCCCAAGATGCCCTTCAG 
Phosphoglycerate kinase 1 Pgk1 18655 AACAACATGGAGATTGGCACATC AGGCAAGGTAATCTTCACACCATTT 
Peptidylprolyl isomerase A Ppia 268373 CGCGTCTCCTTCGAGCTGTTTG TGTAAAGTCACCACCCTGGCACAT 
Ribosomal protein L13A Rpl13a 22121 ATCTTGAGGTTACGGAAACAG TGAGGCAAACAGTCTTTATTGG 
Sex-validation 
Ubiquitously transcribed 
tetratricopeptide repeat 
gene, Y chromosome 
Uty 22290 CGAAATTCAGTTTCATATTGCTCACT TGATGGCAAGCTTTCAATCTGT 
Inactive X specific transcript Xist 213742 ATTGTAGCATACGCATACTTTCAAAGTAT TGTTTGAACTCCCAGACCTCTTC 
Caveolae-related 
Caveolin 1 Cav1 12389 AGGTGACTGAGAAGCAAGTG TCAAAGTCAATCTTGACCACG 
Caveolin 2 Cav2 12390 TTGACTACGCAGATCCTGAG GAAGCCTAGCTTGAGATGAG 
Caveolin 3 Cav3 12391 GGATCTGGAAGCTCGGA AATCTACCTTCACAATGTCCTC 
Cavin 1 Cavin1 19285 GATCTACCAGGATGAAGTCAAGC CTCGTCACCCTCCTTCTCAG 
Cavin 2 Cavin2 20324 GCTCATCTTCCAGGAAGAAAGTG AGGGACTTGTTCTCATCAGC 
Cavin 3 Cavin3 109042 TGCTCTTCAAGGAGGAGACTG CATCCTCTGGCTGATCTGGG 
Cavin 4 Cavin4 68016 GTAATCTTCCAGGAGGACATTCC CCGAGGAGAGCTCTATTGGG 
Popeye domain containing 1 Popdc1 23828 GATGTTGTCTCTAGGATGTACCC ATATTGATACCCAAGAACACCGAG 
Popeye domain containing 2 Popdc2 64082 TTTGAGGAGGTTTCAGGATCAG GAGGACGTCTAGAGGGTAGG 
Popeye domain containing 3 Popdc3 78977 GCTCTGAAGTGGTTAGTTTGG ACTGTCACTCTGATTCTTCCTG 
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Figure 2.2 RT-qPCR data.  A) Amplification plots (semi-log) of Cavin1 (red) and the Pgk1 (blue) 
reference gene. The threshold (green line) is set during the exponential phase of all 
amplification plots. B) Melt-curve analysis of Cavin1 (red) and the Pgk1 (blue) reference gene. 
Data shows single peaks for each curve indicating the presence of a single specific amplicon. 
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2.3.2 Reference Gene Selection 
Due to its practical and conceptual simplicity, qPCR has become the gold standard approach 
for quantifying gene expression. However, despite raising awareness of potential pitfalls of 
qPCR, use of experimentally validated reference genes for data normalisation is still widely 
disregarded (Gutierrez et al. 2008). Using the same general RT-qPCR parameters described in 
Section 2.3.1, five additional genes (Actb, Gapdh, Pgk1, Ppi and Rpl13a) were assessed using 
Bio-Rad CFX Manager Target Stability analysis to determine their usability as reference genes 
in the ageing male and female hearts. This statistical approach is an iterative test of pairwise 
variation (Vandesompele et al. 2002). Two putative reference genes were analysed per plate 
and biological replicates were split into two plates with the results merged using a common 
calibrator sample. The most stably expressed reference gene displays a stability value (M 
value) <1.0 for homogenous samples (Vandesompele et al. 2002).  Pgk1 was chosen as the 
reference gene for all experimental groups as it was found to be stably expressed (M <1.0) 
across all age groups (8, 16, 32 and 48-week), treatments (normoxic and I-R) and sex (male 
and female). 
 
2.4 Reference Gene Stability Across Treatment Groups and Sex 
To assess the stability of the reference gene between treatment groups (normoxic versus I-R) 
and sex (male versus female) Pgk1 transcript expression was further analysed in the baseline 
8-week old hearts (n=6/group). Briefly, equal quantities of total RNA (500ng) was used to 
synthesize cDNA and following RT-qPCR, Pgk1 expression was normalised to the geometric 
mean of two (Rpl13a and Ppia) reference genes. These comparisons were replicated in three 
separate experiments to demonstrate stability and reproducibility. As shown in Figure 2.3, 
differences in Pgk1 reference gene expression was negligible (1.08-fold reduction) in male 
normoxic and I-R 8-week old baseline hearts. In addition, Pgk1 expression was stable (1.05-
fold increase) in female normoxic and I-R baseline hearts. However, the minor differences in 
reference gene expression were normalised for to ensure small additive changes did not 
contribute to the between treatment group analysis. However, comparisons between the 
sexes showed a dramatic difference in reference gene expression, with female hearts 
demonstrating a 3.26-fold reduction in Pgk1 expression levels relative to male matched 
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hearts. This large variation in reference gene expression therefore prohibits direct statistical 
comparisons between the sexes, but does enable the direct comparison (following 
normalisation) of the normoxic and I-R groups within the same sex.  
 
 
Figure 2.3 Reference gene stability assessment relative to post-ischaemia and/or sex 
differences in the murine heart. Shown are boxplots detailing gene expression changes 
determined by RT-qPCR for the Pgk1 reference gene in the male and female 8-week old heart 
following normoxic or post-ischaemic stress (n=6/group; triplicated). Boxes indicate 
interquartile range (25%-75%) with the horizontal bar within each box indicating the median. The 
whiskers show the minimum and maximum values. *P < 0.05 vs. male hearts. 
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2.4.1 Sex Validation 
Due to the large number of mice used and their difference stages of development we chose 
to validate their sex to control for incorrect sex-typing. Each sample was assessed for 
expression of Uty and Xist, which are highly expressed in males and females respectively. The 
Uty gene is located on the Y chromosome, without an X chromosome homolog and is thus 
specific to males. Whilst the Xist RNA gene is located on the X chromosome and is a major 
effector of the X inactivation process specific to females. RT-qPCR was carried out according 
to Section 2.3.1 using Pgk1 as the reference gene. The Cq values (e.g. Uty Cq – Pgk1 Cq) of 
each gene were plotted on a scatterplot showing that each sample clusters either as male 
(Uty expression) or female (Xist expression) as shown in Figure 2.4. 
 
 
Figure 2.4 RT-qPCR sex typing of mice using Uty and Xist transcript expression. Each heart 
clustered specifically to one of two groups confirming the sex of the mice. 
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2.5 Western Immunoblotting 
Immunoblot analysis was employed to confirm myocardial expression of transcripts 
implicated to change in expression in ageing normoxic and ischaemic hearts. Antibodies for 
Gapdh, β-actin, Cav3 and Cavin1 were investigated. β-actin (rabbit polyclonal) was obtained 
from Cell Signalling (Danvers, MA, USA), Cav3 (mouse monoclonal) were obtained from Santa 
Cruz Biotechnology (Dallas, TX, USA), and Gapdh (rabbit polyclonal) and Cavin1 (rabbit 
polyclonal) were obtained from Abcam (Cambridge, MA, USA). Briefly, left ventricle tissue 
(n=6/group) were homogenised using an Ultra Turrax T25a rotor-homogeniser (IKA, Cologne, 
Germany) in RIPA buffer (Sigma-Aldrich, St Louis, MO) containing protease inhibitors (Sigma-
Aldrich, St Louis, MO). Protein content for whole-cell extracts was determined using a Pierce 
BCA kit (Thermo Fisher, Waltham, MA). Firstly, Gapdh and β-actin protein expression in 
normoxic and ischaemic aging hearts were analysed for expression stability. β-actin was 
shown to be more stable in expression relative to Gapdh in normoxic and post-ischaemic 
groups for both sexes and was chosen as the loading control. Samples (=6/group, singlicate) 
were prepared in Laemmli buffer containing 30 μg of protein from whole-cell fractions and 
loaded onto 12% acrylamide gels with equal loading confirmed by Ponceau staining. 
Electrophoresis was carried out at 75 V for 90 minutes. Protein was transferred to an 
Immobilon®-FL PVDF membrane (Merck Millipore, Billerica, MA, USA) and blocked in Licor 
blocking buffer for 120 minutes (Licor, Lincoln, NE, USA). Membranes were then incubated 
with primary antibody (Cav3, 1:1,500; Cavin1, 1:2000, β-Actin: 1:1,500; Gapdh, 1:2000) 
overnight at 4C. Dual coloured labelling was performed using fluorescently labelled 
secondary antibodies. Briefly, membranes were incubated in a 1:20,000 dilution of IRDye® 
680RD donkey anti-rabbit IgG and IRDye® 800CW goat anti-mouse IgG (Licor) secondary 
antibodies for 120 minutes with gentle agitation. The labelled membranes were washed with 
TBS and TBST and scanned using an ODYSSEY® CLx infrared scanner (Licor). Densitometric 
analysis was performed using Image Studio™ 5.0 (Licor) with the protein of interest (Cavin1 
or Cav3) normalised to the stably expressed loading control (Figure 2.5). Data were then log2 
transformed relative to 8-week old heart expression. 
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Figure 2.5 Representative image of reference protein expression stability in ageing male post-
ischaemic hearts. Gapdh showed induction with ageing although this was not statistically 
significant (P= 0.11). β-actin was found to be stably expressed in normoxic and post-ischaemic 
hearts in males and females with representative β-actin image shown in normoxic young (8-
week) and middle aged (48-week old) male hearts (n= 6-7/ group).  
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2.6 Statistical Analyses 
Statistical analysis was performed using Prism 6.0 software (GraphPad, California, USA). Data 
was first assessed for equal variance using Bartlett’s test for equal variances. Parametric data 
comparisons between more than two groups were made via an analysis of variance (ANOVA), 
with Tukey’s post-hoc test applied where differences were detected for gene expression 
analysis. For data that was determined to be non-parametric a Kruskal-Wallis test was 
applied. For pair-wise comparisons a two-tailed Student’s t-test was employed for Western 
blotting. For comparisons between age-matched normoxic vs. post-ischaemic gene 
expression data and age-matched male vs. female recovery and LDH release, a two-way 
ANOVA was employed using Prism 6.0 (Graphpad). For comparisons within normoxic and I-R 
hearts, Tukey’s post-hoc test was applied where differences were detected for gene 
expression analysis. For age-matched comparisons, Sidak’s post-hoc test applied where 
differences were detected for gene expression analysis. Non-parametric data was analysed 
for significance using a Mann-Whitney test. Statistical significance was accepted for P <0.05.  
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3. Chapter Three 
Effects of age on caveolae-related transcript expression in 
normoxic and post-ischaemic male hearts 
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3.1 INTRODUCTION 
Ageing is associated with complex changes at both physiological and molecular levels. The 
ageing heart in both humans and animal models has been shown to display reduced tolerance 
to I-R (Willems et al. 2005; Boengler, Schulz & Heusch 2009). This is evidenced by a loss of 
functional recovery and enhanced cell death, as shown by an increase in lactate 
dehydrogenase (LDH) efflux (Willems et al. 2005; Peart et al. 2014) or markers such as 
tetrazolium chloride staining (Schulman, Latchman & Yellon 2001). Furthermore, approaches 
such as IPC and pharmacological preconditioning which protect the young heart from I-R 
injury appear ineffective in the aged myocardium (Peart et al. 2014; Boengler, Schulz & 
Heusch 2009). The molecular mechanisms behind the loss of cardioprotection in the ageing 
myocardium may include changes in sensitivity of GPCR-mediated signalling, changes in 
control of mitochondrial permeability, altered autophagy, and other mechanisms as 
discussed in Section 1.6.5.  
Recently, specialised micro-domains within the plasma membrane termed caveolae have 
been shown to compartmentalise and concentrate various classes of signalling molecules, 
including important mediators of cardioprotection such as receptor tyrosine kinases, GPCRs 
and their subunits (Insel et al. 2005). It is hypothesised that ischaemic stress and 
cardioprotective interventions generate autacoids (e.g. adenosine, opioids, bradykinin) which 
recruit a number of signalling pathways through activation of their respective receptors and 
subunits, which are co-localised and enriched in caveolae (Hausenloy & Yellon 2010). 
Furthermore, cardioprotective stimuli such as IPC have been shown to increase caveolae 
formation (Tsutsumi et al. 2008). Conversely pharmacological disruption of caveolae impairs 
ischaemic tolerance in cultured cardiomyocytes, similar to results from sI-R in primary 
cardiomyocytes, whilst Cav3-deficienct hearts exhibit impaired ischaemic tolerance (See Hoe 
et al. 2014; Horikawa et al. 2008). The chief structural proteins of caveolae are the caveolins, 
a family consisting of three members: Caveolin-1, Caveolin-2 and Caveolin-3, encoded by 
CAV1, CAV2 and CAV3 genes, respectively (Williams & Lisanti 2004). These proteins form 
oligomers and associate with cholesterol and sphingolipids in the plasma membrane, leading 
to the formation of functional caveolae (Scherer et al. 1997). Whilst Cav1 and Cav2 are 
ubiquitously co-expressed, Cav3 is muscle-specific and responsible for caveolae formation in 
cardiomyocytes, as confirmed in double Cav1 and Cav3-deficient models (Park et al. 2002).  
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In terms of ischaemic tolerance, both Cav1 and Cav3 appear to contribute to cardioprotective 
responses. More specifically, Cav1 peptide has been shown to be cardioprotective while Cav1-
deficiency results in attenuated cardioprotection (Young, Ikeda & Lefer 2001; Jasmin et al. 
2011). Cardiac-specific overexpression of Cav3 results in enhanced ischaemic tolerance 
characterised by enhanced recovery and reduced cell death; conversely Cav3-deficiency 
results in ablation of this protective phenotype (Tsutsumi et al. 2011). The role of Cav2 
remains uncharacterised in the heart, although it has been shown to act as an accessory 
protein by making caveolae more uniform, structurally deeper and more abundant (Fujimoto 
et al. 2000).  
More recently other protein families including the cavins (Cavin1,-2,-3 and -4) and the Popeye 
domain-containing (Popdc1, Popdc2, Popdc3) proteins have been shown to be localised in 
caveolae and contribute to caveolae formation and morphology in a tissue-dependant 
manner (Bastiani et al. 2009; Alcalay et al. 2013). With regards to these two gene families, 
thus far only Cavin1 and Popdc1 have been shown to influence caveolae formation, with 
deficiency in Cavin1 and Popdc1 resulting in reductions of caveolae in the heart (Kasahara et 
al. 2014; Alcalay et al. 2013). At present little is known regarding their expression and 
functional roles in the heart.  
In terms of cardioprotection, Cavin1 has been shown to anchor Trim72, a protein critical for 
membrane repair following I-R (Zhu et al. 2011; Wang et al. 2010). Knockdown of Cavin2- has 
been shown to result in hyper activation of the Akt signalling pathway via Phosphatase and 
tensin homolog attenuation at the sarcolemma (Murayama et al. 2014). In addition, Cavin2 
may target Cavin1 recruitment to the plasma membrane and help stabilise caveolae 
invaginations (Hansen et al. 2009). Cavin3 and Cavin4 are not crucial for caveolae formation 
in the heart (Hansen et al. 2013; Ogata et al. 2014). Cavin4 has been shown to be up-regulated 
in response to hypoxia, and is associated with hypoxia-induced hypertrophy in 
cardiomyocytes (Shyu et al. 2014). Cavin4 expression is perturbed in rippling muscle diseases 
concomitant with loss of Cav3 (Bastiani et al. 2009). 
With regards to the Popdc family, Popdc1-deficient mice demonstrate a loss of 
pharmacological preconditioning and impaired recovery following I-R, perhaps due to 
significantly reduced caveolae formation in these hearts (Alcalay et al. 2013), whilst a role for 
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Popdc2 remains uncharacterised in the heart. Very little is known about the role of Popdc2 in 
the heart except that it is essential for normal heart formation and is enriched in the cardiac 
pacemaker system, whilst the function of Popdc3 remains un-investigated (Kirchmaier et al. 
2012; Schindler et al. 2012). It is likely that Popdcs have critical roles in the heart as differential 
expression of Popdcs has been observed in the context of heart failure (Gingold-Belfer et al. 
2011).  
Surprisingly little is presently known about these caveolae-related proteins in the ageing 
myocardium. However, Cav3 and caveolae appear to be reduced in the aged heart in 
association with a reduced efficacy of pharmacological and ischaeamic preconditioning (Peart 
et al. 2014). The expression pattern of other caveolae-associated proteins remains 
uncharacterised in the ageing heart. Thus, we sought to investigate the expression of 
caveolin, cavins and the Popdc families in the ageing normoxic and post-ischaemic male heart. 
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3.2 METHODS 
 
Langendorff perfusions were carried out on hearts (n=8-10/per group) from 8 (young-adult), 
16 (mature-adult), 32 (adult) and 48 weeks old (middle-aged) male mice as previously 
described in Section 2.1.1. Briefly, 20 min of global normothermic ischaemia was followed by 
60 min of reperfusion whilst normoxic hearts were maintained under aerobic perfusion for 
80 min. 
RNA isolation and cDNA synthesis from normoxic and post-ischaemic left ventricular tissue 
was carried out as described in Section 2.2.1. RT-qPCR was used to analyse expression of 
caveolin, cavin and Popdc transcripts in ageing hearts as detailed in Section 2.3.1. Selection 
of a stable reference gene was carried out according to Section 2.3.2. Normalisation of post-
ischaemic gene expression to normoxia was carried out according to Section 2.4.  
Western immunoblotting was carried to confirm validate the relationship between transcript 
and protein expression changes for Cav3 and Cavin1 according to Section 2.5.  
Statistical analysis was conducted as detailed in Section 2.6, with statistical significance 
accepted for P<0.05.  
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3.3 RESULTS AND DISCUSSION 
3.3.1 Analysis of mRNA abundance in left ventricular tissue and 3T3 and HL-1 cell lines 
The heart is a heterogeneous tissue containing numerous cell types including cardiomyocytes, 
fibroblasts, vascular smooth muscle and endothelium, and varied immune cells. Our initial 
goal was to elucidate the relative abundance of transcripts in left ventricular cardiac tissue 
(from normoxic 8-week old male hearts) and compare these profiles to those for both 
cultured HL-1 cardiomyocytes and 3T3 fibroblasts. Expression values were normalised to Pgk1 
as a reference gene, which was expressed at similar levels (<0.5 Cq difference) within left 
ventricular tissue, HL-1 cardiomyocytes and 3T3 fibroblasts.  
As shown in Figure 3.1 all caveolin transcripts are expressed in cardiac tissue. Cav1 was found 
in similar abundance in 3T3 and HL-1 cells. Interestingly, Cav2 expression was low in both HL-
1 and 3T3 cells when compared to left ventricular tissue. Cav3 expression was modest in HL-
1 cardiomyocytes and was not detected in 3T3 fibroblasts, confirming the muscle-specific 
expression of Cav3. 
Similar to caveolins, all cavin transcripts were modestly expressed in the heart relative to Pgk1 
(>40%). Cavin3 was the most abundant cavin in the heart. Relative expression in this study 
resembles the protein expression of caveolin and cavin for whole heart lysates in prior studies 
(Bastiani et al. 2009; Hansen et al. 2013). Similar to the heart, HL-1 cardiomyocytes and 3T3 
cells showed comparable Cavin1 and Cavin2 expression. Cavin3 cardiac expression appears 
to be predominantly from cardiomyocytes rather than fibroblasts. Levels of Cavin4 expression 
in HL-1 cardiomyocytes and 3T3 fibroblasts were notably less than in left ventricular tissue. 
This difference may reflect major contributions from cells other than cardiomyocytes and 
fibroblasts in the whole myocardial signal. Alternatively, the difference may reflect changes 
in expression due to cell line immortalisation, or their original tissue source. 
Cardiac tissue and HL-1 cardiomyocytes showed moderate Popdc1 expression, with 
expression of Popdc2 the most abundant (90% relative to Pgk1) transcript of those 
investigated. This is consistent with high expression of Popdc2 reported in other studies 
(Andree et al. 2000). Cultured fibroblasts did not express Popdc1 and Popdc2, further 
confirming the muscle-specific expression of Popdc transcripts. Although Popdc3 was 
expressed in the heart, there was no detectable Popdc3 expression in cultured 
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cardiomyocytes or fibroblasts. It is possible that Popdc3 is selectively expressed in ventricular 
but not in atrial cardiomyocytes (e.g. HL-1 cells), with such differential expression previously 
reported by others (Barth et al. 2005). In addition, Popdc3 could potentially be missing in the 
HL-1 cardiomyocytes which has been documented for beta-tubulin II - present in adult 
primary atrial but not in HL-1 cells (Kuznetsov et al. 2014). 
 
 
Figure 3.1 Relative expression of Caveolin, Cavin and Popdc transcripts in left ventricle, HL-
1 cardiomyocytes and 3T3 fibroblasts. The dot-plot presents relative Caveolin, Cavin and 
Popdc gene expression levels in left ventricular tissue (8-week old male mice), cultured HL-1 
cardiomyocytes and cultured 3T3 fibroblasts. Data presented as means relative to Pgk1 
expression.  (n=3/group).  
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3.3.2 Age dependence of myocardial ischaemia-reperfusion injury in males 
The average life-span amounted males are 125 weeks for males and for females 113 weeks 
with no animals normally living beyond past 140 weeks of age (Kunstyr & Leuenberger 1975). 
The time points of adult and aged mice can vary between studies as it is difficult to define 
what characteristics should constitute this. Generally, the 8-week and 16-week old mice have 
been defined as the young and young-mature (respectively) as they reach sexual maturity at 
this time point. The 32-week old is defined as the mature adult which exhibits some age-
related changes, whilst 48-week old is defined as the middle-aged as it approaches 
reproductive senescence which occurs past 52-week old. In terms of human years, the 8-week 
old mice represent ≤20 years old, 16-week with ≈20-years old, 32-week with 27-years old and 
48-week with 38-years old as suggested by Jackson Laboratory for C57/Bl6 mice (Jackson 
Laboratory 2011).  
Functional resistance to ischaemia-reperfusion was assessed by measuring recoveries of left 
ventricular developed pressure in perfused hearts. As shown in Figure 3.2A an age-related 
reduction in functional recovery became apparent in 32 and 48-week old hearts. Additionally, 
post-ischaemic LDH release was enhanced in 48-week old hearts, indicating an increase in cell 
damage and death (Figure 3.2B). 
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Figure 3.2 Myocardial I-R injury in the ageing male heart. Data are shown for: A) left 
ventricular developed pressure; B) cell death following 20 min ischaemia and 60 min 
reperfusion in isolated hearts from 8, 16, 32 and 48-week old male mice Data are expressed 
as mean±SEM; *P < 0.05 vs. 8-week old group. (n=8-12/group). 
 
3.3.3 Reference Gene Stability Analysis in Normoxic and Post-Ischaemic Hearts 
As mentioned in section 2.3.2, use of a stably expressed gene is crucial for accurate data 
normalisation in reverse transcription polymerase chain reaction (RT-qPCR). Five commonly 
used genes were assessed for stability in normoxic and post-ischaemic hearts (8, 16, 32 and 
48-week old). Specifically, β-actin (Actb), Glyceraldehyde 3-phosphate dehydrogenase, 
(Gapdh), Phosphoglycerate Kinase 1 (Pgk1), Cyclophilin peptidylprolyl isomerase (Ppia), and 
Ribosomal Protein L13a (Rpl13a). Stability analysis showed that all reference genes assessed 
were stably expressed (M value <1.0) in both normoxic (Figure 3.3A) and post-ischaemic 
tissue (Figure 3.3B), with Pgk1 shown to exhibit the most stable expression. 
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Figure 3.3 Expression stability values (M) of the putative reference genes tested in the male 
A) normoxic ageing hearts and B) post-ischaemic ageing hearts. The dotted line indicates the 
recommended threshold value of <1.0 for heterogeneous samples. (n=24/group). 
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3.3.4.1 Transcriptional analysis of caveolin expression 
RT-qPCR was used to assess the transcript expression of the three caveolin family members 
in the ageing heart under normoxic conditions and following I-R. Two-way ANOVA yielded a 
significant main effect for age and Cav1 mRNA expression (Table 3.1). As shown in Figure 3.4A 
the expression of Cav1 is reduced in 48-week old hearts relative to all other ages, this is most 
pronounced under normoxic conditions. Specifically, Cav1 declined 1.8-fold in the 48-week 
old normoxic heart compared to the 8-week old group (Figure 3.4A). A similar shift in 
expression for Cav2 was also observed, with two-way ANOVA also identifying a significant age 
effect. This effect was also identified as a down-regulation (1.4-fold) of expression in 48-week 
old normoxic hearts (Figure 3.4B). Analysis of Cav3 expression yielded a significant main effect 
for both age and ischaemia. The interaction of age and ischaemia was also significant, 
indicating that the age effect was greater in the normoxic group when compared to post-
ischaemic hearts (Table 3.1). This can be further observed in Figure 3.4C, which shows Cav3 
mRNA was down-regulated 1.5-fold as early as 16-weeks in the normoxic heart, with a plateau 
in expression through 32- and 48-weeks. However, in the post-ischaemic heart Cav3 
expression is induced above baseline (1.5-fold). As the heart ages this response appears to be 
lost and an age-related decline in Cav3 expression is observed in a similar manner to their 
normoxic counterparts. 
Table 3.1 Two-way analysis of variance of age and post-ischaemic effects on caveolin transcript 
expression 
Gene Factor Mean Square F (DFn, DFd) % of Total 
Variation 
P value 
Cav1 
Age 0.661 5.56 (3, 40) 25.6% 0.0028 
Ischaemia 0.068 0.57 (1, 40) 0.9% 0.4547 
Age*Ischaemia 0.309 2.60 (3, 40) 12.0% 0.0658 
Cav2 
Age 0.392 4.69 (3, 40) 24.7% 0.0067 
Ischaemia 0.056 0.67 (1, 40) 1.2% 0.5348 
Age*Ischaemia 0.062 0.74 (3, 40) 3.9% 0.4173 
Cav3 
Age 0.426 13.33 (3, 40) 27.4% < 0.0001 
Ischaemia 1.050 32.87 (1, 40) 22.5% < 0.0001 
Age*Ischaemia 0.352 11.01 (3, 40) 22.6% < 0.0001 
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Figure 3.4 Age dependent expression of caveolin transcripts in normoxic and post-ischaemic 
male hearts. Shown are boxplots detailing expression changes determined by RT-qPCR for A) 
Cav1, B) Cav2 and C) Cav3 in the normoxic (grey boxes) and post-ischaemic (red boxes) heart. 
Boxes indicate interquartile range (25%-75%) with the horizontal bar within each box indicating 
the median. The whiskers show the minimum and maximum values. * P < 0.05 vs 8-week old 
normoxic; † P < 0.05 vs 8-, 16- and 32-week old normoxic; ‡ P < 0.05 vs 16-week old post-
ischaemic; # P < 0.05 vs age-matched post-ischaemic group (indicated by brackets). (n=6/group). 
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3.3.4.2 Immunoblot analysis of caveolin3 protein expression 
To verify the relationship between Cav3 transcript and protein expression changes 
immunoblot analysis was employed. A 1.5-fold reduction in Cav3 protein expression in 
normoxic hearts was observed in the 48 vs. 8-week old group (Figure 3.5A). Age-dependent 
Cav3 protein repression (1.8-fold) was also observed in post-ischaemic hearts (Figure 3.5B). 
This was consistent with the age-related decrease in Cav3 mRNA expression (Figure 3.4C). 
 
Figure 3.5 Age dependent Cav3 protein expression in normoxic and post-ischaemic male 
hearts. Boxplots are shown detailing Cav3 protein expression in A) normoxic and B) post-
ischaemic ageing hearts. Boxes indicate the interquartile range (25%-75%) with the horizontal 
bar within each box indicating the median. The whiskers show the minimum and maximum 
values. To the right of the graphs representative immunoblot images are shown for Cav3 and 
the β-Actin loading control. * P < 0.05 vs 8-week old. (n=6/group). 
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Of the caveolin transcripts, only Cav3 showed significant down-regulation in both normoxic 
and post-ischaemic ageing hearts. Although Cav3 has previously been shown to be down-
regulated in 74-week old senescent hearts (Peart et al. 2014), here we show down-regulation 
is apparent as early as 16-week in normoxic hearts, and in the 32 and 48-week post-ischaemic 
hearts. The age-related decrease in Cav3 expression correlates with a loss of ischaemic 
tolerance in 32 and 48-week old post-ischaemic hearts, as shown by LDH release and 
functional measurements (Figure 3.2A and B). The reduction in Cav3 protein expression in 
these hearts may lead to reduced caveolae formation, which may contribute to loss of 
ischaemic tolerance in these hearts when compared to young and mature counterparts. This 
is a novel finding, as the age-dependent expression of Cav3 in normoxic and post-ischaemic 
hearts has been uncharacterised until now. 
Caveolae formation in the heart is directly dependent on Cav3, with Cav3-deficiency and 
Cav3-overexpression resulting in ablation and increased caveolae formation, respectively 
(Park et al. 2002; Horikawa et al. 2011). Loss of caveolae formation via Cav3-deficiency is 
associated with loss of IPC, anaesthetic and pharmacological preconditioning in these hearts 
(Tsutsumi et al. 2008; Tsutsumi et al. 2010). The aged heart also exhibits reduced sensitivity 
to various GPCR receptors, including A1AR, Bradykinin, and δ1-opioid receptors, which reduce 
I-R injury in young hearts but not aged hearts (Headrick et al. 2003; Peart et al. 2007). 
Concomitant with loss of GPCR-mediated protection is a reduction of Cav3 which we and 
others (Peart et al. 2014) have observed in older hearts. As many cardioprotective receptors 
and their signalling subunits are co-localised in caveolae, a reduction in caveolae may play a 
key role in insensitivity to GPCR stimuli. In support of this view, both Cav3-deficiency and 
pharmacological disruption of caveolae results in loss of endogenous ischaemic tolerance as 
well as loss of IPC and pharmacological preconditioning (Tsutsumi et al. 2008; See Hoe et al. 
2014).  Conversely, cardiac-specific overexpression of Cav3 has been shown to improve 
recovery of the aged heart, which results in 60–65% recovery of pressure development and 
end diastolic pressure reportedly in the normal range (Kidd et al. 2010). Furthermore, Cav3-
OE inhibits (via ANP) hypertrophy and fibrosis in response to aortic constriction, with 
enhanced survival rates (compared to wild-types), further supporting involvement of Cav3 
and caveolae in stress-resistance in the heart (Horikawa et al. 2011). Taken together, data are 
consistent with some role for caveolae in age-dependant repression of I-R tolerance and loss 
of cardioprotection in the aged heart.  
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3.3.5.1 Analysis of the age-dependence of cavin gene expression in normoxic and post-
ischaemic male mouse hearts 
Significant down-regulation (1.6-fold) of Cavin1 was apparent in both the normoxic 16- and 
48-week old compared to the 8-week group (Figure 3.6A). In the post-ischaemic heart, a 
significant reduction (1.3-fold) in Cavin1 was observed in the 16- and 48-week old groups 
(Figure 3.6A). Two-way ANOVA analysis of this age-related reduction of Cavin1 is further 
demonstrated identifying age as a significant main effect (Table 3.2). Cavin2 expression in the 
normoxic heart was significantly up-regulated (1.4-fold) at 32-weeks with expression 
returning to baseline levels in the 48-week old heart (Figure 3.6B). Cavin2 also demonstrated 
a small (1.2-fold) but significant reduction in the 48-week old post-ischaemic heart (Figure 
3.6B) and was the only cavin transcript to show significant interaction between age and 
ischaemia (Table 3.2). More specifically, Cavin2 showed significant repression in the post-
ischaemic 16-, 32- and 48-week old heart when compared to age-matched normoxic 
counterparts (Figure 3.6B). Cavin3 showed no age-dependent changes in expression in the 
normoxic and post-ischaemic heart. While Cavin4 exhibited a 1.5-fold increase in expression 
at 48-week relative to 16-week old normoxic hearts, no other significant changes were 
observed (Figure 3.6D). However, post-hoc analysis of Cavin4 revealed the reduction of 48-
week old post-ischaemic vs 48-week old normoxic hearts was borderline non-significant (P= 
0.06) 
Table 3.2 Two-way analysis of variance of age and post-ischaemic effects on cavin transcript 
expression 
Gene Factor Mean Square F (DFn, DFd) % of Total 
Variation 
P value 
Cavin1 
Age 1.014 11.03 (3.40) 43.2% < 0.0001 
Ischaemia 0.192 2.10 (1,40) 2.7% 0.1555 
Age*Ischaemia 0.043 0.46 (3,40) 1.8% 0.7090 
Cavin2 
Age 1.184 5.25 (3,40) 14.4% 0.0038 
Ischaemia 0.018 35.30 (1.40) 32.4% < 0.0001 
Age*Ischaemia 0.202 6.02 (3,40) 16.6% 0.0017 
Cavin3 
Age 0.131 1.38 (3,40) 9.1% 0.2626 
Ischaemia 0.001 0.08 (1,40) 0.2% 0.7740 
Age*Ischaemia 0.050 0.52 (3,40) 3.4% 0.6699 
Cavin4 
Age 0.120 2.46 (3,38) 12.8% 0.0774 
Ischaemia 0.008 0.16 (1, 38) 0.3% 0.6914 
Age*Ischaemia 0.196 4.01 (3.38) 20.9% 0.0142 
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Figure 3.6 Age dependent expression of cavin transcripts in normoxic and post-ischaemic male 
hearts. Shown are boxplots detailing expression changes determined by RT-qPCR for A) Cavin1, B) 
Cavin2, C) Cavin3 and D) Cavin4 in the normoxic (grey boxes) and post-ischaemic (red boxes) 
heart. Boxes indicate interquartile range (25%-75%) with the horizontal bar within each box 
indicating the median. The whiskers show the minimum and maximum values. * P < 0.05 vs 8-
week old normoxic; † P < 0.05 vs 16-week old normoxic, ‡ P vs 32-week old normoxic, + P < 
0.05 vs 8-week old post-ischaemic, # P < 0.05 vs age-matched post-ischaemic group (indicated 
by brackets). (n=6/group). 
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3.3.5.2 Immunoblot analysis of Cavin1 protein expression 
To assess whether the age-related reduction in Cavin1 mRNA expression was translated to 
the protein level, immunoblot analysis was employed. In the normoxic heart Cavin1 protein 
was down-regulated (1.4-fold), although borderline non-significant (P=0.051) (Figure 3.7A). 
However, in the post-ischaemic heart an age-related decline (1.6-fold) in Cavin1 protein 
expression was statistically significant as shown in Figure 3.7B. Collectively these data confirm 
that Cavin1 transcript expression changes (Figure 3.6D) translate to shifts in myocardial 
Cavin1 protein expression.  
  
Figure 3.7 Age dependent expression of Cavin1 protein in normoxic and post-ischaemic 
male hearts. Validation of transcript and protein expression changes for left ventricular 
Cavin1 in A) normoxic and B) post-ischaemic ageing hearts. Boxes indicate the interquartile 
range (25%-75%) with the horizontal bar within each box indicating the median. The whiskers 
show the minimum and maximum values. To the right of the graphs representative 
immunoblot images are shown for Cavin1 and the β-Actin loading control. *P < 0.05 vs. 8-
week old. (n=6/group). 
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As the expression patterns of cavins have not been characterised in the ageing heart, we 
sought to assess the age-dependence of cavin expression, which is important in caveolae 
biogenesis and potentially influences caveolae dependent cardioprotection. Compared to 
their caveolin counterparts the functional roles of cavins in the heart remain largely 
uncharacterised. As shown in Figure 3.1, the heart demonstrates high expression of all cavin 
transcripts, in agreement with proteomic analysis in heart (Bastiani et al. 2009). Of the cavin 
transcripts, only Cavin1 and Cavin2 showed significant age-related down-regulation. Cavin1 
and Cavin2 exhibit moderate expression levels in left ventricle and HL-1 cardiomyocytes 
(Figure 3.1), cardiac tissue also demonstrates moderate expression of these at the protein 
level (Bastiani et al. 2009).  Similar to Cav3, Cavin1 appears essential for caveolae formation 
in muscle cells, with Cavin1-deficiency or mutation leading to the loss of caveolae in 
cardiomyocytes and skeletal muscle (Kasahara et al. 2014; Hayashi et al. 2009). Disturbed 
caveolae formation in Cavin1-deficient hearts also impacts Cav3 expression, as these hearts 
display reduced Cav3 protein expression compared to wild types (Bastiani et al. 2009).  In 
further support, Cavin1-deficient animals show 80%-90% loss of caveolin proteins in all tissues 
despite upregulated expression of caveolin mRNAs (Liu et al. 2008). Similarly, mutations in 
CAVİN1 are associated with mis-localisation of all three caveolin family members and reduced 
caveolae in skeletal muscle of patients with muscular dystrophy (Hayashi et al. 2009).  
Besides its role in influencing caveolae formation, recent studies suggest that Cavin1 is also 
important in targeting plasma membrane repair machinery to sites of injury. Cavin1 co-
localises with Trim72, which has been shown to be critical for membrane repair following I-R, 
leading to cardioprotection (Zhu et al. 2011; Cao et al. 2010). The role of Cavin1 in this repair 
mechanism suggests that Cavin1 helps transport and bind Trim72 to cholesterol-rich regions 
(which may be caveolae) thereby anchoring the Trim72 molecule to enable membrane repair 
(Zhu et al. 2013). This repair response was shown to be reliant on presence of Cavin1 and lipid 
rafts/caveolae, as cholesterol depletion via MβCD disrupts the repair response (Zhu et al. 
2011; Wang et al. 2010). Cavin1 knockdown also leads to a loss of Trim72-mediated responses 
following membrane damage (streptolysin O), and enhances cellular LDH release and FM1-43 
dye entry, further implicating caveolae involvement in mediating the plasma membrane 
repair response (Zhu et al. 2011). In both normoxic and post-ischaemic hearts studied here, 
Cavin1 was down-regulated both at the mRNA and protein levels in 48-week old hearts which 
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also correlated with the loss of ischaemic tolerance in these hearts. Taken together, these 
data suggest age-related downregulation of Cavin1 in the older hearts (normoxic or post-
ischaemic) may lead to reduced Cav3 expression, perhaps through aberrant Cav3 trafficking 
to the membrane, which may result in loss of morphological caveolae structures. In addition, 
plasma membrane repair mechanisms may also be impaired in these hearts, which rely on 
caveolae and its structural proteins (Further discussed in detail later in Chapter 7).  
 
3.3.6 Analysis of the age-dependence of Popdc gene expression in normoxic and post-
ischaemic male mouse hearts 
In the normoxic heart, cardiac expression of Popdc1, Popdc2 and Popdc3 did not change with 
age (Figure 3.8). In the post-ischaemic heart, Popdc1 showed a significant decrease 1.4-fold 
decrease in expression in 32- and 48-weeks of age (Figure 3.8A), similar to expression pattern 
observed with Cav3. Popdc2 showed no expression changes with age in the post-ischaemic 
heart (Figure 3.8B). As shown by two-way ANOVA analysis, Popdc1 expression yielded a 
significant main effect for age and ischaemia, similar to that of Cav3 (Table 3.3). This is 
demonstrated by the significant 1.3-fold down-regulation of Popdc1 transcript in 32- and 48-
week old post-ischaemic hearts when compared to their age-matched normoxic counterparts 
(Figure 3.8A). Whilst individually not significant, an age-related decline in Popdc3 expression 
was observed in the post-ischaemic heart as shown in table 3.3. Two-way ANOVA confirmed 
a significant main effect for ischaemia and Popdc3 transcript repression. This repression is 
reversed in the ageing normoxic heart as reported by the significant interaction between age 
and ischaemia. More specifically, we observed significant 2.0-fold down-regulation of Popdc3 
in the 32- and 48-week old hearts when compared to their normoxic age-matched 
counterparts (Figure 3.8C). 
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Table 3.3 Two-way analysis of variance of age and post-ischaemic effects on Popdc 
transcript expression 
Gene Factor Mean Square F (DFn, DFd) % of Total 
Variation 
P value 
Popdc1 
Age 0.211 4.88 (3,37) 18.5% 0.0059 
Ischaemia 0.674 15.56 (1,37) 19.7% 0.0003 
Age*Ischaemia 0.157 3.63 (3,37) 13.8% 0.0216 
Popdc2 
Age 0.363 1.21 (3,37) 8.4% 0.3184 
Ischaemia 0.133 0.44 (1,37) 1.0% 0.5091 
Age*Ischaemia 0.215 0.72 (3,37) 5.0% 0.5486 
Popdc3 
Age 0.028 0.19 (3,35) 0.8% 0.8993 
Ischaemia 3.725 26.20 (1,35) 37.6% 0.0001 
Age*Ischaemia 0.466 3.25 (3,35)  14.1% 0.0323 
 
Members of the Popdc gene family (Popdc1, Popdc2 and Popdc3) are expressed abundantly 
in epithelial, skeletal, cardiac muscle and neuronal cells (Andree et al. 2000; Brand 2005). 
Popdc1 and Popdc2 are also abundantly expressed in cardiac pacemaker and conduction 
regions, and are thought to contribute to pacemaker and normal heart morphogenesis 
(Froese et al. 2012). Consistent with expression pattern of Popdcs, Popdc1 and Popdc2 were 
enriched in ventricular cells and cultured HL-1 cardiomyocytes, while cultured fibroblasts 
showed no expression of Popdc1 and Popdc2 (Figure 3.1). Popdc3 is abundantly expressed in 
the heart, whilst cultured HL-1 cardiomyocytes and fibroblast showed no detectable 
expression (Figure 3.1). As discussed in Section 3.3.1, this lack of Popdc3 expression could 
reflect differential expression observed from atrial vs. ventricular cells. In addition, HL-1 cells 
do not express certain marker proteins found in their adult atrial counterparts such as β-
tubulin II, which may also be the case for Popdc3 although this is speculative (Kuzntesov et al. 
2014). Popdc1 appears vital for normal heart development as mutations in POPDC1 are 
associated with the congenital defect Fallot's tetralogy (Wu et al. 2013). Double Popdc1/2-
deficient mice suffer sudden cardiac death when challenged with swimming stress (Froese et 
al. 2012). Aged (22-34-week old) wild-type animals show a similar decline in cardiac pace-
making following stress-testing, which the authors suggest may be due to age-related loss of 
Popdc1 and Popdc2 expression in these hearts (Froese et al. 2012). The role of Popdc3 in the 
heart is largely unknown, although it has been shown to be down-regulated in the failing 
human heart (Gingold-Belfer et al. 2011).  
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Figure 3.8 Age dependent expression of Popdc transcripts in normoxic and post-ischaemic male 
hearts. Shown are boxplots detailing expression changes determined by RT-qPCR for A) Popdc1, 
B) Popdc2, and C) Popdc3 in the normoxic (grey boxes) and post-ischaemic (red boxes) heart. 
Boxes indicate interquartile range (25%-75%) with the horizontal bar within each box indicating 
the median. The whiskers show the minimum and maximum values. * P < 0.05 vs 8-week old 
post-ischaemic, P < 0.05 † vs 16-week old post-ischaemic, # P < 0.05 vs age-matched post-
ischaemic group (indicated by brackets). (n=6/group). 
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Whilst there were no changes in Popdc1 expression in normoxic hearts, we observed a 
significant age-related reduction in Popdc1 expression in 32 and 48-week old post-ischaemic 
hearts. Interestingly, this pattern of expression paralleled Cav3 expression in post-ischaemic 
hearts.  Additional to the essential role of Cav3 as a caveolae forming coat protein in 
cardiomyocytes, recent evidence suggest that Popdc1 is also essential for caveolae formation. 
Popdc1-deficient cardiomyocytes show significant reduction in caveolae with remaining 
caveolae being larger in size. Popdc1-deficient hearts show a loss of ischaemic tolerance 
leading to enhanced infarct size and impaired recovery following I-R (Alcalay et al. 2013). 
Furthermore, Popdc1-deficient hearts also display loss of IPC and anaesthetic 
preconditioning, similar to Cav3-deficient hearts (Alcalay et al. 2013; Tsutsumi et al. 2008, 
Tsutsumi et al. 2010). Consistent with roles for Cav3 and caveolae in countering heart failure, 
Popdc1 appears to be down-regulated both in murine and human end-stage failure of hearts 
(Gingold-Belfer et al. 2011; Feiner et al. 2011). Very little is known about the functions of 
Popdc2 and Popdc3 in the heart, their expression appears skeletal and cardiac muscle specific 
and is important for muscle differentiation and cardiac morphogenesis (Kirchmaier et al. 
2012). The role of Popdc3 is largely unknown. However, reduced expression of Podpc3 is 
observed in the in the failing human heart and correlated with high risk and poor survival in 
patients with gastric cancer. (Gingold-Belfer et al. 2011; Luo et al. 2012). We observed a 
significant reduction in Popdc3 expression in the post-ischaemic 48-week old hearts although 
what affect this could have in the aged hearts remains unclear. Combined with decrease 
expression of Cav3 and Cavin1 in the 32- and 48-week old post-ischaemic heart, decreased 
Popdc1 expression may exacerbate/accelerate loss of caveolae in the ageing post-ischaemic 
hearts. Thus the combined reduction of these transcripts and proteins may partially be 
responsible for the loss of recovery and attenuated ischaemic recovery in the 32- and 48-
week old hearts.  
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3.4 CONCLUSION 
In this study, we investigated the age-dependent expression of caveolae-related transcripts - 
caveolin, cavin and Popdc families in normoxic and post-ischaemic hearts from male mice. 
The results demonstrate significant age-dependent down-regulation of Cav3 and Cavin1 in 
both normoxic and post-ischaemic tissues. To validate transcriptional changes, Western 
immunoblot analysis of Cav3 and Cavin1 was performed, which confirmed the translation of 
gene changes to shifts in Cav3 and Cavin1 protein expression. Similar to our findings, other 
groups have observed age-related reductions in Cav3 and caveolae formation in hearts (Peart 
et al. 2014; Kidd et al. 2010), bladder smooth muscle (Lowalekar et al. 2012), and neurons 
(Head et al. 2010). These membrane structures and proteins are critical to stress and 
protective signalling as discussed previously. Ageing is associated with reduced myocardial 
ischaemic tolerance and many cardioprotective stimuli, including IPC and GPCR-mediated 
cardioprotective responses which are shown to fail in the aged hearts (Peart et al. 2014). 
These cardioprotective stimuli have been shown to be reliant on Cav3 and caveolae, with 
caveolae depletion and Cav3-deficiency shown to ablate the cardioprotective effects of these 
stimuli (Tsutsumi et al. 2008; Tsutsumi et al. 2010).  
Current investigations of caveolin expression have employed young vs. aged or senescent 
models, with more intermediate levels of 'ageing' not yet studied (Park et al. 2000; Ratajczak 
et al. 2003; Peart et al. 2014). Similar to others, we observe that loss of ischaemic tolerance 
occurs before the senescent phenotype (>74 weeks old). More specifically, loss of ischaemic 
tolerance is apparent in 32-week old hearts and highly significant in the 48-week old hearts 
as shown by LDH release (Figure 3.2B). Although the 32-week old heart does not exhibit 
increased cell death following I-R, significant changes in developed pressure (Figure 3.2A) as 
a measure of functional recovery indicates that the 32-week old heart shows similar loss of 
recovery observed in the 48-week old hearts. Similarly, Willems and colleges (2005) have 
shown significant decrease in developed pressure in middle-aged to mature hearts. 
Coincident with these age-related changes to I-R tolerance, caveolae forming transcripts 
Cav3, Cavin1 and Popdc1 are down-regulated in post-ischaemic middle-aged hearts, with such 
combined loss hypothesized to lead to reduced caveolae formation in cardiomyocytes, 
leading to loss of endogenous cardioprotective responses (e.g. autacoid activation of GPCR).  
In support of this notion, Cav3-overexpression in the senescent heart has been shown to 
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restore caveolae and improve recovery (Kidd et al. 2010). This further suggests an age-related 
decline of caveolae may partially contribute to loss of ischaemic tolerance in these hearts. 
Finally, Cavin1 and Popdc1 have recently also been shown to be critical for formation of 
caveolae in cardiomyocytes (Alcalay et al. 2013; Kasahara et al. 2014). Thus, the age-
dependent loss of Popdc1 and Cavin1 in the post-ischaemic heart, combined with loss of Cav3, 
may contribute to depletion of caveolae (and impaired stress signalling/resistance). There 
was also a notable decline in Popdc3 expression in 32 and 48 week old hearts, although its 
impact on the ageing heart is unknown as the role of Popdc3 remains uncharacterised. Given 
their homology to each other is only 25%, the role of Popdc3 may be substantially different 
to that of Popdc1 (Andree et al. 2000). Taken together, age-related loss of caveolae-forming 
transcripts Cav3, Cavin1 and Popdc1 may result in reduction of caveolae, which may partially 
contribute to loss of ischaemic tolerance and cardioprotective efficacies in the middle-aged 
heart. 
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4. Chapter Four 
Effects of age on caveolae-related transcript expression in 
normoxic and post-ischaemic female hearts 
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4.1 INTRODUCTION 
Ischaemic heart disease (IHD) is the leading cause of death in Australia for both males and 
females (ABS 2014). Epidemiological studies have suggested that prevalence and mortality 
from IHD in males is twice that when compared to females at all ages, with females one-third 
as likely as males to report a heart attack (AIHW 2010).  Women develop IHD on average 10 
years later than men, with myocardial infarction occurring 20 years later (Duvall 2003; Bassuk 
& Manson 2010). However, when post-menopausal females are compared to age-matched 
males this protective effect is shown to be reversed, as there is a 10-fold increase in IHD after 
menopause compared with only a 4.6-fold increase in aged-matched males (Korzick & 
Lancester 2013; Duvall 2003). Several factors have been suggested to contribute to 
development of IHD in women, including traditional Framingham risk factors such as 
hyperlipidaemia, hypertension, smoking and psychosocial factors including mental stress and 
anxiety (Mehta, Wei & Wenger 2015). For over 90% of Australian women, there is at least one 
modifiable risk factor for CVD, whilst half of all women have two or three (AIHW 2010). These 
modifiable risk factors include low fruit and vegetable consumption, being overweight or 
obese, high blood cholesterol and physically inactive (AIHW 2005).  
Circulating estrogen and estrogen receptor (ER) activation have been implicated in the 
current paradigm of sex-related differences in cardioprotection. Indeed, animal models 
support the role of circulating estrogen in reducing atherosclerosis as ovariectomy results in 
increased formation of atherosclerotic plaques whilst estrogen supplement reverses this 
effect on the aorta (Mayer et al. 2005). Plasma estradiol (E2) concentrations in 
postmenopausal women have been reported to be 2.5x to 25x less compared to the cyclic 
variation observed in premenopausal women (Bremnes et al. 2006; Sullivan et al. 1995). 
Indeed, estrogen replacement therapy has been suggested to reduce the occurrence of IHD 
by nearly 50% in treated women compared with non-users (Rosano & Fini 2002). 
Furthermore, ovariectomy in mice results in increased infarct sizes in both young and 
senescent female hearts, further highlighting a role for estrogen (Hunter et al. 2007). 
However, estrogen signalling in itself is not sufficient to explain the sex-related differences, 
as there is a lack of efficacy of hormone replacement therapy in prevention of cardiovascular 
disease in pre- and post-menopausal women (Rossouw et al. 2002; Rossouw et al. 2007).  
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The exact mechanisms of this protection in the female heart is unknown and is thought to 
involve multiple estrogen GPCRs, including estrogen receptor-α (ERα), estrogen receptor-β 
(ERβ) and G-protein receptor 30 (GPR30). Activation of ERs leads to transcriptional and non-
transcriptional effectors (Ostadal & Ostadal 2014). Transcriptional effectors have been shown 
to include increased eNOS and L-type Ca2+ channel gene expression which may be responsible 
for the reduced cell death and increased functional recovery observed in female hearts 
(Murphy 2011; Babiker et al. 2002). Whilst non-transcriptional changes include enhanced 
calcium handling, protein S-nitroyslation, phosphorylation status of survival kinases and 
enhanced mitochondrial survival following I-R in the female myocardium (Deschamps, 
Murphy & Sun 2010). Both acute and chronic estrogen treatment in animal models has been 
shown to enhance dilator sensitivity of the coronary microcirculation through enhanced NO 
production by the endothelium as well as reducing no-reflow zones following I-R  (Thompson, 
Pinkas & Weiner 2000; McCullough et al. 2001). Furthermore, estrogen replacement in aged 
(24-month old) female rats reverses the age-related impairment of flow-induced dilation in 
coronary arterioles by approximately 160% (LeBlanc et al. 2009). 
Sex-related differences in cardiomyocytes may partially contribute to the differences in 
response to disease as they have notable differences in electrophysiology, contractility, 
signalling, metabolism, and cardioprotection (Murphy & Steenbergen 2014). Experimentally, 
the young female myocardium has been shown to be more resistant to variety of stressors 
such as I-R damage and associated arrhythmias, stress-induced hypertrophy and heart failure 
(Bell et al. 2013). Generally, disruption of a gene results in exacerbation of I-R injury in males 
when compared to female counterparts. For example, β2-adrenergic receptor and Ncx-
deficiency has been shown to decrease I-R tolerance in male but not female mice (Cross et al. 
2002; Cross et al. 1998). There are also notable differences in cardioprotective mediator 
response as well. For example, female cardiomyocytes have increased eNOS association with 
Cav3, which is thought to enhance S-nitroyslation of the L-type Ca2+ channel in females (Sun 
et al. 2006). Furthermore, caveolae-derived eNOS has also been shown to enhance S-
nitroyslation of mitochondrial proteins although this remains to be shown for females (Sun et 
al. 2015). Unlike their male counterparts, some of this protection is also retained with ageing 
(Willems et al. 2005). 
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Ageing studies investigating sex-related differences in cardioprotection in mice have 
predominantly used the aged phenotype (>70 weeks old) (see Table 1 of Boengler & Shulz 
2009). However, the reduction in ischaemic tolerance can be seen well before the aged 
phenotype in both sexes (Willems et al. 2005). As discussed in Chapter 3 the exact 
mechanisms behind the loss of cardioprotective signalling in the ageing heart is unknown. 
Furthermore, sex-related differences have not investigated the expression of caveolae coat 
proteins which are also crucial determinants of endogenous cardioprotection. As previously 
discussed, ablation of caveolae results in loss of ischaemic tolerance, whilst overexpression 
results in restoration of ischaemic tolerance in the aged hearts (Tsutsumi et al. 2010; Kidd et 
al. 2010). Changes in Cav3-eNOS association following I-R have also been shown to be a key 
sex-related difference (Sun et al. 2006). However, the expression of caveolins, cavins and 
Popdcs remain largely uncharacterised in the female heart, whose differential expression may 
also contribute to sex-related differences with ageing.   We therefore sought to investigate 
the expression of caveolae-related transcripts in the female normoxic and post-ischaemic 
ageing myocardium in a similar fashion to Chapter 3.  
  
 
 
96 
 
4.2 METHODS 
Langendorff perfusions were carried out on hearts (n=8-10/per group) from 8, 16, 32 and 48 
week old female mice as previously described in Section 2.1.1. Briefly, 20 minutes of global 
normothermic ischaemia was followed by 60 minutes of reperfusion whilst normoxic hearts 
were reperfused for 80 minutes. 
RNA isolation and cDNA synthesis from normoxic and post-ischaemic left ventricular tissue 
was carried out as described in Section 2.2.1. 
RT-qPCR was used to analyse expression of caveolin, cavin and Popdc transcripts in ageing 
hearts as detailed in Section 2.3.1. Selection of a stable reference gene was carried out 
according to Section 2.3.2. Normalisation of post-ischaemic gene expression to normoxia was 
carried out according to Section 2.4. 
Western immunoblotting was carried to confirm validate the relationship between transcript 
and protein expression changes for Cav3 and Cavin1 according to Section 2.5.  
Statistical analysis was conducted on data as per Section 2.6 with statistical significance 
accepted for P < 0.05.  
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4.3 RESULTS AND DISCUSSION 
4.3.1 Functional and oncotic indicators of myocardial injury in post-Ischaemic ageing female 
mouse heart 
Age-related reduction in functional recovery became apparent in the 32- and 48-week old 
female heart when compared to their 8 and 16-week old counterparts (Figure 4.1A). A similar 
reduction in functional recovery was observed in the 32- and 48-week old male hearts 
(Chapter 3, Figure 3.2A). This reduction in functional recovery of the female 32-week old heart 
was not observed by other groups using similar ageing time points and I-R methods (Willems 
et al. 2005). Their results suggested that the reduction in functional recovery is initially 
detected in 48-week old female hearts whilst we observed this in 32-week old hearts. 
Interestingly, the reduction in post-ischaemic recovery in the 32-week old hearts did not 
correlate with enhanced LDH release (Figure 4.1B). Significant LDH release was present only 
in the 48-week old female hearts vs. 8-week old female hearts (Figure 4.1B), similar to male 
counterparts (Figure 4.1B). In contrast to Willems et al. (2005) who showed that female 48-
week old have significantly lower LDH release when compared to male counterparts, our 
findings demonstrated the opposite trend (Figure 4.1B). 
As previously discussed the sex-related differences in humans is often attributed to estrogen 
signalling during pre-menopause. It is difficult to assess whether the loss of ischaemic 
tolerance observed in the 32- and 48-week old female hearts is associated with a decline in 
these protective mechanisms in female hearts. The time frame and duration of menopause is 
unknown and difficult to assess in animal models. However, the reproductive capacity of 
female mice declines after approximately 8 months (34 weeks) as female mice are retired 
from breeding at 8 months because litter size diminishes (Jackson Laboratory 2011). 
Furthermore, rapid deterioration of the follicle reserve has been observed between 48-72 
weeks of age (Niikura, Niikura & Tilly 2009). It is therefore tempting to speculate that the 32- 
and 48-week old mice may be having commenced perimenopause and this may be 
responsible for the significant oncosis present in the 48-week old hearts and reduced recovery 
we observed in the 32- and 48-week old hearts used in this study. 
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Figure 4.1 Recovery from I-R in the ageing female heart. Data are shown for A) developed 
pressure and B) cell death following 20 min ischaemia and 60 min reperfusion in isolated 
hearts from 8, 16, 32 and 48-week old male (white boxes) and female (grey boxes) mice. Data 
are expressed as mean±SEM; *P < 0.05 8-week old female; †P < 0.05 vs 16-week old female, 
‡ P < 0.05, vs 32-week old female; # P < 0.05 male vs female age-matched group (indicated by 
brackets). (n=6-8/group). 
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4.3.2 Reference gene stability in the ageing normoxic and post-ischaemic hearts 
Determination of a stable reference gene was carried out in an identical to the previous male 
study (Section 3.3.3). As shown in Figure 4.2 Ppia, Actb, Pgk1 and Rpl13a were all considered 
stably expressed in both the normoxic and post-ischaemic groups, with minimal difference in 
stability for all four genes. Although Ppia was identified as the most stably expressed gene, 
Pgk1 was selected to allow for more uniform cross comparisons and consistency with the 
findings from the male study in Chapter 3. However, there were large differences in male vs 
female Pgk1 expression (3.26-fold) which prohibited direct across-sex comparisons as 
previously detailed in Section 2.3.3.  
 
 
Figure 4.2 Expression stability values (M) of the five putative reference genes (Actb, Gapdh, 
Pgk1, PPia and Rpl13a) tested in the female A) normoxic ageing hearts and B) post-ischaemic 
ageing hearts (n=24/group). The dotted line indicates the recommended threshold value of 
<1.0 for heterogeneous samples. 
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4.3.3.1 Transcriptional analysis of caveolin expression 
Similar to the male study (as detailed in Chapter 3), RT-qPCR was used to study expression of 
caveolin, cavin and Popdc transcripts in normoxic and post-ischaemic ageing female hearts. 
Cav1 showed a 1.6-fold down-regulation that was significant in the 48-week old hearts when 
compared to 32-week old normoxic hearts (Figure 4.3A). With male hearts demonstrating a 
similar down-regulation of Cav1 at 48-weeks old (Figure 3.4A). Whilst there were notable 
perturbations to post-ischaemic Cav1, its expression returned to baseline levels in the middle-
aged hearts (Figure 4.3A).  However, Two-way ANOVAs on expression levels of Cav1 revealed 
significant effects of age and ischaemia (Table 4.1). This can be visualised in the 48-week old 
post-ischaemic hearts which showed induction (2.0-fold) of Cav1 when compared to age-
matched normoxic counterparts (Table 4.1) (Figure 4.3A), similar to that of males. Normoxic 
Cav2 showed no changes in expression with ageing (Figure 4.3B) while male counterparts 
showed significant down-regulation in the 48-week old normoxic hearts (Figure 3.4B). 
Analysis of Cav2 expression yielded a significant main effect for both age and ischaemia (Table 
4.1). More specifically, Cav2 showed significant induction in the post-ischaemic 32- and 48-
week old hearts when compared to 16-week old hearts (Figure 4.3B). In addition, significant 
increase in Cav2 transcript expression was present in the 32- and 48-week old post-ischaemic 
hearts vs age-matched counterparts (Figure 4.3B) which was not observed in the males. 
A non-significant minor trend in Cav3 down-regulation was observed in the ageing normoxic 
heart as early as 16-weeks of age (Figure 4.3C). This is similar to expression patterns observed 
in the male normoxic heart (Figure 3.4C). Similar to male counterparts, analysis of Cav3 
expression yielded a significant main effect for both age and ischaemia although the 
interaction between age and ischaemic was borderline non-significant (P=0.051) (Table 3.1). 
While Cav3 was down-regulated in the 16-week old post-ischaemic hearts when compared to 
8-week old hearts, the 32- and 48-week old hearts displayed 2.0-fold up-regulation when 
compared to 16-week old post-ischaemic hearts (Figure 4.3C). Cav3 mRNA showed significant 
over-expression (2.0-fold) in the 8-, 32- and 48-week old post-ischaemic female hearts when 
compared to their age-matched normoxic counterparts (Figure 4.5C). Male hearts previously 
demonstrated a significant up-regulation of Cav3 only in the 16- and 32-week old post-
ischaemic heart (Figure 3.4C). Therefore, the induction of Cav3 mRNA following I-R is present 
in both males and females although they differ in the patterns of expression with ageing. 
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Table 4.1 Two-way analysis of variance of age and post-ischaemic effects on caveolin 
transcript expression in the female heart 
Gene Factor Mean Square F (DFn, DFd) % of Total 
Variation 
P value 
Cav1 
Age 1.210 4.36 (3,38) 20.0% 0.0098 
Ischaemia 0.804 2.90 (1,38) 4.4% 0.0967 
Age*Ischaemia 0.998 3.60 (3,38) 16.5% 0.0220 
Cav2 
Age 0.826 3.62 (3,40) 13.1% 0.0211 
Ischaemia 4.820 21.21 (1,40) 25.4% < 0.0001 
Age*Ischaemia 0.847 3.71 (3,40) 13.4% 0.0192 
Cav3 
Age 1.397 6.91 (3,38) 19.7% 0.0008 
Ischaemia 8.158 40.32 (1,38) 38.3% < 0.0001 
Age*Ischaemia 0.571 2.82 (3,38) 8.1% 0.0516 
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Figure 4.3 Age dependent expression of caveolin transcripts in normoxic and post-ischaemic 
female hearts. Shown are boxplots detailing expression changes determined by RT-qPCR for A) 
Cav1, B) Cav2 and C) Cav3 in the normoxic (grey boxes) and post-ischaemic (red boxes) heart. 
Boxes indicate interquartile range (25%-75%) with the horizontal bar within each box indicating 
the median. The whiskers show the minimum and maximum values. * P < 0.05 vs 32-week old 
normoxic; † P < 0.05 vs 16-week old post-ischaemic; # P < 0.05 vs age-matched post-ischaemic 
group (indicated by brackets). (n=6/group).  
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4.3.3.2 Immunoblot analysis of caveolin3 protein expression 
To verify the relationship between Cav3 transcript and protein expression changes 
immunoblotting was used. In the normoxic 48-week old female heart Cav3 showed a 
significant 1.6-fold reduction in protein expression (Figure 4.4A). This finding was similar to 
observations in the male normoxic heart, which demonstrated a significant age-related 
reduction (1.5-fold) in Cav3 (Figure 3.5A). In the post-ischaemic 48-week old female heart, 
Cav3 protein expression was down-regulated 1.7-fold (P=0.07) relative to 8-week old hearts 
(Figure 4.4B). In the male counterparts, Cav3 expression was significantly reduced in both the 
48-week old normoxic and post-ischaemic hearts (Figure 3.5A & Figure 3.5B). Taken together, 
there is an age-related reduction in Cav3 in both the normoxic and post-ischaemic male and 
female hearts.  
 
Figure 4.4 Age-dependent Cav3 protein expression in normoxic and post-ischaemic female 
hearts. Boxplots are shown detailing Cav3 protein expression in A) normoxic and B) post-
ischaemic ageing hearts. Boxes indicate the interquartile range (25%-75%) with the horizontal 
bar within each box indicating the median. The whiskers show the minimum and maximum. 
*P < 0.05 vs. 8-week old. (n=6/group). 
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4.3.3.3 Transcriptional analysis of cavin expression in the ageing female mouse normoxic 
and post-ischaemic female mouse heart 
In the normoxic female heart, Cavin1 showed no changes in expression with ageing and did 
not show significant interaction of age and ischaemia (Table 4.2, Figure 4.5A). Expression 
levels were however different in the male heart, where Cavin1 showed significant down-
regulation in the 16- and 48-week old normoxic heart (Figure 3.6A) and showed significant 
interaction of age. In the post-ischaemic female heart, Cavin1 demonstrated no age-related 
changes in transcript expression (Figure 4.7A) whilst male counterparts showed significant 
down-regulation the in 16 and 48-week old hearts (Figure 3.6A).  Although the post-ischaemic 
female hearts did not show age-related changes compared to their normoxic counterparts, 
the 48-week old post-ischaemic heart showed nearly 2-fold up-regulation of Cavin1 that was 
close to statistical significance (P= 0.05) (Figure 4.5A). Expression of Cavin2 in the ageing 
normoxic and post-ischaemic female hearts was largely stable although there were minor 
significant differences were detected (Figure 4.5B). Post-ischaemic male hearts previously 
demonstrated significant down-regulation of Cavin2 in the 48-week old heart vs 8-week 
(Figure 3.6B). A significant interaction of age and ischaemia was detected for Cavin2; this was 
only significant in the 16-week old hearts which displayed a 1.5-fold reduction in Cavin2 when 
compared to normoxic counterparts. Whereas male counterparts displayed a reduction in the 
16-week old and older hearts.  
Normoxic Cavin3 did not show significant changes with ageing (Figure 4.5C), this was similar 
to male hearts. Significant up-regulation of Cavin3 was present in the 32- and 48-week old 
post-ischaemic heart compared to 16-week old (Figure 4.5C) with this interaction of age an 
ischaemia supported by two-way ANOVA analysis (Table 4.2). This induction of Cavin3 in the 
32-week old hearts was also significant when compared to their-age matched normoxic 
counterparts (Figure 4.5) and was not present in males. In the normoxic ageing hearts, Cavin4 
showed significant 1.6-fold up-regulation the 32-week old hearts when compared to 8- and 
16-week old hearts (Figure 4.5C). Post-ischaemic expression of Cavin4 showed minor changes 
in expression with ageing and returned to baseline levels (Figure 4.5D) similar to males.  
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Table 4.2 Two-way analysis of variance of age and post-ischaemic effects on cavin transcript 
expression in the female heart 
Gene Factor Mean Square F (DFn, DFd) % of Total 
Variation 
P value 
Cavin1 
Age 0.385 0.84 (3,38) 5.1% 0.4816 
Ischaemia 2.511 5.46 (1,38) 11.0% 0.0248 
Age*Ischaemia 0.533 1.16 (3,38) 7.0% 0.3377 
Cavin2 
Age 0.482 4.00 (3,40) 16.5% 0.0038 
Ischaemia 0.000 0.01 (1,40) 0.1% < 0.0001 
Age*Ischaemia 0.842 6.99 (3,40) 28.8% 0.0017 
Cavin3 
Age 1.393 8.07 (3,39) 29.8% 0.0003 
Ischaemia 2.127 12.33 (1,39) 15.2% 0.0011 
Age*Ischaemia 0.376 2.18 (3,39) 8.1% 0.1058 
Cavin4 
Age 1.436 9.92 (3,40) 40.2% < 0.0001 
Ischaemia 0.189 1.31 (1,40) 1.8% 0.2594 
Age*Ischaemia 0.141 0.97 (3,40) 4.0% 0.4142 
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4.5 Age dependent expression of cavin transcripts in normoxic and post-ischaemic female 
hearts. Shown are boxplots detailing expression changes determined by RT-qPCR for A) Cavin1, B) 
Cavin2, C) Cavin3 and D) Cavin4 in the normoxic (grey boxes) and post-ischaemic (red boxes) heart 
(n=6/group). Boxes indicate interquartile range (25%-75%) with the horizontal bar within each box 
indicating the median. The whiskers show the minimum and maximum values. * P < 0.05 vs 32-
week old normoxic; † P < 0.05 vs 16-week old post-ischaemic, # P < 0.05 vs age-matched post-
ischaemic group (indicated by brackets). (n=6/group).  
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4.3.3.4 Immunoblot Cavin1 
In agreement with the transcriptional analysis, Cavin1 protein did not show an age-related 
change in expression in the normoxic female heart (Figure 4.6A). In the male normoxic heart 
a minor trend in down-regulation of Cavin1 (although not statistically significant) was 
observed. In post-ischaemic female hearts, transcriptional analysis suggested no significant 
age-related changes in Cavin1 expression were present. However proteomic analysis of 
Cavin1 showed significant 1.6-fold decrease (Figure 4.6B). Similarly, in the male post-
ischaemic counterpart, there was a 1.6-fold reduction in Cavin1 protein expression in the 48-
week old heart. Collectively the 48-week old male and female post-ischaemic myocardium 
display loss of Cavin1, although this finding was unexpected in the female 48-week old hearts 
as transcriptional analysis suggested no transcriptional changes. 
 
Figure 4.6 Age-dependent expression of Cavin1 protein in normoxic and post-ischaemic 
female hearts. Boxplots are shown detailing Cavin1 protein expression in A) normoxic and B) 
post-ischaemic ageing hearts. Boxes indicate the interquartile range (25%-75%) with the 
horizontal bar within each box indicating the median. The whiskers show the minimum and 
maximum values. To the right of the graphs representative immunoblot images are shown for 
cavin1 and the β-Actin loading control. *P < 0.05 vs. 8-week old. (n=6/group).  
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4.3.3.5 Transcriptional analysis of Popdc expression in the ageing male mouse normoxic and 
post-ischaemic female mouse heart 
A general up-regulated pattern with increased age was observed for Popdc1 similar to male 
normoxic counterparts. In the post-ischaemic female hearts, Popdc1 showed a significant 
down-regulation (2.0-fold) in 16-week old hearts when compared to all other groups (Figure 
4.7A). This interaction of age and ischaemia is also supported by two-way analysis (Table 4.3). 
Whilst male post-ischaemic ageing hearts showed repression of Popdc1 in the 32 and 48-week 
old hearts (Figure 3.6A). Down-regulation of Popdc1 was only present in the 16-week old post-
ischaemic hearts vs age-matched normoxic hearts (Figure 4.7A). Two-way ANOVAs on 
expression levels of Popdc1 revealed significant effects of ischaemia and ageing (Table 4.3) 
although this was largely unaffected with ageing as shown in figure 4.7A. Whilst male 
counterparts previously showed down-regulation in the 32- and 48-week old post-ischaemic 
hearts vs age-matched normoxics (Figure 3.8A). Popdc2 demonstrated no changes with 
ageing (Figure 3.8B) similar to males. Normoxic and post-ischaemic Popdc3 cardiac expression 
showed no changes (Figure 4.7C).  Male counterparts previously demonstrated repression of 
Popdc3 in 32 and 48-week old post-ischaemic hearts. Interestingly, when compared to their 
normoxic counterparts, Popdc3 showed induction with ageing, significant in the 8, 32 and 48-
week old hearts (Figure 4.7C). With this main effect of ischaemia also supported by two-way 
ANOVA analysis (Table 4.3). This was in contrast to male counterparts, which showed 
significant Popdc3 reduction in the 32 and 48-week old post-ischaemic hearts vs normoxic 
counterparts (Figure 3.8C). 
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Table 4.3 Two-way analysis of variance of age and post-ischaemic effects on Popdc 
transcript expression in the female heart 
 
Gene Factor Mean Square F (DFn, DFd) % of Total 
Variation 
P value 
Popdc1 
Age 1.335 3.63 (3,40) 14.4% 0.0208 
Ischaemia 2.307 6.28 (1,40) 8.3% 0.0164 
Age*Ischaemia 2.256 6.14 (3,40) 24.4% 0.0016 
Popdc2 
Age 1.204 4.78 (3,40) 24.7% 0.0063 
Ischaemia 0.091 0.36 (1,38) 0.6% 0.5498 
Age*Ischaemia 0.464 1.85 (3,38) 9.5% 0.1555 
Popdc3 
Age 0.877 6.91 (3,40) 18.9% 0.0007 
Ischaemia 5.798 45.69 (1,40) 41.7% < 0.0001 
Age*Ischaemia 0.133 1.05 (3,40) 2.9% 0.3806 
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Figure 4.7 Age dependent expression of Popdc transcripts in normoxic and post-ischaemic 
female hearts. Shown are boxplots detailing expression changes determined by RT-qPCR for A) 
Popdc1, B) Popdc2, and C) Popdc3 in the normoxic (grey boxes) and post-ischaemic (red boxes) 
heart. Boxes indicate interquartile range (25%-75%) with the horizontal bar within each box 
indicating the median. The whiskers show the minimum and maximum values. * P < 0.05 vs 16-
week old post-ischaemic, # P < 0.05 vs age-matched post-ischaemic group (indicated by 
brackets). (n=6/group). 
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Ageing is associated with increased prevalence of IHD; however, females appear to show a 
reduced prevalence of IHD when compared to age-matched males until after 75 years of age 
(Mosca Barrett-Connor & Wenger 2011). Many studies implicate ER mediated signalling as a 
key contributor in the sex-based differences in cardioprotective signalling, as attenuation of 
cardioprotection is correlated with menopause (see review Yang & Reckelhoff 2011).  Sex-
based studies have largely focused on ERα, ERβ and GPR30 as they are expressed in both the 
male and female left ventricular tissue. Interestingly, female hearts show higher expression 
levels of ERs relative to males (Patterson et al. 2010; Filice et al. 2009). Whilst activation of 
these receptors is cardioprotective there is conflicting evidence as to whether they are 
caveolae-dependant. More specifically, although ERα has been shown to localise in 
endothelial caveolae, conflicting reports exist whether Cav3 and ERα co-localise in 
cardiomyocytes (Chambliss et al. 2000; Chung et al. 2009; Mahmoodzadeh et al. 2006). These 
differences may arise from different cardiomyocyte cell models used, specifically neonatal 
cardiomyocytes compared to adult cells. Thus far only one sex-related study has shown 
differential interaction of Cav3 with eNOS following I-R (Sun et al. 2006). However, the 
expression of caveolae coat proteins remains uncharacterised in the ageing female heart, 
which may contribute to the sex-related differences in cardioprotection. Thus, in a similar 
manner to Chapter 3, we sought to characterise the expression of caveolae coat proteins 
including members of caveolin, cavin and Popdc genes in an attempt to investigate sex-based 
differences. We hypothesised that the female aging myocardium would not show the age-
related loss of caveolae coat proteins observed in the male myocardium. Surprisingly, we 
observed the down-regulation of several crucial caveolae-related transcripts and proteins 
similar to their male counterparts.  
Transcriptional analysis of Cav3 in normoxic female hearts showed a minor down-regulated 
trend in Cav3 as early as 16-week old hearts, similar to expression patterns observed in male 
counterparts. However, proteomic validation showed that the non-significant mRNA 
reduction in Cav3 in the normoxic hearts was significant at the protein level in the 48-week 
old hearts (Figure 4.4A). Conversely the post-ischaemic hearts suggested significant down-
regulation of Cav3 at the transcriptional level as early as 16-weeks old (Figure 4.4C), although 
proteomic validation of Cav3 in the 48-week old heart showed a borderline non-significant 
reduction (P=0.07; Figure 4.5B).  However, given the combined reduction of Cav3, Cavin1 and 
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Popdc1 in the ageing post-ischaemic heart, it is possible that caveolae formation in these 
hearts is significantly reduced although this remains to be shown morphologically (e.g. by 
electron microscopy) and warrants future investigation. Taken together, the post-ischaemic 
female ageing heart shows similar repression of several caveolae-essential coat proteins 
which may impair caveolae formation in the female myocardium. As caveolae forming 
transcripts Cav3 and Popdc1 are down-regulated in the middle-aged hearts, as well as Cavin1 
protein, this may lead to a reduction in cardiac caveolae formation thereby may be partially 
responsible for the loss of ischaemic tolerance in the middle-aged hearts. Interestingly, the 
LDH release observed in the 16- and 32-week old hearts parallels the expression of caveolae 
forming transcripts Cav3 (Figure 4.4C) and Popdc1 (Figure 4.7A), thus suggesting non-
caveolae mechanisms may be responsible for protection observed in these hearts. 
There is conflicting evidence regarding the localisation of ERs in cardiomyocyte caveolae 
(Chung et al. 2009; Mahmoodzadeh et al. 2006). It is possible these differences may be 
species-related (mouse vs. human). If ERs are not enriched in caveolae then ER signalling may 
be preserved in the ageing female heart, thus leading to enhanced recovery even if caveolae 
density is reduced. Indeed, acute ER-α activation has been shown to restore ischaemic 
tolerance in the senescent (>74 week old) female mouse heart and has been suggested as a 
therapeutic in aging women with IHD (Novotny et al. 2009). In addition, activation of the 
cardioprotective GPR30 may also be responsible for I-R tolerance in these hearts and whether 
it selectively partitions in cardiomyocyte caveolae is unknown (Deschamps & Murphy 2009).  
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4.4 CONCLUSION  
In this study, we sought to investigate the expression of caveolae-related transcripts in the 
ageing female heart and whether changes in expression correlated with enhanced 
cardioprotection. However, at the functional level the ageing female heart showed a similar 
loss of ischaemic tolerance comparable to the age-matched male myocardium (Chapter 3). 
More specifically, the protected phenotype observed in mature to middle-aged female hearts 
(32- and 48-weeks) as reported in Willems and colleagues (2005) was not observed. The 
reasons for this discrepancy are unknown as the strain of mouse and I-R protocols are similar 
between studies.  We also observed down-regulation of caveolae transcripts similar to that 
observed in male counterparts, which also coincided with the loss of endogenous ischaemic 
tolerance in the middle-aged hearts. Notably, in the normoxic ageing heart Cav3 showed 
significant down-regulation as early as 16-weeks old. Transcriptional and proteomic analysis 
(p=0.07) of Cav3 demonstrates repression in the 48-week old heart. Recently, Cavin1 and 
Popdc1 have also been shown to be crucial for cardiomyocyte caveolae formation (Kasahara 
et al. 2014; Alcalay et al. 2013). Whilst Cavin1 expression did not change with aging in the 
normoxic heart, the 48-week old post-ischaemic heart showed significant decrease of Cavin1, 
which was confirmed by immunoblotting. The repression of these transcripts and their 
proteins coincide with the loss of cardioprotection in these hearts and may be partially 
responsible for the loss of endogenous protection. There are conflicting reports about the 
caveolae localisation of ER-α localisation in the heart (Chung et al. 2009; Mahmoodzadeh et 
al. 2006). If indeed ER-α does not localise in caveolae, then it is possible ER-mediated 
protection is caveolae/Cav3-independent and may be responsible for the protection observed 
in the female 16- and 32-week old post-ischaemic hearts.  Taken together, the combined 
reduction of Cav3, Cavin1 and Popdc1 in the middle-aged female myocardium may lead to a 
reduction in caveolae density and subsequently responsible for the loss of cardioprotection 
observed in the middle-aged post-ischaemic hearts. Future studies should examine whether 
the age-related reductions of these transcripts result in morphological loss of caveolae in the 
middle-aged female hearts.  
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5. Chapter Five 
RNA interference of Caveolin-3 in the HL-1 cardiomyocyte 
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5.1 INTRODUCTION 
As previously shown in Chapter 3, a decrease in Cav3 expression is associated with the age-
related decline in I-R tolerance. Caveolae influence cell signalling by sequestering receptor 
proteins including GPCRs (and their subunits) and receptor tyrosine kinases (RTKs), these 
receptor families have all previously been shown to play crucial roles in cardioprotection (as 
reviewed by Stary et al. 2012 and discussed in detail in Section 1.7.1.3). The Cav3 structural 
protein is critical for caveolae formation in muscle-type cells including cardiomyocytes as 
demonstrated through Cav3-deficient mice whose hearts lack caveolae (Park et al. 2002). 
Cav3-deficient hearts also display reduced cardioprotection via the loss of IPC, anaesthetic 
and GPCR-mediated preconditioning, demonstrating the importance of caveolae in 
cardioprotection (Tsutsumi et al. 2008; Horikawa et al. 2008). Furthermore, pharmacological 
disruption via MβCD treatment results in depletion of membrane cholesterol, disrupting 
caveolae structure and reducing recovery from I-R (See Hoe et al. 2014; Horikawa et al. 2008; 
Patel et al. 2006; Tsutsumi et al. 2010). In further support of our evidence, aged (74-week old 
mice) mice have been shown to demonstrate a reduction in cardiac caveolae density (Kidd et 
al. 2010; Peart et al. 2014). Conversely, cardiomyocyte-specific Cav3 overexpression results 
in the restoration of caveolae density in the aged heart to comparable levels displayed in 
young wild-type hearts thus leading to improved ischaemic tolerance and recovery in these 
aged hearts (Kidd et al. 2010). A limitation of Cav3-knockout and pharmacological methods is 
that these result in complete ablation of caveolae. Therefore, we sought an approach to 
reduce rather than remove caveolae entirely. For this purpose, we investigated the 
application of RNA interference (RNAi). 
RNA interference (RNAi) is an important natural pathway used in many different organisms 
to regulate gene expression. RNAi typically results in the reduction of gene expression and 
the corresponding protein product by as much as 70-90%, although the degree of knockdown 
is highly dependent on cell type (Ma, Lin & Qiu 2012). This pathway was first discovered by 
Fire, Mello and colleagues in 1998 who published their seminal article describing endogenous 
post-transcriptional mechanisms of suppressing mRNA expression in C. elegans (Fire et al. 
1998). For this discovery they were awarded The Nobel Prize in Physiology or Medicine in 
2006. 
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RNAi exploits endogenous mechanisms that use small RNA fragments such as small interfering 
RNA (siRNA) and microRNA (miRNA) which are used within the cell to fine-tune transcriptional 
activity. Current estimates suggest there are over 1,000 known miRNA in the mammalian 
genome (http://microrna.sanger.ac.uk). Experimental & bioinformatics evidence suggests 
that >30% of protein-coding genes are subject to miRNA-mediated regulation (Chen & 
Rajewsky 2007). Whilst typically involved in gene suppression some evidence exists 
demonstrating miRNAs can also result in gene activation (Zamore & Haley 2005). 
MicroRNAs are transcribed from their own specific genes or from within introns of protein-
coding genes (Saini, Jones & Enright 2007). MicroRNA is first transcribed as a primary miRNA 
(pri-miRNA) of few hundred nucleotides folded into a hairpin loop structure (Figure 5.1A). The 
pri-miRNA is then trimmed by the Drosha enzyme in the nucleus to form a pre-miRNA 
transcript of approximately 70 nucleotides in size (Figure 5.1A). The pre-miRNA is transported 
out of the nucleus via the Exportin-5 protein. Once in the cytoplasm, the enzyme Dicer 
removes the hairpin loop, resulting in a mature miRNA duplex approximately 22-23 base pairs 
in size (Figure 5.1B). One strand (known as the ‘guide’ strand) of the mature miRNA duplex is 
captured by a multi-protein complex known as RNA-induced silencing complex (RISC), the 
accompanying ‘passenger’ miRNA strand is typically degraded (Figure 5.1C). The RISC complex 
uses the miRNA-guide strand for mRNA target recognition through base complementarity 
using the Argonaute family of proteins (Pratt & MacRae 2009). Through Argonaute protein 
subunits, RISC possesses RNase activity and cleaves the target mRNA if perfect 
complementarity between the miRNA and target mRNA occurs (Figure 5.1D). Whilst, 
imperfect base-pairing between the miRNA and target mRNA does not result in cleavage of 
the target mRNA, gene silencing can still occur through translational repression (Figure 5.1E). 
As a consequence of mRNA degradation or translational repression de novo protein synthesis 
is reduced with varying efficacy. Alternatively, double-stranded (dsRNA) can be introduced 
exogenously as small 20-30 nucleotide molecules known as small interfering RNA (siRNA). 
These siRNA molecules can also result in RNAi using similar pathways to miRNA-mediated 
silencing. It is thought that miRNAs are responsible for gene regulation whilst siRNAs are 
defensive mechanisms for genomic integrity in response to foreign or invasive nucleic acids 
such as viruses, transposons and transgenes (Carthew & Sontheimer 2009).  
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Figure 5.1 The RNAi pathway (Taken from He & Hannon 2004). Experimental introduction of 
miRNAs and dsRNAs rely on the same endogenous RNAi mechanisms that occurs naturally 
within the cell.  
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The natural process of RNAi can be experimentally manipulated by adding exogenous miRNA 
genes into cells to target and repress specific mRNA sequences. As an experimental tool of 
investigating gene knockdown there are several advantages to performing RNAi over 
knockout animals and pharmacological approaches. Unlike knockout-organisms where there 
is total depletion of target mRNA, RNAi allows for a reduction rather than ablation of the 
target mRNA and corresponding protein expression. Using RNAi, a reduction of as much as 
70-90% knockdown can be achieved (Hsieh et al. 2004). Traditional gene knockout 
approaches result in an animal that is deficient in the target gene and resulting protein. This 
can result in embryonic lethality which has been estimated to occur in 15% of knockout 
models (NIH 2003). In addition, some knockout models may result in compensatory 
mechanisms occurring. For example, MyoD or Myf5 deficient mice both demonstrate the 
wild-type phenotype. However, the MyoD/Myf5 double-knockout shows complete deficiency 
of both genes and a distinct phenotype (Rudnicki et al. 1992; Rudnicki et al. 1993). When 
compared to pharmacological approach, RNAi is more readily employed since it relies on 
mRNA sequence knowledge which can be designed to more specifically target a single mRNA 
and its resulting protein product. In contrast, many pharmacological approaches are broad 
action or use indirect actions to achieve a desired effect. For example, MβCD results in 
caveolae disruption through cholesterol depletion which will affect other cholesterol 
containing cellular compartments (including planar lipid rafts) and hence may have an 
undesired effect on cells (Mathay & Poumay 2010). To avoid this, Cav3 RNAi has been used 
by others to selectively target caveolae for use in patch-clamp studies to avoid confounding 
effects of lipid raft depletion (Garg, Jiao & Hu 2009; Balijepalli et al. 2006). RNAi allows for 
down-regulation of the target protein without completely ablating its expression which may 
more closely resemble expression perturbations in disease states. 
Experimentally, RNAi can be induced by exogenous introducing miRNA expression vectors or 
siRNA molecules. There are three major technologies used to introduce these exogenous 
molecules into target cells: 1) transfection using cationic lipids or polymers, 2) electroporation 
and 3) viral transduction. Transfection is the most commonly used approach in cell culture 
investigations. This is mainly due to its safety, relative experimental ease and high efficiency 
and reproducibility in dividing cells. However, this approach has a low efficiency of delivery in 
primary and non-dividing cells, as well as in in vivo models (Karra & Dahm 2010). A further 
extensive comparison of the different delivery methods is beyond the scope of this study, but 
is reviewed elsewhere (Louch, Sheehan & Wolska 2011). Chemical transfection employs 
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cationic lipids or polymers which contain diacylglycerol formulations such as DOPC and DOPE. 
These combine with DNA to form moieties that cross the plasma membrane and enter into 
the cell’s nucleus through currently unknown mechanisms (Elouahabi & Ruysschaert 2005). 
Once introduced the effects of transfection are typically transient with the miRNA effects 
lasting for 2-3 days, as the introduced vector isn’t integrated into the genome. As a 
consequence, the vector is diluted out during cell division or degraded by nucleases. 
As previously discussed transfection is most effective in dividing non-primary cells. For this 
reason, we used the HL-1 cardiomyocyte cell line as the experimental model. The HL-1 
cardiomyocyte cell line is an SV40 immortalised cardiac cell line which has been shown to 
resemble adult cardiomyocyte counterparts by expressing adult marker genes and retains a 
cardiac morphology even after high passage counts (Claycomb et al. 1998). More specifically, 
key morphological features such as ANF granules, formation of intercalated discs and 
sarcolemmal Z densities which have all been shown to be present and retained following 
serial passages (Claycomb et al. 1998). Despite continual mitosis, HL-1 cells also display adult 
phenotypic markers such as α-MHC, ANF, α-actin cardiac and Connexin43 (Claycomb et al. 
1998). Although they do not express beta-tubulin II which is found in primary atrial cells 
(Kuznetosv et al. 2015). Similar to its adult primary counterpart, HL-1 cardiomyocytes 
spontaneously contract as shown by electrophysiological characterisation (Claycomb et al. 
1998). HL-1 cells also express many receptors and their respective cytoplasmic targets, this is 
further demonstrated their ability to be pharmacologically preconditioned model prior to 
simulated I-R (Seymour et al. 2003). Collectively, HL-1 cardiomyocytes have become an 
alternative cell-culture model to neonatal and adult cardiomyocyte in the context of 
simulated I-R (Parameswaran et al. 2013).  Furthermore, HL-1 cells do not lose their adult 
cardiomyocyte phenotype and significant attrition once isolated, whereas adult primary 
cardiomyocytes have been shown to have reduced T-tubule density and capacitance as early 
as 24 hours post-isolation (Louch, Sheehan & Wolksa 2011; Zhou et al. 2000). HL-1 
cardiomyocytes are also amenable to transfection via cationic lipids, as commonly used in 
RNAi (Brady et al. 2007; Huang et al. 2010). In the following study we developed protocols to 
introduce miRNA-Cav3 expression vectors into HL-1 cardiomyocytes via cationic lipid 
transfection. A number of parameters were assessed to optimise transfection efficiency to 
maximise Cav3 knockdown and enable the analysis of the functional effects, specifically 
changes in ischaemic tolerance.  
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5.2 METHODS 
5.2.1 Cell culture 
HL-1 cardiomyocytes were cultured and maintained as described in Section 2.1.2. For all 
transfection experiment, HL-1 cells were kept in a logarithmic growth phase at 70-80% 
confluency. We employed HL-1 cells for transfection and sI-R experiments as shown by several 
authors (Brady, Hamacher-Brady and Gottlieb, 2006; Wang et al. 2013; Brady et al. 2007).   
 
5.2.2 Vector construction and purification  
 
Using the online design tool provided by the manufacturer, four pre-designed BLOCK-iT™ miR 
RNAi Select oligonucleotide sequences (Mmi505775; Mmi505776; Mmi505777; Mmi505778) 
targeting different regions of the mouse Cav3 mRNA (Table 5.1 and Figure 53) were cloned in 
to pcDNA™6.2-GW/EmGFP-miR BLOCK-iT™ Pol II miR RNAi expression vectors according to 
supplier’s protocols (Life Technologies, Carlsbad, CA, USA). To control for non-specific RNAi 
effects, an expression vector containing a miRNA targeting the bacterial LacZ gene was also 
constructed for use as a negative control. The miRNA vectors were transformed into TOP10 
E. coli, propagated for 24 hours, and five individual colonies for each miRNA sequence purified 
using the PureLink™ HQ Mini Plasmid Purification kit (Life Technologies). Plasmid DNA 
concentration and purity was assessed via UV spectrophotometry (NanoDrop 2000; Thermo 
Scientific, Waltham, MA, USA). Plasmid integrity was also assessed by 1% agarose gel 
electrophoresis (90V; 90 minutes). Finally, to verify successful and accurate insertion of Cav3 
and LacZ oligonucleotides into the vector, all miRNA vectors were Sanger sequenced using 
BigDye Terminators according to the manufacturer’s protocols (Life Technologies, Carlsbad, 
CA, USA). Sequencing chromatograms were analysed using FinchTV software (PerkinElmer 
Seattle, WA, USA). 
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Table 5.1 Cav3 and LacZ miRNA duplex sequences used to create artificial miRNA hairpins. 
The mature miRNA sequence is underlined on the top strand.  
 
 
  
Vector ID BLOCK-iT 
Identifier 
Strand Sequence (5’-3’) 
Cav3-A Mmi505775 Top TGCTGACAATGTCCTCATTGATGTTCGTTTTGGCCA
CTGACTGACGAACATCAGAGGACATTG 
Bottom CCTGACAATGTCCTCTGATGTTCGTCAGTCAGTGGC
CAAAACGAACATCAATGAGGACATTGTC 
Cav3-B Mmi505776 Top TGCTGTTCCCTTCGCAGCACCACCTTGTTTTGGCCA
CTGACTGACAAGGTGGTTGCGAAGGGAA 
Bottom CCTGTTCCCTTCGCAACCACCTTGTCAGTCAGTGGC
CAAAACAAGGTGGTGCTGCGAAGGGAAC 
Cav3-C Mmi505777 Top TGCTGAGATGTGGCTGATGCACTGGAGTTTTGGCCA
CTGACTGACTCCAGTGCCAGCCACATCT 
Bottom CCTGAGATGTGGCTGGCACTGGAGTCAGTCAGTGGC
CAAAACTCCAGTGCATCAGCCACATCTC 
Cav3-D Mmi505778 Top TGCTGAACAGGCGGTAGCACCAGTACGTTTTGGCCA
CTGACTGACGTACTGGTTACCGCCTGTT 
Bottom CCTGAACAGGCGGTAACCAGTACGTCAGTCAGTGGC
CAAAACGTACTGGTGCTACCGCCTGTTC 
LacZ 
 
- Top TGCTGAAATCGCTGATTTGTGTAGTCGTTTTGGCCA
CTGACTGACGACTACACATCAGCGATTT 
Bottom CCTGAAATCGCTGATGTGTAGTCGTCAGTCAGTGGC
CAAAACGACTACACAAATCAGCGATTTC 
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ATGATGACCGAAGAGCACACGGATCTGGAAGCTCGGATCATCAAGGACATTCACTGCAAGGA
GATAGACTTGGTGAACCGCGACCCCAAGAACATCAATGAGGACATTGTGAAGGTAGATTTTG
AAGACGTGATTGCGGAGCCCGAGGGCACCTACAGCTTCGACGGTGTATGGAAGGTGAGCTTC
ACCACGTTCACCGTCTCCAAGTACTGGTGCTACCGCCTGTTGTCTACACTGCTGGGTGTTCC
ACTGGCCCTGCTCTGGGGATTCCTGTTCGCCTGTATCTCCTTCTGCCACATCTGGGCCGTGG
TGCCCTGCATTAAGAGCTACCTGATCGAGATCCAGTGCATCAGCCACATCTACTCACTGTGT
ATCCGCACCTTCTGCAACCCGCTCTTCGCTGCGTTGGGCCAGGTCTGCAGCAACATTAAGGT
GGTGCTGCGAAGGGAAGGCTAA 
Figure 5.2 Alignment of the four Block-iT miR-Cav3 sequences to the coding sequence of 
Cav3 mRNA. Cav3 miRNA target sequences are underlined (Cav3-A, Cav3-D, Cav3-C and Cav3-
B respectively). Exons 1 and 2 are identified by the black and blue text respectively. 
 
 
 
Figure 5.3 Map of the pcDNA™6.2-GW/EmGFP-miR vector. Each miRNA is inserted between 
the 5’ and 3’ miR flanking regions. Key features of this plasmid are the CMV promoter (PCMV), 
spectinomycin resistance gene and the Emerald Green Fluorescent Protein (EmGFP) gene 
which are co-expressed with the miRNA and allows for visual assessment of transfection 
efficiency (Lipofectamine 2013).  
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5.2.3 Transfection  
Five commonly used chemical transfection reagents were initially trialled using suggested 
manufacturers’ protocols: FuGene (Promega), Lipofectamine LTX® (Life Technologies), 
TransFectin® (Bio-Rad), Lipofectamine® 2000 (Life Technologies) and DharmaFECT1® (GE 
Healthcare). Lipofectamine® 2000 performed the best in the preliminary trials and was used 
in all subsequent transfections. Further optimisation of transfection protocols was carried out 
according to manufacturer’s protocols (Life Technologies, Carlsbad, CA, USA). Briefly, this 
involved systematically addressing each of several critical variables including (but not 
exclusive to) DNA concentration, vector DNA:Lipofectamine® 2000 ratio, cell confluency, 
transfection method (forward or reverse transfection), and cell incubation time in 
transfection complex. All transfections were performed in a final volume of 100 μL for 
Lipofectamine® 2000 in 12-well culture plates (Nunc; Thermo Scientific Waltham, MA, USA). 
The LacZ-miRNA vector was used during transfection optimisation to limit any potential 
deleterious effects of Cav3 knockdown. Transfection complexes were formed using 50 μL of 
Opti-MEM media (Life Technologies) and vector DNA. Algorithmic parameters and more 
specific details are further provided in the results section. Cells were also transfected with 
transfection reagent alone as a mock control. Cells were transfected with the miRNA vector 
for 5 hours then washed twice with PBS before the addition of fully supplemented Claycomb 
media. Transfection efficiency was assessed via GFP expression 48 hours’ post-transfection 
by both fluorescent microscopy and flow cytometry. Based on the optimisation results the 
following standard protocol: 1 μg vector DNA; 1 μL Lipofectamine® 2000 and a density of 2 x 
105 cells were applied when transfecting with the Cav3-miR expression vectors. 
 
5.2.4 Assessment of transfection efficiency   
Prior to the flow cytometric analysis of GFP expression, transfection efficiency was estimated 
via an inverted fluorescent microscope (EVOS® fl; Life Technologies) at 10X magnification. 
Transmitted light channel images were overlayed with the GFP channel to show GFP positive 
cells within the whole population. Flow cytometric assessment of GFP expression was 
performed on a BD FACSVerse (BD Sciences, East Rutherford, New Jersey, USA). Post-
transfection (48 hours) HL-1 cells were trypsinised and then washed with PBS. Cells were 
stained with the cell viability dye 7-aminoactinomycin D (7-AAD) (BD Pharmingen East 
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Rutherford, New Jersey, USA) and incubated for 15 minutes. Using 488 nm lasers, 
fluorescence for GFP and 7-AAD was collected in the FL1 and FL3 channels respectively. 
Scatter plots, quadrants and fluorescence compensation were established using single 
population staining for both fluorescent channels as described by MIT (2015). All flow 
cytometer results were collected using BD CellQuestPro and FACSuite software (BD Sciences).  
 
5.2.5 Simulated Ischaemia-Reperfusion (sI-R)  
 
Simulated ischaemia-reperfusion (sI-R) of HL-1 cells was carried out according to previously 
published protocols (Brady, Hamacher-Brady and Gottlieb, 2006). Briefly, non-transfected 
and transfected HL-1 cardiomyocytes were switched to an ischaemia-mimetic solution (IMS) 
containing 20 mM HEPES (pH 6.6), 125 mM NaCl, 8 mM KCl, 1.2 mM KH2PO4, 1.25 mM 
MgSO4, 1.2 mM CaCl2, 6.25 mM NaHCO3 and 5 mM Na-lactate in a sealed hypoxic 
chamber (STEMCELL Technologies, Vancouver, BC, Canada) and equilibrated with 95% N2/5% 
CO2 for 3 hours. All chemicals were purchased from Sigma-Aldrich. Reperfusion was achieved 
by substitution of ischaemia-mimetic buffer with a normoxic Krebs-Henseleit solution 
containing 20 mM HEPES (pH 7.4), 110 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.25 mM 
MgSO4, 1.2 mM CaCl2, 25 mM NaHCO3 and 15 mM glucose, equilibrated with 95% O2/5% CO2 
for a further 5 hours. For normoxic experiments HL-1 cells were incubated in Krebs-Henseleit 
solution for 8 hours at 37oC, 95% air/5% CO2. LDH activity was measured in supernatants using 
the Cytotox 96® cytotoxity assay (Promega, Madison, WI, USA). Cells were incubated at room 
temperature and protected from light for 30 minutes prior to the addition of Stop Buffer. 
Absorbance at 492 nm was measured using a Modulus II Microplate reader (Promega).  
 
5.2.6 Apoptosis detection 
 
To determine apoptosis after normoxia and sI-R, trypsinised cells from each well were 
resuspended in 1X of Binding Buffer from the Annexin V-PE kit (BD Pharmingen, East 
Rutherford, New Jersey, USA). Briefly, HL-1 cells were stained using 5 μL of Annexin V and 5 
μL of 7-AAD and incubated for 15 minutes. Flow cytometry was carried out on a BD FACSVerse 
(BD Biosciences) equipped with an argon laser. A total of 1 x 104 events were collected per 
sample. The data were analysed with FACSuite software (BD Sciences, San Jose, CA). 
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Adjustment of forward scatter, side scatter and FL channel quadrants were setup using similar 
methods as outlined in Section 5.2.4.  
 
5.2.7 Treatment with MβCD 
The effects of Cav3 RNAi knockdown were compared to those of complete cholesterol 
depletion via MβCD treatment. Prior to simulated I-R, HL-1 cells were treated with 1 mM 
MβCD and incubated for 60 minutes in fully supplemented Claycomb media (10% FBS, 100 
μg/ml Penicillin/Streptomycin, 0.1 mM norepinephrine, 2 mM L-glutamine) then washed 
twice with PBS prior to the addition of IMS solution. Normoxic HL-1 cells incubated with MβCD 
were analysed for drug toxicity using flow cytometric analysis. 
 
 5.2.8. cDNA synthesis, RT-qPCR  
To assess Cav3 mRNA knockdown, total RNA was isolated from 4.0 x 104 HL-1 cells and used 
to synthesise cDNA using the FastLane Cell cDNA kit (Qiagen, Hilden, Germany). Reference 
gene selection for gene expression was performed as previously described in Section 2.3.2. 
RT-qPCR and analysis was carried as described in Section 2.3.1.  
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5.3 RESULTS AND DISCUSSION 
5.3.1 Vector assessment 
Following construction, the size and integrity of each miRNA vector was assessed by agarose 
gel electrophoresis. The properly ligated vector is observed as a 5.8kb band as shown in Figure 
5.4. Due to supercoiling the vector migrates quicker through the gel and thus appears smaller 
in size (Akerman 1998; Cole, Gaigalas & Akerman 2006). Damaged vectors containing DNA 
nicks can also be identified (Figure 5.4, lowest band in lanes 4 and 12) and were discarded. 
According to manufacturer’s instruction, approximately 20% of all constructed miRNA vectors 
contain 1-2bp deletions within the miRNA sequence. To assess for this, all miRNA vectors 
were DNA sequenced using Sanger sequencing (Big Dye Terminators, Invitrogen) to confirm 
that the correct insert sequence was present (Figure 5.5).  Vectors which contained a mutated 
sequence and nicked DNA were discarded.  
Figure 5.4 Agarose gel analysis of miRNA vectors. Purified miRNA vectors were 
electrophoresed on a 1% agarose gel at 90V for 90 min. Lane M, Lambda/HindIII DNA marker; 
lanes 1-3, miRNA-Cav3-A vectors; lanes 4-6, miRNA-Cav3-B vectors; lanes 7-8, miRNA-Cav3-
C; lanes 9-10, miRNA-Cav3-D vectors; lanes 11-13, miRNA-LacZ vectors. 
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Figure 5.5 DNA sequence confirmation of a miRNA-Cav3 vector. The blue highlighted region 
corresponds to the miRNA-Cav3-A insert sequence flanked by the 5’ and 3’ miRNA vector 
regions. 
 
5.3.2 Assessment of transfection efficiency 
Transfection efficiencies were assessed based on the co-expression of the EmGFP reporter 
gene in transfected cells. Firstly, cells were observed via fluorescent microscopy to assess for 
positive transfection and estimate the level of transfection (Figure 5.6). Once confirmed a 
more accurate assessment of transfection efficiency and cell viability was performed using 
flow cytometry. Based on flow cytometric data, initial screening of the transfected HL-1 cells 
demonstrated a small population (20%) of EmGFP positive cells (lower right quadrant) with 
minimal cell death (upper quadrants) prior to optimisation of transfection parameters (Figure 
5.7). 
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Figure 5.6 Prior to flow cytometric analysis, inverted fluorescent microscopic estimation of 
EmGFP expression from transfected HL-1 cells was utilised A) 40X magnificent B) 100X 
magnification. 
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Figure 5.7 Flow cytometric analyses of transfected HL-1 cells. A) Mock-transfected HL-1 cells; 
B) HL-1 cells transfected with pcDNA™6.2-GW/EmGFP-miR-LacZ vector. Quadrants 
correspond to the following phenotypes: Lower left, viable non-transfected; Lower right, 
viable transfected; upper left, non-viable non-transfected; Upper right, non-viable 
transfected. The percentage of cells conferring each phenotype is indicated in its respective 
quadrant. 
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5.3.3 Transfection optimisation 
5.3.3.1 Comparison of popular Liposomal Transfection Reagents  
Five commonly used liposomal transfection reagents were initially trialled for suitability using 
the general parameters supplied by the manufacturer. As shown in Figure 5.8 all five 
transfection reagents were able to deliver the miR-vector into HL-1 cells, although at varying 
efficiencies. Using the supplied general experimental parameters Lipofectamine® 2000 
demonstrated the highest degree of transfection (40% EmGFP-positive viable cells) with a low 
level of cytotoxity (<5% EmGFP-positive non-viable cells). This finding matches previous 
studies which utilised Lipofectamine® 2000 for transfection in HL-1 cardiac cell line (Wang et 
al. 2013; Brady et al. 2007; Hamacher-Brady, Brady & Gottlieb, 2006). Further refining of the 
Lipofectamine® 2000 experimental protocol was necessary to maximise transfection 
efficiency and subsequent gene knockdown. Notable parameters reported to influence 
transfection efficiency are DNA vector concentration, vector-to-lipid ratio, cell density, and 
seeding protocol (Dalby et al. 2004). 
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Figure 5.8 Comparison of five transfection reagents. HL-1 cells were transfected with EmGFP-
miR-LacZ using different transfection reagents. Flow cytometry was used to assess for 
transfection (EmGFP expression) and cell viability (7-AAD staining). The percentage of cells 
conferring each phenotype is indicated in each stacked column. 
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5.3.3.2 Effect of DNA:transfection reagent ratio 
Cationic lipids including Lipofectamine® 2000 are used to transfer nucleic acids into cultured 
cells as they strongly associate with the negative charge of the DNA phosphate backbone 
(Ahmad et al. 2005). By modifying the ratio of DNA to cationic lipid ratio an excess of positive 
charge can be achieved which allows for the complex to closely associate with the negatively 
charged cell membrane and is thought to assist the DNA-lipid moiety in crossing the plasma 
membrane (Ewert et al. 2010). This charge ratio can therefore influence the degree and 
success of transfection, although varying between different cell types. For example, the COS-
7 fibroblast cell line has been shown to be more amenable to transfection using lower lipid 
reagent concentrations compared to the CV-1 fibroblast line which requires higher 
concentrations of lipid reagent to produce comparable transfection levels (Felgner et al. 
1987). 
Using 1 µg of vector DNA, titration of Lipofectamine® 2000 reagent was performed in the 
ranges of 0.5 µL-5 µL as suggested by the manufacturer. Ratios of 1:1 and 1:2 both resulted 
in over 50% transfection efficiency (Figure 5.9 and Figure 5.10). At higher ratios cytoxicity was 
observed by an increase in the number of non-viable cells present. Similar cytotoxic effects 
using high DNA:lipid concentrations have been noted by others (Hofland, Shephard & Sullivan 
1996; Felgner et al. 1987).  
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Figure 5.9 Effect of DNA:Lipofectamine® 2000 ratio on transfection efficiency. HL-1 cells (2 
x 105 cells/well) in 12-well plates were transfected with 1 μg DNA vector and varying 
concentrations of Lipofectamine® 2000. EmGFP expression and cell viability were measured 
by flow cytometry. The percentage of cells conferring each phenotype is indicated in each 
stacked column. 
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5.3.3.3 Effect of vector DNA concentration 
DNA vector concentrations also require optimisation to promote maximal uptake and 
expression in cells. A range of DNA concentrations (1-4 μg) were examined, with the 1:1 
DNA:Lipofectamine® 2000 ratio maintained. Using both 1 μg and 2 μg of DNA vector identical 
transfection efficiencies (53%) were observed (Figure 5.10). Interestingly the transfection 
efficiency did not double with a doubling of the DNA:lipid complex concentration. In fact, at 
higher concentrations (3:3 and 4:4), decreased transfection efficiency and increased cell 
death was observed. This presumably was due to the cytotoxicity of the higher 
Lipofectamine® 2000 concentrations as observed previously in Figure 5.9. This data 
established an upper limit (2 μg) of DNA concentration that could be used without 
compromising cell viability and transfection efficiency. 
 
 
Figure 5.10 Effects of DNA concentration on transfection efficiency. HL-1 cells (2 x 105 
cells/well) were grown in 12-well plates then transfected with varying concentrations of 
miRNA-LacZ vector and Lipofectamine® 2000 at a fixed 1:1 ratio. GFP expression and cell 
viability were measured by flow cytometry. The percentage of cells conferring each 
phenotype is indicated in each stacked column. 
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5.3.3.4 Effect of cell density 
Using 1 μg of vector DNA and a 1:1 ratio, HL-1 cells were assessed for the effects of various 
seeding densities on transfection efficiency. As observed in Figure 5.11 a seeding cell density 
of 2.0 x 105 cells/well (approximately 70% confluency) gave the highest level of transfection. 
With lower and higher cell densities showing decreased transfection levels. It is thought that 
reduced transfection efficiency associated with highly confluent cultures is resultant from 
inhibition of cell growth and metabolism. Conversely, lower densities can also result in 
reduced transfection efficiency due to stunted growth with recovery of cells being also 
affected following transfection (Dalby et al. 2004). Cells should be kept at <80% confluency 
so they are still in the logarithmic stage of growth, as cationic lipid transfection and reporter 
expression are increased in mitotically-active cells (Mortimer et al. 1999). 
 
Figure 5.11 Effects of cell density on transfection efficiency. HL-1 cells of different densities 
(1.0 x 105 to 4.0 x 105 cells/well) were grown in 12-well plates were transfected with 1 μg of 
miR-LacZ vector and 1 μL of Lipofectamine 2000. GFP expression and cell viability were 
measured by flow cytometry. The percentage of cells conferring each phenotype is indicated 
in each stacked column.  
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5.3.3.5 Effect of reverse transfection  
Standard (forward) transfection protocols require cells to be pre-plated into wells and 
allowed to attach and recover for at least 4-6 hours prior to the addition of the DNA 
transfection complex. An alternative method known as reverse transfection involves 
simultaneously transfecting and plating cells. Reverse transfection has been suggested to 
improve transfection efficiency in some cell lines and reduces handling of the cells when 
compared to forward attachment protocol (Reid et al. 2009). It has been suggested the 
improved transfection efficiency using reverse attachment protocol observed in some cell line 
may be due to trypsinisation which may result in increased surface availability for complexes 
to enter (Amarzguioui 2004). Reverse transfection of HL-1 cells did not improve transfection 
efficiency in HL-1 cells as shown in Figure 5.12. 
 
Figure 5.12 Effect of reverse transfection on transfection efficiency. HL-1 cells (2.0 x 105 
cells/well) grown in 12-well plates than were either pre-plated and allowed to attach for 4-6 
hours (forward) prior to transfection (1 μg: 1 μL ratio) or transfected whilst simultaneously 
plating (reverse). GFP expression and cell viability were measured by flow cytometry. The 
percentage of cells conferring each phenotype is indicated in each stacked column.  
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5.3.4 Assessment of Cav3 knockdown 
Following optimisation, a transfection efficiency of approximately 40% was obtainable and 
reproducible. This was comparable to previously reported studies (Wang et al. 2013; Brady et 
al. 2007; Hamacher-Brady, Brady & Gottlieb 2006). Using this established transfection 
protocol, HL-1 cells were transfected with each of the four miR-Cav3 BLOCK-iT vectors. The 
miR-lacZ vector was used as a negative control to control for non-specific transfection effects. 
 
 
5.3.4.1 Transfection efficiencies in HL-1 cells transfected with miRNA-Cav3 vectors 
RNAi using the miRNA vector approach was used to selectively knockdown Cav3 mRNA, which 
is responsible for caveolae formation in cardiomyocytes. We chose the miRNA vector 
approach over small-interfering RNA pathway as the half-life of Cav3 protein was shown to 
be greater than five hours (for >99% de novo protein decay, ≥40 hours is required) (Galbiati 
et al. 1999). Chemical transfection using Lipofectamine® 2000 reagent was used to introduce 
miRNA-vectors into HL-1 cardiomyocytes, similar to others (Brady et al. 2007; Hamacher-
Brady et al. 2006). As shown in Figure 5.13 all four Cav3-miRNA vectors demonstrated a 
transfection efficiency of approximately 40%, with the Cav3-A vector demonstrating the 
highest level (51%) of EmGFP expression. 
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Figure 5.13 Bar graph demonstrating EmGFP expression in transfected cells. Transfection 
efficiency assessed by flow cytometry in HL-1 cells transfected with each of the four miR-Cav3 
vectors (Cav3-A to Cav3-D) and miR-LacZ control vector (n=2/group). Data presented as mean 
± SEM. 
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5.3.4.2 RT-qPCR assessment of Cav3 mRNA knockdown 
As previously discussed in Chapter 2.3.2 the choice of a stable reference gene is critical for 
accurate gene expression analysis. Therefore, a panel of commonly used reference genes 
(Actb, Gapdh, Hprt1, Pgk1 and Ppia) were examined to determine the most stably expressed 
gene. As shown in Figure 5.14 Hprt1 and Ppia were the most stably expressed, Ppia was 
selected as the most stable reference gene and was used to normalise gene expression in the 
miRNA vector transfected cells. 
 
Figure 5.14 Expression stability values (M) of the putative reference genes tested in 
transfected HL-1 cells. The expression of five genes was analysed to determine the most 
suitable reference gene. Genes are ranked from the most stable to the least stable (left to 
right). Dotted line indicates the threshold for stable expression (M-value of <0.5) within 
homogeneous samples. (n=3/group). 
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Following 48 hours post-transfection of Cav3 miRNA vectors, the expression of Cav3 mRNA 
was assessed relative to the LacZ negative control (Figure 5.14). This indicates that the miRNA-
Cav3 expression vectors were expressing miRNA targeting Cav3 mRNA, resulting in its 
reduced expression. However, the level of knockdown was considerably less than the 
expected 70-90% knockdown known to be achievable by RNAi (Sahoo et al. 2009; Schlesinger 
et al. 2011). The miR-Cav3-A vector elicited the greatest degree (33%) of Cav3 mRNA 
knockdown. However as only approximately 40% of HL-1 cardiomyocytes were transfected 
(Figure 5.13), theoretically 60% of HL-1 cells are still expressing normal levels of Cav3 mRNA. 
Therefore, a maximal knockdown (>70% repression in transfected cells) would result in a 
general repression of 28-40% Cav3 transcript. It has been suggested that transfection 
efficiencies should be consistently 80% or greater in order to achieve significant mRNA 
knockdown for RNAi experiments (Wang et al. 2015). For example, transfection efficiencies 
of <60% have been shown to result in implicated knockdown of 70% observed knockdown, 
however such an estimate is in doubt as it can barely distinguish itself from a 1% knockdown 
(Wang et al. 2015). Despite this, statistically significant knockdown was observed with the 
Cav3-A (44%), Cav3-C (17%) and Cav3-D (17%) miRNA vectors (Figure 5.14). Therefore, further 
assessment of the Cav3 protein level or the use of the cells in sI-R was abandoned. 
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Figure 5.15 Gene expression analysis of Cav3 mRNA knockdown in miR-Cav3 transfected 
HL-1 cardiomyocytes. Following transfection with one of the four miRNA-Cav3 vectors (48 
hours) Cav3 mRNA was assessed in HL-1 cardiomyocytes via RT-qPCR (n=3/group). Data 
presented as mean ± SEM; *P <0.05 relative to miR-LacZ negative control. 
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5.3.5 Cholesterol depletion by MβCD in HL-1 cells  
Whilst we were unable to produce a high degree of Cav3 knockdown in HL-1 cells using 
transient transfection (44%), pharmacological approach using cholesterol depletion (via 
MβCD) of cellular rafts were investigated. A concentration of ≥200 μM MβCD has been shown 
to result in complete loss of caveolae and lipid rafts in cardiomyocytes (Hoe et al. 2014). 
Firstly, normoxic time-matched HL-1 cells were screened for potential cytotoxic effects of 
MβCD (1 mM) and was found to be non-cytotoxic as shown by flow cytometric analysis (Figure 
5.15A).  
Simulated I-R resulted in 17.3% cell death as assessed by flow cytometry (Figure 5.16A) and 
enhanced LDH release (Figure 5.16B) compared to normoxic controls. As shown by flow 
cytometry and LDH release, MβCD treatment in sI-R cells resulted in significantly increased 
total cell death when compared to the sI-R only group (Figure 5.16A-B). Thus suggesting that 
depletion of caveolae and/or lipid rafts results in a reduction of ischaemic tolerance. 
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Figure 5.16 Measurements of cell death following sI-R. A) Flow cytometric analysis of total 
cell death (Annexin-V PE and 7-AAD positive) B) LDH efflux analysis of cell viability following 
sI-R with or without MβCD treatment. Data presented as mean ± SEM; *, P <0.05, vs. 
normoxic; †, P <0.05, vs. normoxic + MβCD; ‡, P <0.05, vs. sI-R .(n=3/group).  
 
Prior to sI-R, HL-1 cells were subjected to 60 minutes of MβCD incubation. MβCD treatment 
(1 mM) has been shown to lower membrane cholesterol and flatten caveolae (Patel et al. 
2006). In contrast, others have suggested that MβCD can be cytotoxic (Hinzey et al. 2012). 
However, our analysis demonstrated that the concentration of MβCD used in this study did 
not show any cytotoxic effects (Figure 5.16A). MβCD treatment resulted in a reduction of 
ischaemic tolerance following sI-R, as shown by significantly increased cell death (Figure 
5.16A) and LDH release (Figure 5.16B). Flow cytometry and LDH results show similar 
magnitudes of cell death; with MβCD treatment resulting in ≈50% more cell death when 
compared to sI-R alone. The decline in ischaemic tolerance may be due to the reduced 
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autacoid activation of cell membrane receptors (including GPCRs) leading to attenuated 
survival kinase activation, membrane repair and mitochondrial viability. To support this, Cav3-
overexpression in cardiac mitochondria has been shown to reduce calcium loading, enhance 
respiratory function which results in enhanced preservation of mitochondria associated with 
increased recovery in these hearts (Fridolfsson et al. 2012). Cav3-overexpression in the heart 
has been shown to mimic IPC by phosphorylating survival kinases such as Akt and GSK-3β 
(Tsutsumi et al. 2008). Whilst Cav3 has been shown to be required for sarcolemmal repair as 
Cav3-knockdown results following membrane injury results in reduced plasma membrane 
resealing leading necrosis in these cells (Corrotte et al. 2013). Indeed, the preservation of 
sarcolemmal and mitochondrial integrity has been a noticeable feature of Cav3-
overexpression (Tsutsumi et al. 2008).  
Besides being involved in activation of cardioprotective signalling, caveolae have also been 
shown to house many ion channels related to the contractile function in many species and 
models including pig coronary arteries, rat bladder and rat skeletal muscle tissue (Graziani et 
al. 2004; Cristofaro et al. 2007; Vega Moreno et al. 2012). To highlight its role in contractile 
function, MβCD treatment of normoxic Langendorff hearts have been shown to lead to 
significant reduction of LVDP and EDP (Hoe et al. 2014). Similarly, post-ischaemic hearts 
showed severely reduced recovery following 1 mM MβCD treatment which resulted in 
approximately 10% recovery of LVDP compared to baseline (Hoe et al. 2014). Conversely, 
Cav3 transgenic overexpression restores caveolae formation in the senescent heart to levels 
observed in the young heart resulting in enhanced post-ischaemic recovery in the senescent 
hearts (Kidd et al. 2010). Thus methods leading to preservation of caveolae in the aged hearts 
may be attractive targets for IHD by reducing I-R injury as well as contractile dysfunction. 
As previously discussed the success and degree of transfection and resulting knockdown is 
highly dependent on cell type (Kim & Eberwine 2010).  Our extensive optimisation as well as 
other groups report 40% transfection efficiency in HL-1 cells, thus leaving 60% untransfected 
population which may present significant hurdles in terms of detecting functional changes. 
Perhaps to overcome this hurdle, other groups employing HL-1s have selectively studied only 
GFP positive populations by the use of fluorescence microscopy in the context of autophagy 
(Brady et al. 2007; Rikka et al. 2011). Using fluorescent microscopy transfected populations 
can be individually identified and these populations can be surveyed for changes in functional 
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responses. Terminally differentiated cells such as isolated and cultured cardiomyocytes can 
be difficult to chemically transfect cells and may require non-liposomal methods to achieve 
higher efficiencies of gene knockdown (Thiel & Nix 2006). The use of electroporation has been 
shown to achieve >70% knockdown of target gene in cardiomyocytes, whilst adeno-
associated virus (AAV) transduction has been shown to achieve 90% transfection efficiency in 
adult cardiomyocytes (Louch, Sheehan & Wolska 2011; Dandapat et al. 2008). Indeed, AAV 
vectors have been used to overexpress Cav3 in cardiomyocytes (Tsutsumi et al. 2008; Rikka 
et al. 2011) and in the study of autophagy in adult cardiomyocytes (Quinsay et al. 2010).  
Alternatively, GFP positive cells can be further enriched using a fluorescently activated cell 
sorter or via stable transfection. Fluorescently activated cell sorters can enrich up to 4.5 x 106 
GFP positive cells, yielding a homogenous population (>95% GFP), which can then be used for 
further downstream experiments such as sI-R (Basu et al. 2010). Whilst stable transfection 
relies on the incorporation of the plasmid DNA into the host genome which is a rare event (>1 
in 104 cells) and requires the use of cytotoxic drugs for selection (Mortensen et al. 2004). The 
use of siRNA transfection in HL-1 cardiomyocyte instead of miRNA expression vectors may 
also improve transfection efficiency (Takeuchi, Kim & Matsuoka 2013; Rikka et al. 2011). It is 
possible that siRNAs molecules are able to cross the membrane more efficiently than the 
larger plasmid moieties resulting in higher transfection efficiency and knockdown as seen 
when combined with electroporation (Louch, Sheehan & Wolska 2011).  However, other 
groups have also noted low transfection efficiencies in cardiomyocytes using liposome-
mediated siRNA transfections, which led to the use of AAV vectors as a delivery method (El-
Armouche et al. 2007). 
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5.4 CONCLUSION 
In this study, we sought to selectively deplete caveolae formation in HL-1 cardiomyocytes via 
knockdown of Cav3 using RNAi. A commonly used cationic lipid, Lipofectamine® 2000 has 
been shown to significantly increase transfection in primary neurons and amenable to 
transfection in HL-1 cardiomyocyte cells (Dalby et al. 2004; Wang et al. 2013; Brady et al. 
2007). Through extensive optimisation of several crucial transfection parameters, we were 
able to achieve >40% transfection efficiency in HL-1 cardiomyocytes. This level of transfection 
efficiency is comparable to previously published studies (Brady et al. 2007; Rikka et al. 2011). 
Knockdown of Cav3 at the mRNA level was observed although the degree of reduction was 
low (reduction of 28-40%). This can be partially attributed to the high number of non-
transfected HL-1 cardiomyocytes (≈60%) in the total cell population which still express Cav3 
mRNA at normal levels. As previously discussed even with 100% knockdown in all transfected 
cells a maximal global reduction of ≥90% is possible. Studies looking at cell-specific 
ultrastructural changes such as Brady et al. (2007) are not as reliant on high levels of 
transfection compared to studies looking at global changes (e.g. LDH release, mRNA and 
protein expression) following gene knockdown. Indeed, Rikka et al. (2011) have used both 
liposomal and adenoviral approaches to transfect HL-1 cells, perhaps to overcome the 
challenging chemical transfection efficiency. For these reasons we decided not to further 
pursue RNAi in HL-1 cells with regards to Western immunoblotting and sI-R.  
To support caveolar involvement, we employed non-specific pharmacological depletion of all 
lipid rafts using MβCD which has been previously shown to ablate caveolae formation in the 
heart (Horikawa et al. 2008). Loss of GPCR and anaesthetic-mediated loss of cardioprotection 
following MβCD treatment has been observed (Patel et al. 2006; Horikawa et al. 2008), here 
we show that MβCD treatment prior to sI-R results in significant attenuation of ischaemic 
tolerance in cultured cardiomyocytes (Figure 5.15A and 5.15B). However other groups have 
shown that there are no differences in cell death between MβCD-treated cells and sI-R only 
group (Horikawa et al. 2008; Tsutsumi et al. 2014). Interestingly MβCD treated sI-R 
cardiomyocytes show similar expression of apoptosis-related genes (Casp3, BID, and BAD) 
and anti-apoptotic genes (Bcl2 and Iap2) when compared to sI-R group without MβCD 
treatment (Tsutsumi et al. 2014). The reasons for these discrepancies are unknown. Notable 
differences between the studies include the cell culture model, where adult primary 
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cardiomyocytes were used in place of immortilised HL-1 cardiomyocytes, and sI/R times. 
Future studies should also examine the expression of these genes in the model used here. 
Although we were unable to achieve significant knockdown of Cav3 by RNAi, we were able to 
show caveolar involvement in modifying ischaemic tolerance in HL-1 cardiomyocytes by using 
cholesterol depletion. In conclusion, caveolae may modify ischaemic tolerance by its 
involvement in signal transduction from the membrane leading to activation of survival 
kinases, plasma membrane repair mechanisms and mitochondrial protein-S nitroyslation. 
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6. Chapter Six 
Expression of miRNAs associated with ischaemia, senescence 
and caveolae transcripts in the ageing heart. 
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6.1 INTRODUCTION 
As discussed in the preceding chapter, miRNAs are a class of small (typically 18-25 nucleotides 
in size) single-stranded, non-coding RNAs that regulate gene expression at the post-
transcriptional level. Their regulatory roles have been implicated in most biological processes 
including cell proliferation, development, differentiation and apoptosis (Kuppusamy, Sperber 
& Ruohala-Baker 2013). Based on recent estimates, the human and mouse genome 
contains >1,000 known miRNAs which are thought to regulate >30% of the genome 
(http://microrna.sanger.ac.uk) with the mouse heart shown to express over 300 miRNAs as 
determined by high throughput sequencing (Matkovich 2014). As a single miRNA can target 
more than one mRNA, miRNAs can regulate multiple downstream targets affecting multiple 
regulatory networks in the cell. For example, miR-1 has been implicated in targeting multiple 
components of MAPK (i.e. p38 and phosphor-Erk1/2) signalling as well as targeting the 
sodium-calcium exchanger Ncx1 in the heart (Karakikes et al. 2013; Kumarswamy et al. 2012). 
Differential expression of miRNAs has been associated with a variety of diseases including 
cancer, autoimmune and cardiovascular disease (Li & Kowdley 2012). More specifically, the 
involvement of miRNAs has been observed in cardiovascular diseases such as myocardial 
infarction, heart failure, and cardiac hypertrophy. In addition, dysregulation of miRNA has 
been associated with ageing and senescence in the heart [Jung & Suh 2012; Ucar et al. 2012].  
As previously discussed, the ageing heart has been shown to involve complex molecular and 
cellular changes. These include increased fibrosis with a loss of contractile tissue, 
mitochondrial DNA deletions and significant transcriptional changes, which may explain the 
age-related loss of ischaemic tolerance [Moslehi, DePinho & Sahin 2012]. These 
transcriptional changes may be in part due to changes in the regulatory miRNA expression. 
Indeed, miRNAs have been shown to contribute to adverse outcomes and pathological 
remodelling following stress such acute myocardial infarction, transverse aortic constriction 
and are differentially expressed with ageing (Boon et al. 2014; Zhang, Azhar & Wei 2012; 
Bernardo et al. 2012). Furthermore, cardioprotective strategies such as IPC and IPOST have 
been shown to differentially activate the expression of several ‘protectomiRs’, where ablation 
of a single miRNA is sufficient to abolish the protective signalling (Yin, Salloum & Kukreja 2009; 
Varga et al. 2014). Similarly, cytoprotective responses such as caloric restriction also suppress 
circulating miRNA dysfunction that would otherwise occur with ageing (Dhabi et al. 2013). 
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In this study we investigated the expression of several candidate miRNAs suggested by the 
literature to be differentially expressed in response to ischaemia-reperfusion and 
ageing/senescence (Table 6.1). For example, members of the miR-34 family have been 
implicated in myocardial infarction and transverse aortic constriction by interacting with 
genes involved in cell survival, angiogenesis, immune and cardiac function (Bernardo et al. 
2012). Furthermore, miRNAs represent a novel class of pharmacological targets in the heart 
for restoring cardioprotection as knockdown of miR-34a has been shown to enhance I-R 
tolerance in the senescent mouse heart (Boon et al. 2013). Other prominent ageing-related 
miRNAs investigated in this study are shown in table 6.2. Besides investigating senescence 
and I-R related miRNAs, bioinformatics analysis was used to screen for candidate miRNAs 
predicted to target the caveolae-related transcripts Cav3 and Cavin1 which were previously 
shown to be down-regulated in the normoxic and post-ischaemic ageing hearts (Chapter 3). 
Cardiac ageing is associated with a series of events including left ventricular hypertrophy, 
diastolic dysfunction, increased risk of atrial fibrillation, valvular degeneration and fibrosis 
which render the heart susceptible to stress such as ischaemia (Zhuo et al. 2014). AMI/I-R in 
both humans and animal models has been shown to lead to differential expression of miRNAs 
and is associated with adverse outcomes in patients (Bostjancic, Zidar & Glavac 2009; Gidlöf 
et al. 2008). More specifically, miRNA expression from cardiomyocytes, fibroblasts and 
endothelial cells contribute to pathogenesis of I-R injury by regulating genes involved in 
inflammation, fibrosis, apoptosis and angiogenesis (Sala et al. 2014). Although the expression 
of signature miRNAs involved in ischaemia-reperfusion are relatively well characterised in 
young hearts, expression of I-R related miRNAs have not been characterised in ageing models 
of post-ischaemic hearts with most age-related studies opting to characterise senescence-
related miRNAs in aged and senescent hearts. Notable miRNAs reported to be affected by I-
R and used in this study were miR-1, miR-15, miR-20a, miR-21 and miR-92a (Boštjančic & 
Glavač 2014). As the expression of these prominent miRNAs remained uncharacterised in the 
ageing myocardium, we sought out to characterise several miRNA candidates involved in I-R 
injury by a variety of mechanisms (I.e. apoptosis/remodelling) which may be contribute to the 
decline of ischaemic tolerance in the ageing heart.  
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6.2 METHODS 
6.2.1 Tissue samples and miRNA isolation. 
Normoxic and post-ischaemic ageing male hearts (8, 16, 32 and 48 weeks old) were selected 
from the tissue biobank as described in Section 2.2.1. Hearts were removed from RNAlater 
preservative and dissected and homogenised as previously detailed in section 2.2. Total RNA 
containing miRNA fraction was extracted using miRNeasy columns (QIAxcel, Maryland) 
according to manufacturer’s protocol.  To determine yield and purity of RNA containing 
miRNA, NanoDrop ND-1000 (Thermo Fisher Scientific, MA, USA) was used. 
 
6.2.2 cDNA synthesis 
Following miRNA extraction, the NCode miRNA First-Strand cDNA Synthesis Kit (Life 
Technologies) was used to synthesise cDNA from 1.0 µg of cardiac total RNA containing the 
miRNA. Due to their small size (22nt) the mature miRNA first requires polyadenylation, 
secondly an oligo-dT adapter primer is used to prime the cDNA synthesis reaction. This 
adapter primer contains a unique proprietary sequence at its 5’ end, which allows for 
amplification of cDNA using a complimentary universal primer paired with a primer specific 
to the miRNA sequence of interest (Figure 6.1). 
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Figure 6.1 Overview of the cDNA synthesis procedure from miRNA (Image from: 
http://www.quantabio.com/product_mirna.php?base_id=95107) 
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6.2.3 RT-qPCR 
Mature miRNA sequences were obtained from the miRBase database and used as the 
template to design the miRNA specific primer (Table 6.1). OligoAnalyzer (IDT) was used to 
design the miRNA primers at Tm of 58*C with BLAST used to ensure primer specificity to the 
miRNA target. Optimal qPCR cycling conditions consisted of an initial denaturation at 95°C for 
3 minutes followed by 40 cycles of 95°C for 15 seconds and 58°C for 30 seconds. After the 
final PCR cycle, reactions underwent melt curve analysis to detect non-specific amplicons. We 
noted, unlike mRNA amplicons, miRNA amplicons displayed broad peaks, which were 
attributed to variable poly-A tailing of templates which may generate templates of few 
nucleotide differences in length. Reference gene selection for gene expression normalisation 
was performed using CFX-Manager (Bio-Rad) GeNORM analysis. The reference gene panel 
was composed of miR-24, miR-26, miR-103, miR-191, RNU1A and RNU6, with miR-191 shown 
to be most stable in expression across both the normoxic and the post-ischaemic hearts 
(Figure 6.3A and 6.3B, respectively).  
 
6.2.4 Bioinformatics analysis 
For miRNA that showed significant changes, miRWalk 1.0 (Dweep et al. 2011) was used 
generate a list of validated mRNA targets. The validated mRNA targets were uploaded into 
Database for Annotation, Visualization and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov/). The most relevant Gene Ontology (GO) terms generated by 
DAVID were represented with their gene clusters and number of genes.  These genes were 
further used to generate a list of cardinally ordered top 5 cellular compartments by gene 
ontology (http://geneontology.org/). 
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Table 6.1 miRNA RT-qPCR primer sequences 
Gene name 
Gene 
symbol 
NCBI GeneID miRNA specific primer (5'-3') 
Reference Genes    
microRNA 26a-1 Mir26a-1 387218 CAAGTAATCCAGGATAGGCTAA 
microRNA 103-1 Mir103-1 723824 GCATTGTACAGGGCTATGA 
microRNA 191 Mir191 387186 GAATCCCAAAAGCAGCTGA 
U1a1 small nuclear RNA Rnu1a1 19842 CGACTGCATAATTTGTGGTAG  
U6 small nuclear RNA Rnu6 19862 CCGGCAGCACATATACTAAAA  
Ischaemia-Reperfusion 
microRNA 1a-1 Mir1a-1 387136 GTGGAATGTAAAGAAGTATGTATA 
microRNA 15b Mir15 387175 CAGCACATCATGGTTTACAA 
microRNA 20a Mir20a 387139 ACTAAAGTGCTTATAGTGCAG 
microRNA 21a Mir21a 387140 GCTTATCAGACTGATGTTGA 
microRNA 24-1 Mir24-1 387142 CTCAGTTCAGCAGGAACAGA 
microRNA 92-1 Mir92-1 751549 TATTGCACTTGTCCCGG 
Senescence and Aging 
microRNA 22 Mir22 387141 AAGCTGCCAGTTGAAGA 
microRNA 34a Mir34a 723848 CAGTGTCTTAGCTGGTTGT 
microRNA 34c Mir34c 723932 CAGTGTAGTTAGCTGATTGC 
microRNA 146 Mir146 387164 GAACTGAATTCCATGGGTT 
microRNA 146b Mir146b 751550 AGAACTGAATTCCATAGGCT 
microRNA 378a Mir378 723889 GGACTTGGAGTCAGAAGG 
Caveolae-related 
microRNA 22 Mir22 387141 AAGCTGCCAGTTGAAGA 
microRNA 92-1 Mir92-1 751549 TATTGCACTTGTCCCGG 
microRNA 101b Mir101b 724062 CAGTACTGTGATAGCTGAA 
microRNA 485 Mir485 723875 CTGGCCGTGATGAATTC 
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6.3 RESULTS AND DISCUSSION 
Normalisation of miRNA expression to unstable reference genes has been shown to drastically 
affect expression of miRNAs following I-R (Brattelid et al. 2011). The use of small nuclear RNAs 
including RNU6 and RNU1A as reference genes still remains popular even without 
experimental assessment of stability. Furthermore, RNU6 and RNU1A are small nuclear RNAs 
and thus do not accurately represent the miRNA population. Although the commonly used 
RNU6 was stable in expression in the normoxic ageing hearts, post-ischaemic heart showed 
RNU6 was unstable further highlighting the necessity of experimental validation between 
experimental conditions. In addition, other studies have shown RNU6 to be up-regulated in 
aged hearts (Zhang et al. 2012). As shown in Figure 6.2, all miRNAs candidates assessed for 
stability showed stable expression in the ageing normoxic and post-ischaemic hearts, whereas 
RNU6 and RNU1A were less suitable (> 1.0 M-value), specifically in the post-ischaemic heart 
(Figure 6.2B). Indeed, noticeable differences in RNU6 expression can be seen in infarcted 
zones when compared to sham and border zones (Hullinger et al. 2012). GeNORM analysis 
identified miR-191 as the most stably expressed miRNA in both the normoxic and post-
ischaemic heart. Therefore, miR-191 was chosen as the reference miRNA for normalisation in 
all subsequent RT-qPCR miRNA assays. 
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Figure 6.2 Bar graphs of expression stability of miRNA and small nuclear miRNAs 
normalisers in the normoxic and post-ischaemic ageing male hearts. Reference gene analysis 
in ageing A) normoxic and B) post-ischaemic mouse left ventricular tissue using miRNAs (miR-
24, miR-26, miR-103 and miR-191) and small nuclear RNA (RNU6 and RNU1A) as candidates. 
The dotted line indicates the recommended threshold value of <1.0 for heterogeneous 
samples.  
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6.3.1 Reference miRNA Stability Across Treatment Groups  
Similar to Chapters 3 and 4, based on the expression of miR-191 reference gene in the 
normoxic and post-ischaemic hearts, a normalisation factor was applied to post-ischaemic 
hearts to allow for more uniform cross comparisons between these two groups. As shown in 
Figure 6.3, there were minimal differences in the baseline expression (p=0.92) of miR-191 
reference gene in the 8-week old hearts (1.1-fold) in both the normoxic and post-ischaemic 
groups.   
 
Figure 6.3 Assessment of miR-191 stability relative to post-ischaemia in the normoxic 
murine heart. Shown are boxplots detailing gene expression changes determined by RT-qPCR 
for the miR-191 reference gene in the male 8- and 48-week old heart following normoxic or 
post-ischaemic stress. Boxes indicate interquartile range (25%-75%) with the horizontal bar 
within each box indicating the median. The whiskers show the minimum and maximum values. 
(n=6/group) 
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6.3.2 Ischaemia-Reperfusion Related miRNAs in the Normoxic & Post-Ischaemic Ageing 
Male Hearts 
Of the six I-R related miRNAs assessed in this study, only miR-15 and miR-92a showed 
significant age-related changes in expression. In the normoxic heart, miR-15 and miR-92a 
showed significant 2.2-fold downregulation in the 8-week old hearts (Figure 6.3A and 6.3F, 
respectively).  Surprisingly, the expression of these miRNA did not show changes in the post-
ischaemic ageing hearts. Analysis by two-way ANOVA indicated significant interaction of age 
and ischaemia (Table 6.2) which can be seen in the 2.2-fold overexpression of miR-15 and 
miR-92a in the 48-week old post-ischaemic hearts when compared to normoxic age-matched 
counterparts (Figure 6.4A and 6.4F, respectively).  Whilst for miR-24 this was borderline non-
significant (P= 0.06) (Figure 6.4E) in the 48-week old post-ischaemic hearts by post-hoc 
analysis.  
 
Table 6.2 Two-way analysis of variance of age and post-ischaemic effects on I-R-related 
transcript expression 
Gene Factor 
Mean 
Square 
F (DFn, DFd) 
% of Total 
Variation 
P value 
miR-1 
Age 0.057 0.47 (3,40) 3.0% 0.7030 
Ischaemia 0.311 2.54 (1.40) 5.3% 0.1190 
Age*Ischaemia 0.149 1.22 (3,40) 7.7% 0.3161 
miR-15b 
Age 0.319 3.73 (3,36) 11.3% 0.0196 
Ischaemia 2.046 24.42 (1,36) 24.7% < 0.0001 
Age*Ischaemia 0.829 9.89 (3,36) 30.0% < 0.0001 
miR-20a 
Age 3.400 6.86 (3,32) 25.6% 0.0011 
Ischaemia 8.902 17.96 (1,32) 22.3% 0.0002 
Age*Ischaemia 2.605 5.26 (3,32) 19.6% 0.0046 
 
miR-21 
Age 1.882 3.90 (3,32) 22.9% 0.0175 
Ischaemia 0.000 4.45e-004 (1,32) 0.1% 0.9833 
Age*Ischaemia 1.779 3.69 (3,32) 21.7% 0.0218 
 
miR-24 
Age 0.071 0.24 (3,40) 1.4% 0.8674 
Ischaemia 0.000 0.02 (1,40) 0.1% 0.8827 
Age*Ischaemia 1.264 4.26 (3,40) 23.9% 0.0105 
miR-92a 
Age 0.172 1.03 (3,39) 4.4% 0.3885 
Ischaemia 2.013 12.10 (3,39) 17.3% 0.0013 
Age*Ischaemia 0.988 5.94 (3,39) 25.5% 0.0019 
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Figure 6.4 Age-dependent expression of I-R related miRNAs in normoxic male and post-
ischaemic hearts. Shown are boxplots detailing gene expression changes determined by RT-
qPCR for A) miR-1, B) miR-15, C) miR-20a, D) miR-21, E) miR-24 and F) miR-92a expression in 
the ageing normoxic left ventricle. Boxes indicate the interquartile range (25%-75%) with the 
horizontal bar within each box indicating the median. The whiskers show the minimum and 
maximum values. * P < 0.05 vs. 8-week old normoxic; † P < 0.05 vs. 16-week old normoxic; ‡ 
P < 0.05 vs. 32-week old normoxic; # P < 0.05 vs age-matched post-ischaemic group (indicated 
by brackets). (n=6/group). 
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The most characterised cardiac miRNA is the muscle-specific miR-1, which accounts for 40% 
of the total miRNA levels in the heart (Rao et al. 2009). Conflicting reports exist regarding the 
differential expression of miR-1, as it has been observed to be up- and down-regulated of 
miR-1 as a result of I-R/AMI (Zhu & Fan 2012). We observed a minor trend in up-regulation of 
miR-1 with ageing in the normoxic hearts, although not statistically significant. This 
observation is in agreement with human atrial biopsies of miR-1 (Boon et al. 2013). It is 
questionable whether this trend of up-regulation would continue significantly in the 
senescent normoxic heart (72-weeks old) as others have shown that no changes in miR-1 
expression at this time point (Zhang, Azhar & Wei 2012). It is noteworthy that the samples 
used in this study were ventricular which have been shown to have unique transcriptional 
profile (Ng, Wong & Tsang 2010). IPOST (vs. sham) has been shown to significantly induce 
expression of several miRNAs including miR-1, miR-15b, miR-21, miR-24 and miR-26 (Tu et al. 
2013). These IPOST-related miRNAs showed no changes in expression in the post-ischaemic 
ageing hearts used in this study. Although miR-15 and miR-92a were decreased in expression 
in the 48-week old normoxic heart (Figure 6.4B and 6.4F), there was no differential expression 
observed in their post-ischaemic counterparts (Figure 6.4B and 6.4F). However, the up-
regulated expression of miR-15b found in this study (Figure 6.4B) is not consistent with the 
induced expression of miR-15b in IPOST and its role as an antiangiogenic miRNA. 
Bioinformatic functional clustering of miR-15b validated targets are mostly involved in 
transcription and cell proliferation processes (Table 6.4). As previously discussed, although 
miR-15b and miR-92a showed no aged-related changes in expression in post-ischaemic 
hearts, it is possible that they may be induced in expression relative to their normoxic 
counterparts. Indeed, ischaemia results in elevated levels of miR-15b and miR-92a (Hullinger 
et al. 2012; Frank et al. 2012). To further support the notion that miR-15b and miR-92a may 
be induced in the 48-week old post-ischaemic hearts relative to normoxic counterparts, 
inhibition of these miRNAs following I-R has been shown to be cardioprotective (Bonauer et 
al. 2009; Hinkel et al. 2013).  Consistent with these reports, we observed up-regulation of 
miR-15b and miR-92a in the 48-week old post-ischaemic hearts when compared to their 
normoxic age-matched counterparts (Figure 6.4). MiRNA-92a belongs to the miR 17-92 
cluster which is antiangiogenic, whilst miR-15b has also been to be antiangiogenic (Liu et al. 
2012).  Consistent with this, mRNA targets for both miR-15b and miR-92a are enriched in 
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transcriptional and cell proliferation-related clustering as shown in Tables 6.3 and 6.4, 
respectively. More specifically, miR-15b is a positive regulator of many transcriptional 
activities as well as being implicated in cell differentiation. For example, miR-15 can halt 
cardiomyocyte division by repressing cell cycle genes such as checkpoint kinase 1 (Porello et 
al. 2011). Induction of this miRNA is consistent with the compromised division of 
cardiomyocytes in the aged hearts which display adverse remodelling following I-R (as 
previously discussed in Section 1.6).  Similarly, miR-92a is implicated to be involved in nucleic 
acid-related processes as well as cell proliferation. In terms of cell proliferation, miR-92a has 
been shown to be involved in controlling angiogenesis by targeting proangiogenic proteins, 
such as the integrin subunit alpha5 (Bonauer et al. 2009). Similarly, functional annotation 
implicates miR-92a involvement in the regulation of cellular response to stress and blood 
vessel morphogenesis (Table 6.4).  
We also observed a 1.8-fold induction of miR-24 in the 48-week old post-ischaemic hearts 
relative to their age-matched counterparts, although this was borderline non-significant (P= 
0.06). MiR-24 appears to be a pro-apoptotic miRNA and similar to miR-92a in its role as a 
critical regulator of endothelial cell apoptosis and angiogenesis. In the heart, miR-24 
overexpression has been shown to trigger endothelial apoptosis and impairs angiogenesis 
whilst miR-24 inhibition shown to increase vascularisation and improve cardiac function after 
MI (Meloni et al. 2013; Fiedler et al. 2011). The induction of this miRNA in the 48-week old 
post-ischaemic hearts is coincident with the loss of cardioprotection in these hearts and its 
role as a pro-apoptotic miRNA. Taken together, induction of both these I-R responsive miRNAs 
(miR-15b, miR-24 and miR-92a) may contribute to loss of ischaemic tolerance and adverse 
remodelling following I-R in the 48-week old hearts and their induction in the middle-hearts 
is also consistent with their role as pro-apoptotic miRNAs.  
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Table 6.3 Enrichment of miR-15b targets using DAVID functional annotation clustering 
showing regulatory networks implicated by the mRNA targets of this miRNA. 
GO Domain 
 
GO Term Number of 
Genes 
Gene Symbols Top 5 Cellular 
Compartments 
Cell Component Transcription 
factor complex 
8 
CLOCK, HIF1A, 
POU5F1, SMAD2, 
SMAD3, SMAD4, 
SMAD5, SMAD7  
CHOP-C/EBP 
complex 
 
SMAD protein 
complex 
 
RNA 
polymerase II 
transcription 
factor complex 
 
Nuclear 
transcription 
factor complex 
 
Transcription 
factor complex 
Molecular 
Function 
Sequence-
specific DNA 
binding 
11 
CEBPB, DDIT3, 
FOXA2, ISL1, 
NEUROD1, NKX2-2, 
NKX6-1, PDX1, 
POU5F1 RELA, 
ZEB2 
Biological 
Process 
Negative 
regulation of cell 
proliferation 
10 
ADORA2A, BCL2, 
CDKN1A, FGF2, 
HMOX1, IFITM3, 
PDX1, SMAD4, 
TNF, TRP53 
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Table 6.4 Enrichment of miR-92a targets using DAVID functional annotation clustering 
showing regulatory networks implicated by the mRNA targets of this miRNA. 
GO Domain 
 
GO Term Number of 
Genes 
Gene Symbols Top 5 Cellular 
Compartments 
Cell Component Transcription 
factor complex 
16 
CREB1, CTNNB1, 
E2F1 E2F2, E2F6, 
GATA6, HOXA9, 
NKX2-1, NKX2-5, 
POU5F1, RBL2, 
SMAD4, SOX2, 
SPIB, YY1, ZEB1, 
 
 
 
 
 
 
 
 
Cell 
 
Cell part 
 
Intracellular 
part 
 
Membrane-
bounded 
organelle 
 
Organelle 
Molecular 
Function 
Cyclin-dependent 
protein kinase 
inhibitor activity 
5 
CASP3, CDKN1C, 
CDKN1A, CDKN2A, 
CDKN1B 
Negative 
regulation of 
molecular 
function 
11 
ADORA1, CASP3, 
CDKN1A, CDKN1B, 
CDKN2A, DHCR24, 
HIPK3, HMOX1, 
MYC, NR4A1, 
PDCD4 
Biological 
Process 
Regulation of 
cellular response 
to stress 
3 
CDKN2A, HIPK3, 
PDCD4 
Blood vessel 
morphogenesis 
16 
ACVR1, B4GALT1, 
BMP4, CTGF, 
CTNNB1, CXCR4, 
DICER1, FGF10, 
FGF2, FGFR1, 
HMOX1, MAPK14, 
NKX2-5, PTEN, 
TDGF1, TGFBR2 
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6.3.3 Ageing and Senescence-Related miRNAs 
Of the six senescence and ageing associated miRNAs investigated only miR-22 (Figure 6.5A) 
and miR-378 (Figure 6.5F) showed significant differential expression. More specifically, miR-
22 was down-regulated 1.8-fold in the 48-week old normoxic heart relative to 8-week old 
controls. Two-way ANOVA indicated that significant interaction of ageing and I-R was present 
only for miR-22 (Table 6.5) as shown by the 2.3-fold induction of miRNA-22 (Figure 6.5A) in 
the 48-week old post-ischaemic hearts compared to age-matched normoxic hearts. Whilst an 
age-related decline in miR-378 was observed, with both 16-week (1.5-fold) and 48-week old 
(1.7-fold) normoxic hearts demonstrating significant down-regulation relative to 8-week. 
Conversely, in the post-ischaemic ageing heart, only miR-378 repression in expression that 
was borderline non-significant (P= 0.06) (Figure 6.5F). Specifically, there was a decrease in 
expression at both 32 and 48-week (1.2-fold) old hearts relative to 8-week old male hearts 
(Figure 6.5F).  
 
Table 6.5 Two-way analysis of variance of age and post-ischaemic effects ageing and 
senescence-related transcript expression. 
Gene Factor 
Mean 
Square 
F (DFn, DFd) 
% of Total 
Variation 
P value 
miR-22 
Age 0.729 2.90 (3,39) 13.2% 0.0460 
Ischaemia 0.766 3.05 (1, 39) 4.6% 0.0885 
Age*Ischaemia 1.258 5.01 (3.39) 22.8% 0.0049 
miR-34a 
Age 0.104 0.42 (3,38) 2.9% 0.7388 
Ischaemia 0.538 2.35 (1.38) 5.4% 0.1332 
Age*Ischaemia 0.208 0.84 (3,38) 5.7% 0.4797 
miR-34c 
Age 0.863 2.57 (3,38) 16.2% 0.0687 
Ischaemia 0.365 1.09 (1,38) 2.3% 0.3039 
Age*Ischaemia 0.093 0.28 (3,38) 1.8% 0.8413 
miR-146a 
Age 0.228 1.31 (3,39) 8.4% 0.2835 
Ischaemia 0.197 1.14 (1,39) 2.4% 0.2931 
Age*Ischaemia 0.166 0.96 (3,39) 6.1% 0.4208 
miR-146b 
Age 0.694 2.58 (3.40) 12.7% 0.0667 
Ischaemia 2.244 8.35 (1,40) 13.7% 0.0062 
Age*Ischaemia 0.436 1.62 (3,40) 8.0% 0.1996 
miR-378 
Age 1.118 9.24 (3,38) 35.7% 0.0001 
Ischaemia 0.701 5.80 (1,38) 7.5% 0.0210 
Age*Ischaemia 0.195 1.61 (3,38) 6.2% 0.2033 
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Figure 6.5 Age-dependent expression of ageing/senescence related miRNAs in normoxic 
and post-ischaemic male hearts. Shown are boxplots detailing gene expression changes 
determined by RT-qPCR for A) miR-22, B) miR-34a, C) miR-34c, D) miR-146a, E) miR-146b and 
F) miR-378 in the normoxic (grey boxes) and post-ischaemic (red boxes) heart. Boxes indicate 
the interquartile range (25%-75%) with the horizontal bar within each box indicating the 
median. The whiskers show the minimum and maximum values. *, P < 0.05 vs. 8-week old 
normoxic; †, P < 0.05 vs. 16-week old normoxic; ‡, P < 0.05 vs. 32-week old normoxic; +, 
P<0.05 vs. 8-week old post-ischaemic; # P < 0.05 vs age-matched post-ischaemic group 
(indicated by brackets). (n=6/group). 
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Ageing is associated with changes in mRNA expression, which has been shown to impact a 
variety of cellular pathways, including apoptosis, remodelling and angiogenesis in both 
normoxic and post-ischaemic hearts (Ashton et al. 2006). Similarly, differential expression of 
miRNAs is observed with cellular senescence, which supresses variety of cellular pathways 
such as cell proliferation, differentiation and metabolism (Dhabhi et al. 2011). Senescence is 
characterised by complex miRNA-related processes such as reduced telemetric length, cell 
division, mitochondrial metabolism and increased fibrosis in the heart (Kovacic et al. 2011; 
Jazbutyte et al. 2013; Boon et al. 2013). Deep sequencing of aged hearts (>74 weeks old) has 
been shown to identify differential expression of 65 miRNAs, of which 55% were up-regulated 
and 45% down-regulated compared to young counterparts (Zhang, Azhar & Wei 2012). Whilst 
several deep sequencing datasets are available for the aged heart, detailed functional 
clustering/annotation has yet to be performed to identify affected mRNA networks. This is 
perhaps owing to the lack of validated mRNA targets of the differentially expressed miRNAs 
(Zhang, Azhar & Wei 2012; Zhang et al. 2014; Boon et al. 2013). Based on literature analysis, 
several miRNA candidates (miR-34a, miR-34c, miR-22, miR-15, miR-146a, miR-146b and miR-
378) related to ageing/senescence were investigated in the normoxic and post-ischaemic 
aging heart. Members of the miR-34 family have become promising strategies as the 
inhibition of miR-34 family has been shown to ablate age-related loss of cardioprotection as 
well as resistance to moderate transverse aortic constriction (Boon et al. 2013; Bernardo et 
al. 2014). 
Of the miRNAs assessed, only miR-378 showed significant down-regulation in both groups 
(Figure 6.5F) although the down-regulation of miR-378 was borderline non-significant in the 
post-ischaemic hearts. However, other studies have reported an up-regulation of miR-378 in 
43-week old normoxic hearts when compared to 4-week old counterparts (Knezevic et al. 
2012). Similarly, we observed a decline in miR-22 expression at 48-weeks old (Figure 6.5A). 
Whilst others have observed an age-related increase in miR-22 in the aged and senescent 
heart (Jazbutyte et al. 2013). The reason for this discrepancy is unknown, however noticeable 
differences between the studies are differences in species (C57/Bl6 mouse compared to 
Sprague-Dawley rat), tissue analysed (left ventricular vs whole heart), treatment (heart 
explant vs Langendorff) and reference gene used for normalisation (RNU6). Targets of miR-
378 have been suggested to include Igf1r and Grb2. Activation of Igf1r by Igf1 has been shown 
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to be cardioprotective (Buerke et al. 1995).  Grb2 has complex interactions with tyrosine 
kinases such as Egfr and Fgfr2 by regulating their internalisation and phosphorylation status 
(Ahmed et al. 2013; Yamazaki et al. 2002). In the heart, Grb2-/+ mice show reduced phospho-
p38 and phospho-JNK when challenged with transverse aortic constriction (Zhang et al. 2003). 
As discussed in Section 1.6.5, the aged heart shows reduced expression of phospho-p38 
MAPK. Bioinformatic analysis also implicates miR-378 involvement in telomeres, telomerase, 
cellular ageing, and immortality (Table 6.7), with telomeres reduced and telomerase activity 
decreased in the aged heart as previously detailed in Section 1.6.1. However, miR-378 has 
been shown to be down-regulated with hypoxia and its overexpression has been shown to 
result in reduced cell death following hypoxia (Fang et al. 2012).  These observations are 
consistent with the ischaemic-intolerant phenotype observed in the ageing hearts used in this 
study which displayed significant repression of miR-378 in the 32 and 48-week old (borderline 
non-significant) post-ischaemic hearts.  
Although miR-22 was down-regulated in the 48-week old post-ischaemic heart, similar to miR-
15b and miR-92a, miR-22 was induced in expression relative to its age-matched normoxic 
counterpart in the 48-week old hearts (Figure 6.5A). Overexpression of miR-22 has been 
shown to contribute to cellular senescence and migration of cardiac fibroblasts (Jazbutyte et 
al. 2013).  Consistent with this, bioinformatics analysis of miR-22 suggested that it is mostly 
involved in transcription related process (Table 6.6). Bona fide target of miR-22 has been 
shown to be mimecan although the effects of increased mimecan expression on human 
ventricular remodelling are currently controversial (Jazbutyte et al. 2013; Motiwala et al. 
2013).  
Expression of members within the miR-34 family has been shown to be dysregulated with 
ageing in the heart and the brain (Boon et al. 2013; Li et al. 2011a). In the heart, miR-34 
expression is dysregulated with cardiac stress such as myocardial infarction and transverse 
aortic constriction (Bernardo et al. 2012). In aged hearts (74 weeks old), miR-34a expression 
shows 2.0-fold induction (vs 8 week old) and is inversely correlated with its targets Pten and 
Pnuts expression (Boon et al. 2013). Inhibition of miRNA-34a in the aged hearts has been 
shown to enhance ischaemic tolerance and recovery when compared to age matched wild-
types (Boon et al. 2013). Although we did not find changes in miR-34a expression in the hearts 
used in this study, other groups have shown that 32-week old normoxic hearts show 
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significant up-regulation of miR-34a expression which correlated inversely with significantly 
reduced Pnuts expression in these hearts (Ito, Yagi & Yamakuchi 2010). Future studies should 
investigate the expression of Pnuts and whether its expression is affected with ageing. Several 
of the miRNAs candidates related to ageing and senescence used in this study only miR-378 
showed significant down-regulation in the 48-week old post-ischaemic hearts. However, 
when compared to 48-week old normoxic hearts, there was significant up-regulation of miR-
22 in the 48-week old post-ischaemic hearts. It has been suggested that miRNA dysregulation 
may start at mid-life and does not become apparent until the aged phenotype (Li et al. 2011). 
To further support this notion, time-course analysis of miR-34a expression does not show 
noticeable changes in 18-week old mouse brain with miR-34a expression changes becoming 
apparent in 52-78 week old hearts (Li et al. 2011). Similarly, in the mouse brain, aged-related 
reduction in mitochondria-related transcripts does not become apparent until 72-96 weeks 
of age (Manczak et al. 2005). In C. elegans, miRNA dysregulation occurs at the post-
reproductive phase past mid-life (Ibáñez-Ventoso et al. 2006). 
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Table 6.6 Enrichment of miR-22 targets using DAVID functional annotation clustering showing 
regulatory networks implicated by the mRNA targets of this miRNA. 
GO Domain 
 
GO Term Number of 
Genes 
Gene Symbols Top 5 Cellular 
Compartments 
Cell Component Chromosome 6 
DNMT3B, H1FO, 
H2AFX, H2AFZ, 
SYCP3, TRP53, 
Intracellular 
membrane-
bounded 
organelle 
 
Intracellular 
organelle 
 
Membrane-
bounded 
organelle 
 
Organelle 
 
Nucleus 
 
 
 
Molecular 
Function 
Transcription 
factor activity 
11 
ESR1, ETS1, KLF6, 
MYC, NFAT5, 
POU5F1, PPARA, 
RERE, SOX11, SP1, 
TRP53 
Biological 
Process 
Transcription 15 
ANG, ESR1, ETS1, 
IGHMBP2, KLF6, 
MAX, MCM7, MYC, 
NFAT5, POU5F1, 
PPARA, RERE, 
SOX11, SP1, TRP53 
 
 
Table 6.7 Enrichment of miR-378 targets using DAVID functional annotation clustering 
showing regulatory networks implicated by the mRNA targets of this miRNA. 
GO Domain 
 
GO Term Number of 
Genes 
Gene Symbols Top 5 Cellular 
Compartments 
Cell Component 
Chromosomal 
part 
6 
DNMT3B, H1FOO, 
H2AFX, H2AFZ, 
SYCP3, TRP53 
 
Nucleus 
 
Organelle 
lumen 
 
Intracellular 
organelle 
lumen 
 
Nuclear part 
 
Nuclear lumen 
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6.3.4 Bioinformatic prediction of caveolae-related miRNA 
Bioinformatic prediction using miRWalk was used to select the top miRNAs targeting Cav3 
and Cavin1. Several public databases are available, which predict miRNA binding sites to 
target genes by the use of varying algorithms dependent on the site (Dweep, Sticht, & Norbert 
2013). Although the use of such databases has widely helped study miRNA-mRNA 
interactions, they are also believed to generate false positive rates of >0.3 or specificity that 
is often less than 70% (Zheng et al. 2013). In this study, we used the miRWalk database as it 
incorporates other popular miRNA prediction databases (i.e. TargetScan and miRanda) which 
have been suggested to minimise the possibility of introducing false positives and/or 
negatives. Following database analysis, miR-101b, miR-22 and miR-92a were top predictors 
for Cav3 (Table 6.9), while for Cavin1 the top predictors were miR-485 and miR-22. 
Following RT-qPCR, miR-101b, miR-22 and miR-92a showed decreased transcript expression 
in the 48-week old normoxic heart (Figure 6.6). Expression of these miRNAs did not correlate 
inversely with the reduced Cav3 expression previously shown in the 16-, 32-, and 48-week old 
hearts (Figure 3.3C). Similarly, no corresponding miRNA expression was found in the post-
ischaemic hearts for the miRNAs targeting Cav3 (Figure 3.4C) with these miRNAs also not 
showing any changes in expression (Figure 6.6). More specifically, as Cav3 in the normoxic 
heart is down-regulated as early as 16-weeks, we did not observe any miRNAs that fit this 
profile. For the miRNAs targeting Cavin1, miR-22 and miR-481 also did not show inverse 
patterns of expression in the normoxic heart and post-ischaemic hearts (Figure 6.7A and 
Figure 6.7B, respectively). 
Previous studies have shown that caveolin expression can be controlled by miRNA processes 
as Cav1 has been shown to be a validated target of miR-802 (Lin et al. 2011). However, the 
top miRNA predicators for Cav3 and Cavin1 did not show inverse correlation to their 
respective mRNAs with only miR-92a and miR-22 showing significant change in the normoxic 
heart although this also did not correlate inversely with Cav3 expression. As shown in table 
6.9, note the varying consensus of miRNA databases on Cav3 target prediction, i.e. miR-92a 
is not predicted to target Cav3 according to miRDB or RNA22 whilst the other three databases 
suggest miR-92a interacts with Cav3.  Besides miRNA-mediated mechanisms, other possible 
mechanisms that may influence gene expression include transcriptional factors, which 
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influence gene expression at the transcriptional level. In the case of Cav3, myogenin has been 
shown to interact with the Cav3 promoter while Id2 has been shown to inhibit promoter 
activation by myogenin (Biederer et al. 2000; Martínez-Moreno et al. 2007). Other 
mechanisms that have been shown to modulate gene expression include complex interaction 
of epigenetic changes such as DNA methylation and histone acetylation/deacetylation 
(Gonzalo 2010).  
 
Table 6.8 Bioinformatic prediction of miRNAs targeting Cav3 using miRWalk, which uses 
several other popular databases to predict miRNA targets of a given gene. Green highlight; 
Predicted target from database, red highlight; not predicted target from database; yellow 
highlight; sum of all database predictions. 
Gene 
Name 
MicroRNA miRanda miRDB miRWalk RNA22 Targetscan SUM 
Cav3 Mmu-miR-101b 1 1 1 0 1 4 
Cav3 Mmu-miR-22 1 1 1 0 1 4 
Cav3 Mmu-miR-92a-2 1 0 1 0 1 3 
Cav3 Mmu-miR-412 1 0 1 0 1 3 
Cav3 Mmu-miR-464 1 0 1 0 1 3 
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Figure 6.6 Age-dependent expression of Cav3-related miRNA transcripts in normoxic and 
post-ischaemic male hearts. Shown are boxplots detailing gene expression changes 
determined by RT-qPCR for A) miR-22, B) miR-101b and C) miR-92a targeting Cav3 in the 
normoxic (grey boxes) and post-ischaemic (red boxes) heart. Boxes indicate the interquartile 
range (25%-75%) with the horizontal bar within each box indicating the median. The whiskers 
show the minimum and maximum values. *, P < 0.05 vs. 8-week old normoxic; †, P < 0.05 vs. 
16-week old normoxic; ‡, P < 0.05 vs. 32-week old normoxic; #, P < 0.05 vs age-matched post-
ischaemic group (indicated by brackets). (n=6/group). 
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Figure 6.7 Age-dependent expression of Cavin1-related miRNA transcripts in normoxic and 
post-ischaemic male hearts. Shown are boxplots detailing gene expression changes 
determined by RT-qPCR for A) miR-22 and B) miR-485 targeting Cavin1 in the normoxic (grey 
boxes) and post-ischaemic (red boxes) heart. Boxes indicate the interquartile range (25%-
75%) with the horizontal bar within each box indicating the median. The whiskers show the 
minimum and maximum values. *, P < 0.05 vs. 8-week old normoxic; †, P < 0.05 vs. 16-week 
old normoxic; ‡, P < 0.05 vs. 32-week old normoxic; #, P < 0.05 vs age-matched post-ischaemic group 
(indicated by brackets). (n=6/group). 
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6.4 CONCLUSION 
In this study, we investigated the expression of several miRNAs genes in the ageing normoxic 
and post-ischaemic mouse heart. The miRNAs chosen were based on previous studies, which 
reported their association with ischaemia and ageing/senescence. Additionally, 
bioinformatics analysis was used to predict miRNA candidates that may regulate Cav3 and 
Cavin1 transcripts, as these were previously shown to be altered in the ageing heart (Chapter 
3). Although most miRNA investigations use high-throughput methods such as next-
generation sequencing or microarrays, we selected a candidate gene approach employing RT-
qPCR exclusively. This method has been shown to be reliable platform for detecting miRNA 
expression (Mestdagh et al. 2014; Wang 2009). Here, we also show the feasibility of using 
SYBR Green-based method using online tools and universal priming which can quantitate 
miRNAs that are relatively low in expression in the heart (e.g. miR-34c), despite the universal 
RT priming method used in this experiment criticised for low specificity which we did not 
observe in this study (via capillary electrophoresis of amplicons) (Chugh & Dittmer 2012).    
Transcriptional regulation is mechanistically complex and multifaceted, involving the use of 
mRNA transcriptional factors, which can induce miRNA and mRNA expression and conversely 
use of miRNAs to suppress mRNA expression. Furthermore, the recent discovery of “sponge 
miRNA” which bind to multiple miRNAs adds to the stunning complexity of gene regulatory 
network within the cell (Matkovich, Hu, & Dorn 2013; Hansen et al. 2013). The aims of this 
study were to investigate the expression of several miRNAs candidates based on 
ageing/senescence, ischaemia-reperfusion and miRNAs targeting caveolae transcripts (Table 
6.2). Of the miRNAs assessed related to ageing/senescence, only miR-378 showed consistent 
down-regulation in both the normoxic and post-ischaemic heart ageing hearts. The reduced 
miR-378 in the 32- and 48-week old hearts has mixed implications, as Grb2 reduction would 
be consistent with the loss of phospho-p38 MAPK signalling in the aged heart. Of the miRNAs 
associated with I-R, only miR-15 and miR-92a showed significant down-regulation in the 
normoxic hearts but not in the post-ischaemic hearts ageing. However, in the 48-week old 
post-ischaemic hearts miR-15 and miR-92a was elevated vs. age-matched normoxic 
counterparts. The induction of miR-15 and miR-92a was consistent with the stress-intolerant 
48-week old hearts. In addition, several of the miRNAs were investigated were implicated to 
be ‘protectomiRs’ (miR-1, miR-15, miR-21, miR-24 and miR-26), shown to be up-regulated in 
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IPOST methods. There were no protectomiRs changes in the ageing post-ischaemic hearts. 
However, when compared to their 48-week old normoxic counterparts, we observed up-
regulation of miR-15 and miR-24 which was not consistent with the suggested role of these 
miRNAS as “protectomiRs”.  Lastly, bioinformatic prediction of miRNAs targeting caveolae 
transcripts Cav3 and Cavin1 was employed to see whether the reduction in these transcripts 
was miRNA-related process in the ageing hearts. There was no inverse expression correlation 
observed with miRNAs that were predicted to target Cav3 and Cavin1 in the ageing hearts 
(Figure 6.5 and Figure 6.6), although it remains a possibility other miRNAs and/or 
transcriptional factors may be involved in the down-regulation of Cav3 and Cavin1.  
It must be noted that the middle-aged phenotype time points used in this study is typically 
different to the ‘aged’ phenotype (>70 weeks old) is typically used in ageing studies (Li et al. 
2011). As discussed in Section 6.3.2, age-related perturbations in miRNA expression appear 
during the aged time point (>70 weeks old), which has also been the predominant time point 
used in majority of ageing studies (Boon et al. 2013; Jazbutye et al. 2013). In addition, I-R 
protocols (i.e. Langendorff vs left anterior descending artery ligation) also vary between 
studies, with assessment of cardiac function following myocardial infarction being up to 8-
weeks post treatment in some cases as demonstrated by Bernardo and colleges (2012). 
Therefore, one of the limitations of this study is due to the shorter reperfusion protocol (60 
minutes). Due to this limitation, cardiac remodelling and other processes may require longer 
reperfusion times to become apparent (as seen in Bernardo et al. 2012), which may not have 
been detected with the Langendorff model used in this study. Another limitation of this study 
is the possibility of confounding gene expression due to use of left ventricular tissue, which 
contains considerable amounts of fibroblasts and endothelial cells (Banerjee et al. 2007). For 
example, miR-34a has been shown to be present in both cardiomyocytes and endothelial cells 
(Boon et al. 2013).  
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7. Chapter Seven 
Plasma membrane repair-related transcript expression in the 
normoxic and post-ischaemic ageing heart 
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7.1 INTRODUCTION 
As previously detailed in Section 1.7, the plasma membrane plays an integral part in 
cardioprotective signalling (Boengler, Schulz & Heusch 2009). By compartmentalising many 
cardioprotective receptors such as GPCRs the A1AR, δ-opioid receptor, and RTKs such as EGFR 
and their subunits, activation of cardioprotective receptors in the plasma membrane has been 
shown to enhance survival signalling leading to enhanced ischaemic tolerance and recovery 
(Lasley 2012; Patel et al. 2006). Ischaemic stress has been shown to results in multiple tiny 
breaks in the plasma membrane that, without immediate repair results in irreversible cell 
injury leading to necrosis (Jennings et al. 1983). Indeed, commonly used indicators of cell 
death detect changes in membrane permeability, such as LDH release or changes in 
membrane folding, including annexins. Injury to the plasma membrane frequently occurs in 
cells subjected to high levels of mechanical activity including skeletal and cardiac muscle cells. 
These cells experience constant mechanical stress, where up to 25% of cell wounding has 
been observed as a result (McNeil & Steinhardt 2003; Clarke et al. 1995). Cells which undergo 
a second disruption of the plasma membrane have been shown to repair the damage more 
rapidly than the initial wound, thus suggesting the presence of active processes (Togo et al. 
1999). Alterations in plasma membrane repair mechanisms are also associated with variety 
of diseases including muscular dystrophy, cancer invasion and in type 1 and 2 diabetes (He et 
al. 2012; Jaiswal et al. 2014; Howard et al. 2011).  
Most plasma membrane repair mechanisms are Ca2+-dependant and require the concerted 
effort of several cytoskeletal and plasma membrane proteins (Andrews, Almeida & Corette 
2014). Although the plasma membrane can reseal naturally via thermodynamic processes, 
this recovery is limited (McNeil & Kirchhausen 2005). Thus, the cell possesses a ‘toolkit’ of 
repair proteins, including ferlins, annexins, calpains, acid-spingomyolinases and the tripartite 
motif family of proteins, with representative members are shown in Table 7.1. Depending on 
the size of the wound, repair to the damage sites has been shown to involve complex events 
including: 1) remodelling of the cortical skeleton around the wound site, 2) changes in 
endocytic/exocytic events around the wound, 3) patch formation and 4) closure of the wound 
(Corrotte et al. 2013). To orchestrate this task, membrane repair involves the use of several 
different classes of proteins with differing roles such as proteases (calpains), calcium 
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sensing/binding proteins (annexins), E3 ubiquitin protein ligases (TRIMs), and 
spingomyolinases (SMPDs).  
Membrane-repair mechanisms have been shown to be reliant on caveolae and their coat 
proteins for normal trafficking and targeting to sites of injury (see Table 7.1 and Figure 7.1) 
(Cai et al. 2009; Zhu et al. 2011). Preservation of sarcolemmal integrity has been shown to be 
a noticeable feature of Cav3-overexpression and IPC, which may enhance these membrane-
repair mechanisms in the heart (Tsutsumi et al. 2008; Murry et al. 1990). Indeed, membrane-
repair mechanisms are crucial mediators of cardioprotective mechanisms such as IPC and 
IPOST as ablation of plasma membrane repair gene Trim72 results in loss of cardioprotection 
in murine hearts (Zhang et al. 2011; Cao et al. 2010). Furthermore, membrane-repair-related 
machinery are also implicated in the repair of the sarcomeric contractile apparatus which may 
be relevant to cardioprotection in terms of recovery following I-R (Cooper & Head 2014; 
Inserte et al. 2009). In this study, we investigated the expression of membrane repair-related 
transcripts, which are involved in several different stages of the membrane and sarcomeric 
repair which are typically associated with caveolae and remain largely uncharacterised in the 
ageing heart.  
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Figure 7.1 Current plasma membrane repair signalling paradigm A) Membrane repair 
requires the concerted effort of several classes of proteins, which interact with caveolins and 
caveolae. B) Damage to the membrane causes influx of calcium ions, which causes activation 
of calpains, annexins and other calcium sensitive proteins which help incorporate vesicles 
fusion to ‘patch’ the membrane. C) Within seconds the calcium concentration returns to 
normal levels when membrane integrity is restored, leading to inactivation of the repair 
complex.  (Taken from Wallace & McNally 2009).  
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Table 7.1 Representative members used in this study of membrane-related repair family 
proteins consisting of Ferlins, Annexins, Calpains, Spingomyolinases and Tripartite motif. It 
must be noted that this is not a comprehensive list, with other notable families such as ESCRT, 
Synaptotagmins and other genes also participate in the membrane repair processes (Jimenez 
et al. 2014). 
Family (Symbol) Members Localises/Interacts 
with 
Caveolins/Cavins 
Sarcomeric 
Repair 
Ferlin Dysferlin,  
Myoferlin 
+ 
- 
+ 
- 
 
Annexin (Anxa) 
Annexin-1 
Annexin-5  
Annexin-6 
- 
- 
+ 
+ 
- 
- 
 
Calpain (Capn) 
Calpain-1 
Calpain-2 
Calpain-3 
- 
+ 
- 
+ 
- 
+ 
Acid-Spingomyolinases 
(Smpd) 
Spingomyolinase-1 
Spingomyolinase-2 
? 
- 
- 
- 
Tripartite motif (Trim) Trim-54 
Trim-72 
- 
+ 
+ 
- 
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7.2 METHODS 
Langendorff perfusions were carried out on hearts (n=8-10/per group) from 8, 16, 32 and 48 
week old female mice as previously described in Section 2.1.1. Briefly, 20 minutes of global 
normothermic ischaemia was followed by 60 minutes of reperfusion whilst normoxic hearts 
were reperfused for 80 minutes. 
RNA isolation and cDNA synthesis from normoxic and post-ischaemic left ventricular tissue 
was carried out as described Section 2.2.1. 
RT-qPCR was used to analyse expression of Trim, Ferlin, Anxa, Capn and Smpd transcripts 
(Table 7.2) in ageing hearts as detailed in Section 2.3.1. Selection of a stable reference gene 
was carried out according to Section 2.3.2. Normalisation of post-ischaemic gene expression 
to normoxia was carried out according to Section 2.4. 
Western immunoblotting was carried to confirm validate the relationship between transcript 
and protein expression changes for Trim72 according to Section 2.5.  
Statistical analysis was conducted on data as per Section 2.6 with statistical significance 
accepted for P<0.05.  
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Table 7.2 RT-qPCR primer sequences for plasma membrane repair transcripts. 
Gene name 
Gene 
symbol 
NCBI 
GeneID 
Forward primer (5'-3') Reverse primer (5'-3') 
Tripartite motif-containing 
Trim54 Trim54 58522 CAGCCGCAGACAGAAGCAAC CTTGCGCTCCTCCAAAACCG 
Trim72 Trim72 434246 GCCTCAAGACACAGCTTCC GCACCGCTACAGTCTTCTC 
Annexins 
Annexin1 Anxa1 16952 CCTACCCTTCCTTCAATGTATCC TGCTTCATCCACACCTTTAACC 
Annexin5 Anxa5 11747 GACAAGTACATGACCATATCAGGA GAATAGACTTCACGACAGCCA 
Annexin6 Anxa6 11749 CGCATACAAAGACGCCTATGAG AAATCCTCGCTCACAACATCG 
Ferlins 
Dysferlin Dysf 26903 CTGCGATGTTTCCCTCTATGTG CGTCCACTTCTATTTCTCCTCC 
Myoferlin Myof 226101 CTGAACGAAGCCTCCTGAC GTGATGCCGCCTTATCTCC 
Calpains 
Calpain1 Capn1 12333 AATCTCCCAAACTCCCCTTCCC CGCTTCTTCTGTACTTGGGCTG 
Calpain2 Capn2 12334 AGAGTTCTAGCCAAACGCC CTCCCATCTTCATCCAGCA 
Calpain3 Capn3 12335 TCCATTGACGATGGCACGAA TCCGTGCAATCAACTCCCCC 
Sphingomyelinases 
sphingomyelin 
phosphodiesterase 1, acid 
lysosomal 
Smpd1 20597 CCTTAACCCTGGCTACCGA CAAGATGTAGGTCTCGTGGT 
sphingomyelin 
phosphodiesterase 2, 
neutral  
Smpd2 20598 GCTCTGATGATGGCTGTACC AGAGACTGCCTTGTAAAGCAC 
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7.3 RESULTS & DISCUSSION 
7.3.1.1 Transcriptional analysis of trim expression  
RT-qPCR was used to assess the expression of several families of proteins involved in plasma 
membrane repair and sarcomere maintenance as listed in Table 7.1. 
Trim74 expression was stable with ageing in both normoxic and post-ischaemic hearts (Figure 
7.2A). In the normoxic hearts, Trim54 showed 2-fold overexpression with ageing in the 16, 32 and 
48-week old hearts when compared to 8-week old (Figure 7.2B). This trend was also present 
within the post-ischaemic hearts which showed ~1.3-fold induction of Trim54 in the 32 and 48-
week old hearts vs 8-week old post-ischaemic hearts (Figure 7.2B). These findings are further 
supported by two-way ANOVA analysis which identified significant effect of age and ischaemia 
whilst the significant interaction of age and ischaemia was borderline non-significant (Table 7.3). 
When compared to age-matched normoxic counterparts, there was reduction (~1.4-fold) of 
Trim54 transcript in the ageing post-ischaemic hearts which was significant in the 16 and 48-week 
old post-ischaemic hearts (Figure 7.2B) 
 
Table 7.3 Two-way analysis of variance of age and post-ischaemic effects on Trim transcript 
expression 
Gene Factor Mean Square F (DFn, DFd) % of Total 
Variation 
P value 
Trim72 
Age 0.3373 3.02 (3,39) 17.8% 0.0413 
Ischaemia 3.285e-005 2.94e-004 (1,39) 0.1% 0.9864 
Age*Ischaemia 0.096 0.86 (3,39) 5.0% 0.4716 
Trim54 
Age 1.384 33.60 (3,36) 55.4% < 0.0001 
Ischaemia 1.302 31.63 (1,36) 17.4% < 0.0001 
Age*Ischaemia 0.108 2.62 (3,36) 4.3% 0.0654 
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Figure 7.2 Age-dependent expression of Trim transcripts in normoxic and post-ischaemic male 
hearts. Shown are boxplots detailing expression changes determined by RT-qPCR for A) Trim72 
and B) Trim54 in the normoxic (grey boxes) and post-ischaemic (red boxes) heart. Boxes indicate 
interquartile range (25%-75%) with the horizontal bar within each box indicating the median. The 
whiskers show the minimum and maximum values. * P < 0.05 vs 8-week old normoxic; † vs 16-
week old normoxic; ‡ P < 0.05 vs 8-week old post-ischaemic; + P < 0.05 vs 16-week old post-
ischaemic; # P < 0.05 vs age-matched post-ischaemic group (indicated by brackets). (n=6/group). 
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7.3.1.2 Transcriptional analysis of trim expression  
As Trim72 is known to interact with Cav3 and showed a possible down-regulation in the normoxic 
48-week old hearts, immunoblotting was used to verify the Trim72 transcript and protein 
expression. As shown in Figure 7.3A, normoxic 48-week old hearts showed a 2-fold down-
regulation of Trim72 that was borderline non-significant (P= 0.07) whilst post-ischaemic 48-week 
old hearts did not show this age-related decrease (Figure 7.3B). 
 
Figure 7.3 Age-dependent expression of Trim72 protein in normoxic and post-ischaemic male 
hearts. Validation of transcript and protein expression changes for left ventricular Trim72 in A) 
normoxic and B) post-ischaemic ageing hearts. Boxes indicate the interquartile range (25%-75%) 
with the horizontal bar within each box indicating the median. The whiskers show the minimum 
and maximum values. To the right of the graphs representative immunoblot images are shown 
for Trim72 and the β-Actin loading control. (n=6/group) 
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The TRIM family of proteins consists of numerous members, which have been shown to regulate 
a variety of cellular functions including immunity, cell cycle, autophagy and membrane repair 
(Alloush & Weisleder 2013; Micale et al. 2012; Mandell et al. 2014). Targeting of Trim72 to injury 
sites requires Cav3 and Cavin1 as knockdown of either Cav3 or Cavin1 results defective trafficking 
of Trim72 to membrane injury sites (Cao et al. 2010; Zhu et al. 2011). The role of Trim72 in 
membrane repair is thought to be in recruitment of repair components, including dysferlin and 
annexin5. Trim72 is also though to serve as a scaffold to facilitate membrane repair (Cao et al. 
2010). It has been proposed that the oligomerisation of Trim72 at the injury site provides 
anchorage for fusion of intracellular vesicles to the damaged sarcolemma. In support of this is the 
observation that Trim72-deficient mice lack intracellular vesicle accumulation following 
membrane injury when compared to wild-types (Cai et al. 2009). Besides its role in membrane 
repair mechanisms, Trim72 may also be involved in activation of survival kinases, as Trim72-
deficient hearts demonstrate reduced phospho-Akt and Erk1/2 activation following IPC (Cao et 
al. 2010). Conversely, Trim72-overexpression results in significant activation of phospho-Akt and 
Erk1/2 (Cao et al. 2010). The enhanced survival kinase expression in these hearts may be due to 
Trim72’s role as an inhibitor of IRS1, an upstream activator of PI3k. Indeed, Trim72 and IRS1 are 
associated together as shown by co-immunoprecipitation (Lee et al. 2010). Owing to its success 
in animal models, recombinant Trim72 has been suggested to be a therapeutic for IHD although 
its efficacy in the aged heart is unknown and may be affected due to reduction of Cav3, Cavin1 
and caveolae in the aged post-ischaemic hearts (Chapter 3) (Liu et al. 2015; Peart et al. 2014). 
Trim54 (aka Murf3) is an E3 ubiquitin protein ligase that plays a role in degradation of sarcomeric 
proteins, stabilization of microtubules and myogenesis (Olivé et al. 2015). In the heart, Trim54 
together with Murf1 and Calpain1, help maintain contractility by marking damaged and 
aggregated proteins such as FHL2 and γ-filamin for degradation (Fielitz et al. 2007). To further 
highlight their importance, Trim54-deficiency results hypertrophic cardiomyopathy and 
decreased fractional shortening compared to wild-types (Fielitz et al. 2007). Following I-R Trim54-
deficiency has been shown to results in cardiac rupture in 77% of Trim54-deficient hearts whilst 
this dramatic rupture was not observed in sham and wild-type mice (Fielitz et al. 2007). The 
molecular mechanisms leading to this cardiac rupture after MI remain unknown.  
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7.3.2.1 Transcriptional analysis of annexin expression   
Transcriptional analysis of Anxa1 and Anxa6 did not show changes in expression in the normoxic 
and post-ischaemic ageing heart (Figure 7.4A-C, respectively). For Anxa5, highly significant effect 
of age was identified using two-way ANOVA analysis (Table 7.4). Anxa5 showed a significant 2.6-
fold down-regulation in the 16 week-old normoxic hearts with the 32 and 48-week old normoxic 
hearts showing 1.6-fold decrease (Figure 7.4C). Whilst this age-related reduction of Anxa5 was 
also present in the post-ischaemic ageing hearts, it was only significant in the 16-week old hearts 
vs 8-week old hearts (Figure 7.4B).  
 
Table 7.4 Two-way analysis of variance of age and post-ischaemic effects on annexin transcript 
expression 
Gene Factor Mean Square F (DFn, DFd) % of Total 
Variation 
P value 
Anxa1 
Age 0.325 1.77 (3,36) 10.3% 0.1696 
Ischaemia 0.854 4.66 (1,38) 9.0% 0.0373 
Age*Ischaemia 0.249 1.35 (3,38) 7.9% 0.2712 
Anxa5 
Age 1.146 10.25 (3,36) 42.5% < 0.0001 
Ischaemia 0.289 2.58 (1.36) 3.6% 0.1167 
Age*Ischaemia 0.099 0.89 (3,36) 3.7% 0.4570 
Anxa6 
Age 0.014 0.39 (3,40) 2.7% 0.7591 
Ischaemia 0.002 0.08 (1,40) 0.2% 0.7891 
Age*Ischaemia 0.027 0.77 (3,40) 5.3% 0.5182 
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Figure 7.4 Age dependent expression of annexin transcripts in normoxic and post-ischaemic 
male hearts. Shown are boxplots detailing expression changes determined by RT-qPCR for A) 
Anxa1, B) Anxa5 and C) Anxa6 in the normoxic (grey boxes) and post-ischaemic (red boxes) heart. 
Boxes indicate the interquartile range (25%-75%) with the horizontal bar within each box 
indicating the median. The whiskers show the minimum and maximum values. * P < 0.05 vs 8-
week old; † vs 8-week old post-ischaemic. (n=6/group). 
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The annexin family consist of twelve ubiquitously expressed genes that are Ca2+ and phospholipid-
binding proteins. Annexins participate in a variety of cellular processes, including the regulation 
of membrane dynamics, cell migration, calcium handling and apoptosis (Monastyrskaya 2009; 
Camors, Monceau & Charlemagne 2005). We investigated expression of Anxa1, Anxa5 and Anxa6 
as they have been implicated in formation of repair patches following plasma membrane injury 
(McNeil et al. 2006; Bouter et al. 2011; Swaggart et al. 2014). Of the annexins transcripts 
investigated, only Anxa5 showed a significant change in expression with ageing. Anxa5 was down-
regulated with ageing in the normoxic hearts (Figure 7.4B). Anxa5 has been shown to participate 
in membrane repair by the formation of two-dimensional ordered arrays of trimers on 
phosphatidylserine exposing membranes (Bouter et al. 2011). The authors proposed that the two-
dimensional array formed strengthens the membrane and prevents the expansion of the tear 
(Bouter et al. 2011). Interestingly, Anxa5-deficient mice are fertile and show normal development 
with no changes in blood plasma biochemical parameters (Brachvogel et al. 2003). However, the 
authors did not investigate muscle histology or markers of oncosis/necrosis (e.g. CK, LDH or 
troponin), although it is possible that Anxa5-deficiency does not result in impairment plasma 
membrane integrity by itself (Brachvogel et al. 2003). It is unclear whether repair-patch formation 
in the aged hearts is significantly affected partly owing to lack of kinetic investigations. In end-
stage human heart failure, expression of Anxa5 has been shown to be induced and cluster in the 
cytosol of cardiomyocytes with a lack of organisation (Song et al. 1998; Benevolensky et al. 2000; 
Matteo & Moravec 2000). It is interesting to speculate whether this lack of organisation could be 
from the reduction of Cav3/Cavin1-mediated targeting to sites of injury in the failing hearts 
(Ratajczak et al. 2003).  
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7.3.3.1 Transcriptional analysis of ferlin expression   
Dysf did not show any changes in expression with ageing in the normoxic and post-ischaemic 
hearts (Figure 7.5A). In the normoxic hearts, Myof showed 1.4-fold up-regulation in the 48-week 
old hearts vs 16 and 32-week old hearts (Figure 7.5B). Post-ischaemic Myof expression was 
unaffected with ageing (Figure 7.5B).  
Table 7.5 Two-way analysis of variance of age and post-ischaemic effects on ferlin transcript 
expression 
Gene Factor Mean Square F (DFn, DFd) % of Total 
Variation 
P value 
Dysf 
Age 0.307 1.94 (3,38) 11.2% 0.1401 
Ischaemia 0.278 1.75 (1,38) 3.4% 0.1938 
Age*Ischaemia 0.337 2.12 (3,38) 12.3% 0.1138 
Myof 
Age 0.692 3.93 (3,40) 17.7% 0.0151 
Ischaemia 0.188 1.07 (1,40) 1.6% 0.3077 
Age*Ischaemia 0.807 4.58 (3,40) 20.6% 0.0075 
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Figure 7.5 Age dependent expression of ferlin transcripts in normoxic and post-ischaemic male 
hearts. Shown are boxplots detailing expression changes determined by RT-qPCR for A) Dysf and 
B) Myof in the normoxic (grey boxes) and post-ischaemic (red boxes) heart. Boxes indicate the 
interquartile range (25%-75%) with the horizontal bar within each box indicating the median. The 
whiskers show the minimum and maximum values. †, P < 0.05 vs. 16-week old normoxic; ‡, P < 
0.05 vs 32-week old normoxic. (n=6/group). 
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The ferlin family of genes consists of the highly homologous dysferlin (Dysf), myoferlin (Myof), 
otoferlin (Otof) and fer-like family. The ferlin family is part of the dystrophin complex with 
disruption of this complex associated with cardiomyopathy and muscle diseases (i.e. Miyoshi 
myopathy) as a result of plasma membrane instability (Heydemann & McNally 2007). Dysferlin-
deficient mice display defective plasma membrane sealing with progressive muscular dystrophy 
(Bansal et al. 2003). Dysf interacts with several membrane repair related proteins in the 
sarcolemma including Cav3, annexins and calpains (Kobayashi et al. 2012). Cav1 and Cav3-
deficient cells show abnormal Dysf trafficking, similar to aberrant Dysf localisation in 
caveolinopathies suggests that caveolins may be important in targeting of Dysf to the membrane 
(Hernández-Deviez  et al. 2008; Matsuda et al. 2001). More specifically, mutations in Cav3 result 
in retention of Dysf-Trim72 complexes in the Golgi apparatus suggesting caveolins help target 
plasma membrane machinery to sites of injury (Cai et al. 2009).   
The role of Dysf seems to involve, in conjunction with acid-spingomyolinase targeting of vesicular 
and lysosome fusion to injury sites as Dysf-deficient mice show reduced tethering of lysosomal 
exocytosis (Defour et al. 2014). In addition, Dysf-deficient mice show Anxa1 and Anxa2 
accumulation at the site of injury (Lennon et al. 2003). Upon injury, Calpain-mediated cleavage of 
Dysf into Mini-dysferlinC72 patches appears to be the first-response accumulating at the exposed 
edge of the membrane (Lek et al. 2013). Within 10 seconds after injury, Trim72 mobilisation leads 
to formation of Mini-dysferlinC72 and Trim72 lattices which help reseal the membrane with 
Annexin1 (Lek et al. 2013). As the aged post-ischaemic hearts show significant down-regulation 
of Cav3 (Chapter 3, Figure 3.5B), it is possible that the targeting of these Dysf and Trim72 patches 
to sites of injury may be affected by the decreased expression of Cav3. This remains to be shown 
in the ageing hearts and should be investigated using imaging techniques and/or 
immunocopreciptation.  
Another member of the ferlin family, myoferlin, is up-regulated (mRNA) in response to damaged 
myotubes and in Dysf-deficient mice, with up-regulation of myoferlin thought to act as 
compensatory response (Davis et al. 2008; Demonbreun et al. 2010). In COS-7 cells, myoferlin 
participates in membrane repair that is dependent on Cav1 expression as Cav1 knockdown results 
in loss of this repair response (Bernatchez et al. 2009). In the same study, myoferlin was shown 
 
 
199 
 
to partially colocalise with another membrane-repair protein known as Dynamin-2 and also Cav1. 
The resulting protein complexes have been shown to be necessary for membrane-repair response 
in COS-7 cells (Bernatchez et al. 2009). In the ageing hearts used in this study, Myof showed 
significant up-regulation in 48-week old vs. 16 and 32-week old normoxic hearts whilst its 
expression in the post-ischaemic hearts did was not altered (Figure 7.5B). The exact role of 
myoferlin in cardioprotection is currently unknown. 
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7.3.4.1 Transcriptional analysis of calpain expression   
In the normoxic and post-ischaemic ageing heart, Capn1 (Figure 7.6A) and Capn2 (Figure 7.6B) 
expression did not show any changes in the ageing. Minor down-regulation (1.3-fold) of Capn2 in 
the 48-week old post-ischaemic vs age-matched normoxic hearts was detected (Figure 7.6B). 
Unlike Capn2 and Capn3, effects of ageing were highly significant for Capn3 as shown by two-way 
ANOVA analysis (Table 7.6). Capn3 showed a significant 4-fold up-regulation in the 32 and 48-
week old normoxic hearts when compared to younger hearts (Figure 7.6C). Similarly, this affect 
was also present in the post-ischaemic ageing hearts which showed 3-fold overexpression when 
compared to younger hearts (Figure 7.6C).  Similar to Capn2, repression (1.6-fold) of Capn3 in the 
48-week old post-ischaemic vs age-matched normoxic hearts was observed (Figure 7.6C). 
 
Table 7.6 Two-way analysis of variance of age and post-ischaemic effects on calpain transcript 
expression 
Gene Factor Mean Square F (DFn, DFd) % of Total 
Variation 
P value 
Capn1 
Age 0.507 1.38 (3,38) 8.4% 0.2647 
Ischaemia 1.599 4.34 (1,38) 8.8% 0.0440 
Age*Ischaemia 0.269 0.73 (3,38) 4.5% 0.5380 
Capn2 
Age 0.130 1.80 (3,40) 9.2% 0.1627 
Ischaemia 0.771 10.65 (1,40) 18.1% 0.0023 
Age*Ischaemia 0.064 0.88 (3,40) 4.5% 0.4574 
 
Capn3 
Age 11.42 49.05 (3,40) 73.3% < 0.0001 
Ischaemia 2.174 9.34 (1,40) 4.7% 0.0040 
Age*Ischaemia 0.332 1.42 (3,40) 2.1% 0.2498 
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Figure 7.6 Age dependent expression of calpain transcripts in normoxic and post-ischaemic 
male hearts. Shown are boxplots detailing expression changes determined by RT-qPCR for A) 
Capn1, B) Capn2 and C) Capn3 in the normoxic (grey boxes) and post-ischaemic (red boxes) heart. 
Boxes indicate the interquartile range (25%-75%) with the horizontal bar within each box 
indicating the median. The whiskers show the minimum and maximum values. * P < 0.05 vs 8-
week old normoxic; † P < 0.05 vs 16-week old normoxic; ‡ P < 0.05 vs 8-week old post-ischaemic; + 
P < 0.05 vs 16-week old post-ischaemic. (n=6/group). 
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Calpains are cytosolic Ca2+-activated cysteine proteases that are thought to be involved in variety 
of cardiovascular diseases such as heart failure, diabetes, and ischaemia-reperfusion (Letavernier 
et al. 2012). Fifteen calpain genes are encoded in the human genome, with the heart 
demonstrating high expression of Calpain1, 2, 3 and 4 (Sorimachi & Ono 2012; Sandmann, Yu & 
Unger 2001). I-R results in activation of several families of calpains which target numerous 
proteins in the cell including contractile proteins (i.e. troponin, vinculin) and membrane 
associated proteins (i.e. dystrophin) (Neuhof & Neuhof 2014; Müller, Hryshko,  Dhalla & 2013). 
Calpains have been implicated in plasma membrane repair by cleaving Dysferlin into mini-
dysferlinC72 which forms patches with Trim72 at sites on injury (Lek et al. 2013). There were no 
changes in Capn1 and Capn2 expression in the ageing normoxic and post-ischaemic hearts (Figure 
7.6A and 7.6B).  
However, compared to their age-matched normoxic counterparts, the 48-week old post-
ischaemic hearts showed significant down-regulation of Capn2 and Capn3 (Figure 7.6A-B). Capn1 
and Capn2 have been suggested to be the essential calpains but not Capn3 in the plasma 
membrane repair response of muscle fibres (Mellgreen et al. 2009). However, mutations and/or 
deficiency of Capn3 and Capn4 also have been shown to result in disruption of plasma membrane 
repair in skeletal and cardiomyocytes (Huang et al. 2008; Taneike et al. 2011). Capn3 has been 
shown to cleave membrane-repair proteins such as Anxa1, Anxa2 and AHNAK which reduces their 
affinity to Dysferlin and may therefore disrupt Dysferlin-mediated repair (Lennon et al. 2003; 
Huang et al. 2008). Therefore, significant induction of Capn3 in the post-ischaemic hearts (figure 
7.11C) may impair repair mechanisms associated with Anxa1, Anxa2 and AHNAK. Besides its 
association with plasma membrane repair, Capn3 is associated with sarcomeric remodelling by 
cleaving myofibrillar proteins such as titin and vimentin (Guyon et al. 2003). Enhanced activity of 
calpains in the heart has been shown to result in sarcomeric disruption, myocardial stunning and 
ventricular remodelling after myocardial infarction (Galvez et al. 2007; Barta et al. 2005; Kudo-
Sakamoto et al. 2014; Ma et al. 2012). However, it is of note that some Calpain3 activity is required 
for normal sarcomeric maintenance as Capn3-deficient mice show evidence of insoluble protein 
aggregates in skeletal muscles, similar to clinical observations in patients with CAPN3 mutations 
(Kramerova et al. 2005; Hauerslev et al. 2012). Taken together, combined up-regulation of Trim54 
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and Capn3 in the 32- and 48-week old hearts may result in increased degradation of sarcomeric 
contractile apparatus which may subsequently be responsible for decreased contractile efficiency 
observed in the 32- and 48-week old male hearts (Figure 3.2A).  
 
7.3.5.1 Transcriptional analysis of Smpd expression   
Smpd1 expression showed no changes in the normoxic ageing male heart (Figure 7.7A). Although 
there was a minor down-regulated trend of Smpd1 in the 16 and 48-week old post-ischaemic 
heart hearts (Figure 7.7A) as further suggested by two-way ANOVA analysis (Table 7.7), post-hoc 
analysis showed this trend was not significant. Expression analysis of Smpd2 revealed non-
significant up-regulation in the 16 and 32-week old normoxic heart relative to 8-week old 
counterparts. This trend for Smdp2 became significant in 16- and 32-week old post-ischaemic 
hearts (relative to 8-week old), whilst at the 48-week old time point its expression returned close 
to baseline (Figure 7.7B). 
 
Table 7.7 Two-way analysis of variance of age and post-ischaemic effects on acid-
spingomyolinase transcript expression 
Gene Factor Mean Square F (DFn, DFd) % of Total 
Variation 
P value 
Smpd1 
Age 0.186 4.23 (3,37) 20.1% 0.0115 
Ischaemia 0.494 11.23 (1,37) 17.8% 0.0019 
Age*Ischaemia 0.031 0.70 (3,37) 3.3% 0.5590 
Smpd2 
Age 1.789 9.14 (3,38) 38.1% 0.0001 
Ischaemia 0.280 1.43 (1,38) 2.0% 0.2391 
Age*Ischaemia 0.404 2.07 (3,38) 8.6% 0.1211 
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Figure 7.7 Age dependent expression of acid-spingomyolinase transcripts in normoxic and post-
ischaemic male hearts. Shown are boxplots detailing expression changes determined by RT-qPCR 
for A) Smpd1 and B) Smpd2 in the normoxic (grey boxes) and post-ischaemic (red boxes) heart. 
Boxes indicate the interquartile range (25%-75%) with the horizontal bar within each box 
indicating the median. The whiskers show the minimum and maximum values. * P < 0.05 vs. 8-
week old post-ischaemic; † P < 0.05 vs 16-week old post-ischaemic; ‡ P < 0.05 vs 32-week old post-
ischaemic. (n=6/group). 
 
The acid spingomyolinase (Smpd) family consists of four members comprising of Smpd1, Smpd2, 
Smpd3 and Smpd4. The encoded proteins differing in optimum pH activity, cation dependence, 
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tissue distribution and subcellular distribution (Marchesini & Hannun 2004). Clinically, SMPD-
deficiency due to SMPD1 gene mutations results in the lysosomal storage-related 
neurodegenerative disease Niemann–Pick type (Schuchman & Wasserstein 2015). SMPDs 
participate in pathophysiology of cardiac and vascular dysfunction with various SMPD inhibitors 
suggested to be therapeutics for IHD (Pavoine et al. 2009). Smpds convert sphingomyelin, which 
are enriched in caveolae, into ceramide (Liu & Anderson 1995). Following I-R, ceramide formation 
is enriched in regions of Ca2+ influx, with preconditioning and pharmacological inhibition of Smpd 
shown to reduce I-R-induced cell death and decrease ceramide synthesis (Argaud et al. 2004). 
However, some expression of Smpd appears necessary as pharmacological inhibition of Smpd1 
following membrane disruption results in impaired restoration of plasma membrane integrity 
(Tam et al. 2010). Indeed, delivery of recombinant human ASM to Niemann–Pick type A fibroblast 
has been shown to restore membrane integrity (Tam et al. 2010).  
Smpds can influence the degree of Cav3-Cavin1 co-localisation as delivery of Smpd has been 
shown to result in significant increase of this co-localisation when compared to mock controls 
(Corette et al. 2013). The exact mechanism of this interaction is currently unknown, however, 
such enhanced co-localisation would assist in plasma membrane repair mechanisms and both 
Cav3 and Cavin1 are crucial to this process by mechanisms discussed previously (Corette et al. 
2013; Zhu et al. 2011). In the ageing post-ischaemic hearts, Smpd1 did not show significant 
changes with ageing although a minor trend was present in the 48-week old hearts. However, its 
activity as a plasma membrane repair protein may be compromised as Smpd1-mediated repair 
has been shown to be reliant on Cav3 and possibly Cavin1, which as discussed previously in 
Chapter 3 are down-regulated in the middle-aged hearts (Defour et al. 2014; Corrette et al. 2013). 
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7.4 CONCLUSION 
In this study, we investigated the expression of a variety of membrane repair-related transcripts 
in the ageing male normoxic and post-ischaemic hearts, which were largely uncharacterised in 
the ageing heart. As previously discussed, membrane repair mechanisms have been shown to be 
crucial mediators of cardioprotective responses such as IPC and IPOST, as deficiency of a plasma 
membrane repair protein, Trim72, results in a loss of cardioprotection (Cao et al. 2010; Zhang et 
al. 2011). Caveolae and its coat-proteins have been implicated in the membrane repair response 
as knockdown of Cav3, Cav1 and Cavin1 results in ablated membrane-repair response (Corrotte 
et al. 2013; Zhu et al. 2011). Indeed, preservation of the sarcolemmal structures and membrane 
integrity as shown by decreased Troponin leakage following I-R are features of the Cav3-
overexpression and IPC (Tsutsumi et al. 2008; Murry, Jennings & Reimer 1986). Involvement of 
caveolae was noted as early as 1981 in Duchenne muscular dystrophy samples as noted by 
significant increase in the number of caveolae seen under EM in these samples (Bonilla, Fischbeck 
& Schotland 1981). It has been proposed that formation of caveolae at the site of injury which 
combine with caveolae-like vesicle to internalise and isolate the damaged site leading to repair 
(Corrette et al. 2013). 
 To further highlight to role caveolae and its coat proteins, mutation in CAV3 and CAVİN1 result 
in several forms of muscular dystrophies, which affect sarcolemma membrane stability and 
disorganization of skeletal muscle T-tubule network (Gazzero et al. 2010; Hayashi et al. 2009). 
Expression for most of the plasma membrane-repair transcripts investigated in this study were 
unaffected by ageing, most notably Trim72, Capn1 and Anxa6. Although Anxa5 and Smpd1 
showed minor down-regulated trends in the 48-week old post-ischaemic hearts, whilst being non-
significant, the loss of Cav3 and Cavin1 in the ageing post-ischaemic hearts (Chapter 3) may 
disrupt their roles in repair response (I.e. for Trim72) as they have been shown to be reliant on 
caveolae and their coat proteins for targeting to disruption sites (Cao et al. 2010; Zhu et al. 2011). 
For example, Cav3-deficiency disrupts the targeting of dystrophin-glycoprotein complex, 
associated with plasma membrane stability, to caveolae in conjunction with the loss of α-
sarcoglycan expression (Woodman et al. 2002).  
As shown in Chapter 3, the ageing heart displays reduced contraction efficiency following I-R. In 
addition to membrane repair mechanisms, we investigated transcripts related to sarcomeric 
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remodelling which certain members of the membrane repair related transcripts shown to also 
participate in this process. Degradation of contractile-related proteins is a normal physiological 
process whereby damaged and misfolded proteins are removed by the ubiquitin proteasome 
system in the heart (Willis et al. 2009). As shown in Figure 3.2A, the 32- and 48-week old male 
hearts show reduced recovery following I-R which may be due to enhanced degradation of 
contractile apparatus from proteases, (i.e. Calpains), increased protein turnover (via Trim52) or 
reduced efficacy or repair mechanisms (i.e. Annexins). Members of Calpains, Trim, Annexins and 
Dysferlins have been shown to localise in sarcomeric apparatus such as T-tubules in muscle fibres 
and are thought to maintain the integrity of the T-tubule network (Waddell et al. 2011; Voigt et 
al. 2013).  As previously discussed, Capn3 and Trim54 are associated with sarcomeric remodelling 
by cleaving myofibrillar proteins and ubiquitin-mediated muscle protein turnover respectively 
(Guyon et al. 2003; Perera, Mankoo & Gautel 2012). Significant-up regulation of Trim54 was 
observed in both the normoxic and post-ischaemic ageing hearts. As a result of significant 
induction of Capn3 and Trim54 in the 32- and 48-week old post-ischaemic hearts, enhanced 
degradation of sarcomeric proteins may occur as overexpression of Trim54 has been shown to 
result in loss in expression of FHL2 and γ-filamin (Fielitz et al. 2007). However, this remains to be 
shown.  
Recently, Poloxemer 188, a biocompatible polymer has been proposed as a novel therapeutic for 
patients with muscular dystrophies (i.e. Duchenne) and has been shown to protect against 
ischaemic injury in skeletal muscle  (Murphy et al. 2010), neurons (Colbassani et al. 1989), heart 
failure (Juneman et al. 2012) and various types of cellular of injuries in other tissues (see review 
Moloughney & Weisleder 2012).  Future studies, using kinetic measurements, should investigate 
whether the middle-aged and aged hearts show attenuated repair mechanisms when compared 
to young/mature counterparts. Immunoblot analysis should be performed on Anxa5 and Smpd1 
for comparisons in the 8- and 48-week old hearts as a trend in decrease was detected in these 
hearts. In addition, the substrates of Capn3 and Trim54 should be investigated whether enhanced 
degradation/cleavage occurs in the aged hearts as a result of increased expression of these 
transcripts. Future studies should also investigate the expression of notable transcripts crucial for 
membrane-repair including members of EHD, dynamin, dystrophin complex.  
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8. Chapter Eight 
Conclusion 
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8.1 FINAL CONCLUSION 
Ischaemic heart disease is the most prevalent CVD (44%) and the largest single leading cause of 
death in Australia with over 19,000 reported deaths in 2011 (ABS 2011; Heart Foundation 2012). 
The incidence of IHD increases with age, affecting 29% of those aged 75 years and over and 47% 
of those aged 85 years and over. Timely reperfusion of the ischaemic myocardium can result in 
preservation of over 50% of the myocardial tissue (Schömig, Ndrepepa & Kastrati 2006). However, 
reperfusion is a ‘double-edged sword’ as restoration of blood flow may contribute to as much as 
50% of the final infarct size (Jennings et al. 1960). Cardioprotection are interventions designed to 
prevent or reduce injuries (oncosis, arrhythmias, contractile dysfunction) from myocardial 
infarction, especially those caused by I-R (Heusch 2013). Experimentally, cardioprotection can be 
exploited via ischaemic conditioning methods (e.g. IPC and IPOST) or pharmacologically (e.g. A1AR 
and δ-opioid receptor activation).  Although these interventions are successful in reducing infarct 
size and post-ischaemic dysfunction in young hearts, there is an age-related impairment of these 
methods in the aged hearts. Both IPC and pharmacological agonism have been shown to be reliant 
on the presence of caveolae, which house a variety of cardioprotective receptors as well as their 
signalling subunits (Tsutsumi et al. 2008; Peart et al. 2014).  
As we and others have shown, concurrent with the reduction of ischaemic tolerance in the aged 
hearts is the age-related decline of Cav3 protein expression, which is critical for cardiomyocyte 
caveolae formation (Chapter 3; Kidd et al. 2010; Peart et al. 2014). To further support the role of 
caveolae in modifying ischaemic tolerance in the aged heart, restoration of caveolae in the aged 
heart results in enhanced recovery of these hearts (Kidd et al. 2010). Conversely, depletion of 
caveolae via MβCD and Cav3-deficiency results in reduced ischaemic tolerance (Chapter 5, See 
Hoe et al. 2014). In addition to the reduction of Cav3, here we show that there is also age-related 
loss of Cavin1 and Popdc1 which have recently also been shown to be crucial determinant of 
cardiomyocyte caveolae and may also enhance the loss of caveolae in these hearts. Surprisingly, 
the female ageing myocardium showed similar mRNA expression patterns of Cav3, Cavin1 and 
Popdc1 especially in the post-ischaemic hearts.  Furthermore, the age-related reduction of post-
ischaemic Cav3 and cavin1 protein in the middle-aged female hearts was also similar to their male 
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counterparts. Taken together, age-related decrease in caveolae forming transcripts may be 
responsible for reduction of caveolae in the male and female middle-aged heart as we and others 
show (Peart et al. 2014). Consequently, the reduction in caveolae may underpin the middle-aged 
hearts sensitisation to ischaemic insult and desensitisation to cardioprotective therapies. We then 
investigated whether the reduction of Cav3 and cavin1 may be due to miRNA-mediated 
repression of these transcripts. The age-related decrease of Cav3 and cavin1 did not show 
inverse-correlation with candidate miRNAs predicted to target these transcripts although it 
remains a possibility that other miRNAs not used in this study may be control their expression. Of 
the miRNAs assessed, the induction of miR-15b, miR-22 and miR-92a in the middle-aged hearts 
was consistent with their respective roles in the cell and may contribute loss of cardioprotection 
in these hearts. Lastly, we investigated the expression of several plasma membrane repair 
transcripts, which remain largely uncharacterised in the ageing heart.  
Membrane-repair mechanisms are crucial mediators of cardioprotective mechanisms such as IPC 
and IPOST (Zhang et al. 2011; Cao et al. 2010). Furthermore, members of plasma membrane repair 
machinery such as Trim72 require presence of Cav3 and Cavin1 in order to be targeted to sites of 
injury. Of the plasma membrane repair transcripts, we did not detect significant differences in the 
post-ischaemic ageing hearts although Anxa5 and Smpd1 showed a minor trend in down-
regulation in the middle-aged post-ischaemic hearts. Although the expression of Trim72, Anxa5 
and Smpd1 did not show significant changes in the post-ischaemic heart, their targeting to sites 
of injury may be affected by the decreased Cav3 and Cavin1 expression although this remains a 
hypothesis. We also investigated the expression of Trim54 and calpain transcripts which are 
implicated in the maintenance of the sarcomere. In the 32- and 48-week old post ischaemic hearts 
there was a notable induction of Trim54 and Capn3, and may be partially responsible for reduced 
recovery in the 32- and 48-week old hearts although it remains to be shown their substrates are 
affected by this induction. 
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Key findings in of this study; 
 Loss of endogenous cardioprotection is evident in the 48-week old male (middle-aged) 
hearts as shown by enhanced LDH release (Figure 3.2B). Although LDH release was not 
significant in the 32-week old heart, there is evidence of post-ischaemic dysfunction as 
shown by reduced pressure developed pressure in these hearts similar to that of 48-week 
old hearts (Figure 3.2A).  
 Cav3 mRNA expression is down-regulated in the normoxic hearts as early as 16-week old 
hearts (Figure 3.4C) with the 48-week old hearts shown to display significant down-
regulation at the proteomic level (Figure 3.5A). Similarly, the 32 and 48-week old post-
ischaemic hearts showed down-regulation of Cav3 transcript (Figure 3.4C), with significant 
Cav3 protein down-regulation observed in the 48-week old heart (Figure 3.5B). The 
reduction in Cav3 protein in the 48-week old heart correlated with the significant 
reduction of ischaemic tolerance in these hearts. 
 Transcriptional analysis showed significant Cavin1 down-regulation in the normoxic 48-
week old male hearts (Figure 3.6A) although this was borderline non-significant at the 
proteomic level (Figure 3.7A). The post-ischaemic heart also showed significant Cavin1 
down-regulation in the 48-week old heart as shown by RT-qPCR (Figure 3.6A) and 
immunoblotting (Figure 3.7B). The reduction in Cavin1 protein in the 48-week old heart 
correlated with the significant reduction of ischaemic tolerance in these hearts. 
 Although Popdc1 and Popdc3 did not show significant changes in the normoxic ageing 
male hearts, there was an age-related repression these transcripts in the post-ischaemic 
male hearts. More specifically, Popdc1 mRNA showed significant down-regulation in the 
32 and 48-week old hearts whilst Popdc3 showed trend towards significant down-
regulation (P=0.15) in the 48-week old hearts (Figure 3.8A and 3.8C). Notably, there was 
also reduction of these transcripts in the 32 and 48-week old post-ischaemic hearts when 
compared to their age-matched normoxic counterparts (Figure 3.8A and 3.8C).  
 Post-ischaemic female hearts showed significant reduction in recovery in the 32 and 48-
week old hearts similar to that of male counterparts (Figure 4.1A). Reduced recovery 
observed in the 32-week old hearts did not match the LDH release which also did not show 
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significant changes when compared to younger phenotypes. Significant LDH release was 
observed in the 48-week old female myocardium when compared to 8 and 16-week old 
counterparts (Figure 4.1B). Furthermore, we observed that contrary to other authors, the 
48-week old female hearts displayed marked LDH release when compared to their age-
matched male counterparts (Figure 4.1C). The menopausal state of the 48-week old hearts 
used in this study is unknown and future investigations should address this.  
 Although transcriptional analysis did not suggest significant down-regulation of Cav3 in 
female 48-week old normoxic hearts (Figure 4.3C), immunoblotting showed significant 
down-regulation of Cav3 (Figure 4.4A). Conversely, although transcriptional analysis 
showed significant Cav3 reduction in the ageing post-ischaemic female heart (Figure 4.3C), 
Cav3 down-regulation was borderline non-significant at the proteomic level (Figure 4.4B). 
Altogether the age-related down-regulation of Cav3 appears present in the middle-aged 
female post-ischaemic heart similar to that of male counterparts.  
 Transcriptional analysis and immunoblotting of Cavin1 in the female normoxic ageing 
hearts revealed no significant changes (Figure 4.5A & Figure 4.6A). However, although the 
post-ischaemic suggested no age-related transcriptional changes (Figure 4.5A), significant 
down-regulation of Cavin1 protein was observed in the 48-week old hearts (Figure 4.6B).  
The combined reduction of Cav3 and Cavin1 protein in the 48-week old post-ischaemic 
hearts coincided with the loss of I-R tolerance in these hearts.  
 Of the three Popdcs mRNAs, only Popdc3 showed significant age-related changes in the 
female myocardium. More specifically, Popdc3 showed significant induction in the 32- and 
48-week old post-ischaemic hearts when compared to age-matched normoxic 
counterparts (Figure 4.7C).  
 Of the miRNAs assessed, only miR-378 was consistently down-regulated in the normoxic 
and post-ischaemic heart (Figure 6.4E) although it remains to be shown whether its targets 
Igf1r and Grb2 are down-regulated in the ageing hearts used in this study.  
 Relative to their normoxic age-matched counterparts, we report up-regulation of I-R-
related miRNAs: miR-15, miR-20a, miR-24 and miR-92a in the post-ischaemic 48-week old 
heart (Figure 6.3), consistent with literature reports and their roles as pro-apoptotic 
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miRNAs. Similarly, for the ageing/senescence related miRNAs, we observed significant up-
regulation of miR-22 (Figure 6.4A) in the 48-week old post-ischaemic hearts vs age-
matched normoxic, consistent with its role in cardiac ageing.  
 There was no inverse correlation in expression detected for miRNAs targeting Cav3 and 
Cavin1 used in this study. 
 After extensive optimisation of several crucial parameters for transfection, a modest 
degree transfection was achieved using Cav3 miRNA vectors, comparable to that of the 
literature. However, this degree of transfection has been suggested to produce unreliable 
knockdown and was abandoned in lieu of pharmacological approaches. 
 To show caveolae involvement in modifying ischaemic tolerance, pharmacological 
approach using cholesterol depletion (via MβCD) of cellular rafts was investigated. MβCD 
treatment following sI-R enhanced cell death compared to non-treated sI-R cells as shown 
by LDH release (Figure 5.16A) and Annexin V-PE and 7-AAD staining (Figure 5.16B).  
 Of the membrane-related transcripts, only Anxa5 showed significant down-regulation 
with ageing in the normoxic 16-, 32- and 48-week old hearts (Figure 7.4B). Whilst a minor 
down-regulated trend for Anxa5 and Smpd1 was observed in the 48-week old post-
ischaemic hearts (vs 8-week old) which should be confirmed via immunoblotting.  
 Protease transcripts Trim54 and Calpain3 showed significant up-regulation in the 32- and 
48-week old post-ischaemic male hearts (Figure 7.2B and Figure 7.6C, respectively), which 
may contribute to post-ischaemic contractile dysfunction in these hearts by increased 
degradation of contractile proteins. However, this remains to be shown. 
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8.2 LIMITATIONS 
As access and availability of human ventricular samples are rare, we were unable to compare 
between murine and human tissue models as to whether the age-related loss of Cav3, Cavin1 and 
Popdc1 also occurs in the ageing human hearts. The reduction in morphological caveolae should 
be confirmed using electron microscopy especially in the female hearts as this has not been 
shown in the female hearts whilst morphological reduction in caveolae has been confirmed in 
male hearts by other investigators (Peart et al. 2014). Although Cav3 and Cavin1 has been shown 
to be crucial for plasma membrane repair in vitro, it remains to be demonstrated whether the 
reduction of Cav3 and Cavin1 in the middle-aged hearts is sufficient enough to reduce the efficacy 
of plasma membrane repair mechanisms in middle-aged hearts used in this study. Although 
Popdc1 showed significant transcriptional down-regulation in the ageing post-ischaemic male 
hearts, it remains to be shown whether this repression results in significant proteomic reduction. 
Significant up-regulation of miR-15b, miR-20a, miR-22, miR-24 and miR-92a were observed in the 
48-week old post-ischaemic myocardium relative to their age-matched normoxic counterparts. 
This may contribute to loss of ischaemic tolerance in these hearts by mechanisms detailed in 
Chapter 6. However, it remains to be shown whether their targets are significantly affected by 
this change in expression. Similarly, whilst significant repression of miR-378 was observed in the 
32- and 48-week old normoxic and post-ischaemic male hearts, it remains to be shown whether 
its mRNA targets are also impacted. Due to lack of concise indicators and lack of literature 
availability in menopausal state of the mice hearts, we are unaware of the progression of 
menopause and whether it even occurred in the 32- and 48-week old hearts used in this study. It 
is noteworthy that other studies may have avoided this uncertainty by the use the aged (74-week 
old) phenotype which is labelled as post-menopausal. Although we were unable to achieve high 
(>70%) transfection efficiencies using chemical transfection, the use of AAV vectors and or the 
recently released Lipofectamine 3000 may have resulted in greater transfection rates suitable for 
functional studies (sI-R etc.). Although we detected an increase in Capn3 and Trim54, it remains 
to be shown whether this age-related induction of these transcripts result in increased 
degradation to their substrates.  
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8.3 FUTURE DIRECTIONS 
The down-regulation of Popdc1 should be confirmed via immunoblotting in the aged male and 
female hearts. Similarly, immunoblotting of Anxa5 and Smpd1 should also be employed as a small 
trend in decrease was observed for these transcripts in the 48-week old post-ischaemic vs 8-week 
old hearts. Although we investigated the expression of Cav1 mRNA in the ageing heart, future 
studies should also look at phospho-Cav1 as phosphorylation of caveolins appear important for 
attachment of caveolae to the plasma membrane (Sowa et al. 2003). Furthermore, 
phosphorylation of caveolins has also been implicated in internalisation of caveolae which may 
relay cardioprotective signalling downstream. Therefore, a reduction in phospho-Cav1 may also 
explain reduced caveolae-mediated signalling in these hearts as phospho-Cav1 has been shown 
to be required for anaesthetic preconditioning (Patel et al. 2007). Other post-translational 
modification observed for caveolins is nitroyslation, which as mentioned previously plays a crucial 
role in cardioprotection, acylation of Cav1 which is has been shown to bind Cav1 to G-protein 
Gi1α in caveolae, and palmitoylation of Cav1, required for coupling Cav1 to the c-Src tyrosine 
kinase (Bakhshi et al. 2010; Galbiati et al. 1999; Lee et al 2001). Measurement of circulating 
estrogen in the ageing female heart may also be of interest and whether this correlates with the 
reduction of ischaemic tolerance in the 48-week old hearts. Future investigations should also 
replicate the male plasma membrane study on females in a similar fashion to Chapter 3 and 4. 
The mRNA targets of miR15b, miR-20a, miR-22, miR-24, miR-92a and miR-378 should be 
investigated in the normoxic and post-ischaemic ageing hearts which should be inversely-
correlated with their expression. Additionally, >74 week-old mice (aged) should be used in further 
miRNA characterization to observe whether the senescence-related miRNAs such as miR-34a and 
miR-34c show differential expression at this time point as shown by others (Boon et al. 2013). 
Although there is plethora of literature available regarding the efficacy of canonical 
cardioprotective signalling, the efficacy of the plasma membrane repair mechanism in the aged 
heart remains largely uncharacterised. The association of plasma membrane repair protein 
Trim72 with Cav3 and Cavin1 should be compared in the young hearts vs. aged hearts whether 
the age-related reduction Cav3 and Cavin1 affects co-localisation of these proteins in the 
normoxic and post-ischaemic hearts. Methods to investigate this association could be co-
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immunoprecipitation and/or confocal microscopy. Using immunoblotting, the substrates of 
Trim54 (i.e. FHL2 and γ-filamin) and Calpain3 (i.e. titin and vimentin) should also be investigated 
whether increased degradation of their substrates is present in the 32- and/or 48-week old post-
ischaemic hearts used in this study (Fielitz et al. 2007). Overexpression of Capn3 and Trim54 could 
also help elucidate whether enhanced levels of these transcripts could result in increased 
cleavage their substrates. This may help partially explain the reduced recovery following I-R in the 
middle-aged hearts. The expression of other plasma membrane repair proteins such as dynamin1, 
dynamin2 and S100A11 should also be investigated. The expression of plasma membrane repair-
related transcripts should also be investigated in female hearts whether there are any sex-related 
differences. The expression of caveolar bulb proteins such as EHD and Pacsin family of proteins 
should also be investigated as they have been shown to influence caveolae formation and 
morphology (Moren et al. 2012). The use of high-throughput technologies such as next-
generation sequence or microarrays could be broadly used to investigate the expression of miRNA 
targets that showed significant changes in expression simultaneously also could be used to view 
regulatory networks affected by ageing i.e. plasma membrane repair mechanisms. The 
application of these technologies on the ageing female hearts used in this study would also help 
further elucidate sex-related differences.  Although transgenic models have clearly shown Cav3 
to be crucial determinant of cardioprotective signalling, currently no transgenic studies have 
investigated cavin1 terms of cardioprotection and should be investigated using deficiency and/or 
overexpression models (Tsutsumi et al. 2008; See Hoe et al. 2014).  
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